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ABSTRACT 
 
Epidemiological trends suggest that obesity is becoming a major public health 
problem. Although obesity contributes toward cardiovascular risk by promoting the 
development of hypertension, dyslipidaemia and diabetes mellitus (conventional risk 
factors), there is increasing evidence to suggest that excess adiposity may increase risk 
through effects on cardiovascular target organs that are independent of conventional risk 
factors. These obesity-induced effects may be produced by mediating damage and 
dysfunction of large vessels and the heart, and by promoting the development of cardiac 
hypertrophy. However, the independent effect of excess adiposity on large vessels has not 
been confirmed in all studies. Moreover, whether the impact of excess adiposity on cardiac 
hypertrophy or cardiac damage and dysfunction is dependent on an interaction with blood 
pressure (BP) is uncertain. In the present thesis I addressed these questions. 
Before evaluating these questions I first identified the preferred clinical index of 
adiposity when predicting BP. In this regard, some, but not all studies support the notion that 
indexes of central adiposity (waist circumference or waist-to-hip ratio) are the preferred 
predictors of conventional BP over indexes of general (body mass index) or subcutaneous 
(skin-fold thickness) adiposity. Moreover, to my knowledge no study has been conducted in 
a large study sample to evaluate whether indexes of central adiposity are the preferred 
predictors of ambulatory BP, a measure of BP that is more closely associated with 
cardiovascular events than conventional BP. In the first study conducted in a relatively large, 
randomly selected population sample (n=300) with a high prevalence of excess adiposity 
(65%), I demonstrated that waist circumference is the only clinical index of adiposity that is 
associated with an increased conventional and ambulatory systolic and diastolic BP, 
independent of other indexes of adiposity. 
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With regards to the effects of excess adiposity on large arteries, there is 
inconsistency in the reports demonstrating relations between indexes of adiposity and large 
artery dysfunction (arterial stiffness) independent of factors such as BP, heart rate and 
diabetes mellitus. As convincing independent relations between clinical indexes of adiposity 
and arterial stiffness have been noted in older, but not in younger populations, I 
hypothesized that age may determine whether excess adiposity promotes increases in 
arterial stiffness independent of confounders. Indeed, in 508 randomly selected persons 
from a population sample with a high prevalence of excess adiposity (~63% overweight or 
obese), I was able to show that age markedly influenced the independent relationship 
between indexes of central adiposity and an index of large artery stiffness in women but not 
in men after adjusting for confounders. The adjusted effect of indexes of central obesity on 
arterial stiffness was ~5-fold higher in older than in younger women. 
 With respect to the impact of excess adiposity on cardiac growth, although severe 
obesity is associated with an enhanced impact of BP on left ventricular mass (LVM), there is 
uncertainty as to whether the same effects occur in milder forms of excess adiposity, data 
confounded by the high prevalence of participants receiving antihypertensive therapy in 
previous studies. In the present thesis I demonstrated in a randomly recruited population 
sample of 398 participants with a high prevalence of mild-to-moderate obesity and 
hypertension (~41%), but in whom antihypertensive use was limited (~17%), that adiposity is 
indeed associated with an enhanced impact of conventional and ambulatory BP or arterial 
stiffness on LVM index and wall thickness independent of additional conventional risk 
factors. 
 With regards to the impact of obesity on cardiac function, although obesity is a risk 
factor for heart failure independent of other conventional cardiovascular risk factors, whether 
this effect occurs through changes in cardiac systolic chamber function is uncertain. In the 
present thesis I provide the first evidence to show in an animal model of genetic 
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hypertension and dietary-induced obesity, that dietary-induced obesity promotes the 
progression from compensated cardiac hypertrophy to cardiac pump dysfunction without 
promoting hyperglycaemia. This effect was attributed to alterations in both intrinsic 
myocardial systolic dysfunction and cardiac dilatation, effects that were associated with 
excessive cardiomyocyte apoptosis and activation of enzymes that promote myocardial 
collagen degradation. 
Therefore in the present thesis I provide evidence to support the notion that waist 
circumference should be measured when predicting BP changes, that excess adiposity does 
indeed decrease large vessel function independent of conventional risk factors, but that this 
effect is age-dependent, and that the deleterious effects of excess adiposity on cardiac 
hypertrophy and cardiac pump function are indeed dependent on an interaction with BP, but 
not other confounders. 
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PREFACE 
 
Epidemiological trends suggest that obesity is becoming a major public health 
problem in developing countries such as South Africa. The major health risk associated with 
obesity is through strokes, heart failure and potentially myocardial infarction effects which 
have largely been attributed to the impact of adipose tissue on hypertension, dyslipidaemia 
and diabetes mellitus. Although the latter health risks can be managed using therapeutic 
agents, there is increasing evidence to suggest that excessive adipose tissue may promote 
cardiovascular damage through an impact of factors that are not normally accounted for in 
risk assessment and which are not necessarily targeted by current therapeutic agents. 
Although the obvious solution to this conundrum is to target lifestyle or institute weight loss 
programmes on a large scale, weight reduction programmes seldom result in obese 
individuals reaching target body weights and frequently result in an inability to maintain 
these programmes. Consequently, clarity is required on whether obesity does indeed 
produce cardiovascular damage through mechanisms that are not accounted for by 
conventional risk assessment and to determine the mechanisms of these effects. It is only 
once the mechanisms are established that more appropriate therapeutic strategies can be 
planned. The present thesis was therefore designed to address some outstanding issues 
with respect to the potential mechanisms that may explain obesity-induced effects on the 
cardiovascular system independent of conventional cardiovascular risk factors. 
 In the present thesis I addressed the question of the ability of obesity to promote 
cardiovascular disease by assessing a number of preclinical cardiovascular target organ 
changes. This approach was adopted as prospective observational studies with hard end-
points such as cardiovascular events or death in patients would go beyond the scope of a 
PhD thesis. Furthermore, many of the questions addressed in the present thesis required 
analysis of cardiovascular changes as continuous rather than discrete traits. In this regard, I 
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assessed outstanding issues with respect to excess adiposity as independent predictors of 
large artery dysfunction, and addressed the question of whether or not obesity promotes 
cardiac hypertrophy and dysfunction in-part by enhancing blood pressure effects on the 
heart and the potential mechanisms thereof. Moreover, in order to assess the impact of 
excess adiposity on target organ changes I first had to establish the most appropriate clinical 
index of excess adiposity that predicts blood pressure. The outcomes of the present thesis 
suggest that obesity does indeed produce large artery damage, but that this is only 
something to be concerned about in older women. Moreover, the outcomes of the present 
thesis indicate that the adverse effects of obesity on the heart (both hypertrophy and 
dysfunction) may in fact depend more on blood pressure than what was previously 
suggested. These data therefore provide insights into potential therapeutic approaches in 
patients with obesity, in that blood pressure reduction may be the key to preventing the so-
called independent effects of obesity on the heart. 
The present thesis is written as a series of semi-independent chapters each with its 
own introduction, methods, results and discussion. However, the thesis begins with a 
chapter that reviews the present scientific literature in the field, underscores the relevant 
deficiencies in the literature and ultimately leads the reader to the reasons for performing the 
studies described in the present thesis. Moreover, the present thesis ends with a conclusion 
chapter which summarises the findings of the studies and places the studies in the context 
of our present understanding of the field. In support of the present thesis, the data given in 
chapters 2 and 3 have been published in the Journal of Hypertension (Majane et al 2007) 
and the American Journal of Hypertension (Majane et al 2008). The data provided in other 
chapters is presently in-preparation for submission to international journals for consideration 
for publication. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
             Current Understanding and Controversies of the 
         Impact of Excess Adiposity on Blood Pressure and 
     Cardiovascular Organ Damage. 
 
 
 
 
 
 
 
 
 
   
 
2 
1.1 Introduction 
 
The prevalence of obesity is increasing in both developed and in developing 
countries (Ogden et al 2007, Flegal et al 2002, Bourne et al 2002). In the United States 
of America in 2004, ~31% of men and ~33% of women were obese and ~3% of men and 
~7% of women were considered to be extremely obese (a body mass index [BMI] > 40 
kg/m2) (Ogden et al 2007). In South Africa, a country which from an economic 
perspective is considered to be a developing nation, at approximately the turn of the 
century, ~29% of men and ~57% of women were obese (Bourne et al 2002). There is 
now increasing evidence to indicate that obesity, once established, is difficult to manage. 
Indeed, weight reduction programs seldom result in obese individuals reaching target 
body weights (Lang and Froelicher  2006, Ogden et al 2007) and frequently result in an 
inability to maintain these weight reduction programs (Latner et al 2002, Perri and 
Corsica 2002, Anderson et al 2001). The important question therefore is whether there is 
a cause for concern with respect to the medical implications of excess adiposity and 
exactly why should we be concerned. 
Obesity is certainly associated with a considerable morbidity and mortality (Pi-
Sunyer 1993, Bellanger and Bray 2005, McGee 2005, Giusti 2007, Allison et al 1997, 
Formiguera and Cantón 2004, Heitmann et al 2000, Lahmann et al 2002) and a large 
component of this morbidity and mortality is through an increased risk for cardiovascular 
events (Eckel et al 2002, Klein et al 2004a). Indeed, obesity is a risk factor for heart 
failure (Bahrami et al 2008, Ingelsson et al 2005, Kenchaiah et al 2002, Kenchaiah et al 
2004, Poirier et al 2006, Wong and Marwick 2007, Contaldo et al 2002), myocardial 
infarction (Yusuf et al 2005, Steyn et al 2005) and cerebrovascular events (stroke) (Kurth 
et al 2002, Ahluwalia et al 2003, Suk et al 2003). This increased risk for cardiovascular 
events is in-part attributed to the association between obesity and classical 
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cardiovascular risk factors, including hypertension, diabetes mellitus, and dyslipidaemia 
(National Task Force on the Prevention and Treatment of Obesity, Overweight obesity 
and health risk 2000, Yki-Jarvinen and Koivisto 1983, Despres et al 1989, Harris et al 
2000, Zhu et al 2005, Wilson et al 2002, Engeli and Sharma 2000, Grundy 2000, Eckel 
et al 2002, Klein et al 2004a, De Lusignan et al 2006). 
With respect to the impact of excess adiposity on blood pressure (BP), this effect 
may be mediated largely through an impact of visceral, rather than general fat (Kanai et 
al 1990, Zhu et al 2005). This has important implications as measures of central (waist 
circumference and waist-to-hip ratio) as opposed to general (BMI) body fat are more 
likely to predict the effects of excess adiposity on BP and hence a portion of 
cardiovascular risk. Nonetheless, as shall be further discussed, these data are not 
entirely supported by all studies. Moreover, as shall also be highlighted, studies 
conducted comparing the impact of indexes of adiposity on 24-hour ambulatory BP 
profiles, a measure of BP that predicts cardiovascular events beyond conventional BP 
measurements (see later discussion), have been limited in a number of respects. 
Consequently, in the first part of my thesis I explored whether any one clinical index of 
central as opposed to general or subcutaneous (skin-fold thickness) fat predicts 24-hour 
ambulatory BP beyond the others. Therefore, in the first part of the present chapter I will 
first highlight the evidence to suggest that visceral fat may contribute toward increases in 
BP and underscore the controversies in this regard. 
Although as previously indicated, obesity increases the risk for cardiovascular 
events in-part through an impact on classical cardiovascular risk factors, there is now 
increasing evidence to suggest that the adverse effects of obesity on the cardiovascular 
system are still present even after adjustments for these risk factors. Indeed, obesity is a 
risk factor for the development of heart failure (Kenchaiah et al 2002, Kenchaiah et al 
2004, Bahrami et al 2008, Ingelsson et al 2005), myocardial infarction (Yusuf et al 2005, 
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Steyn et al 2005), and stroke (Kurth et al 2002, Suk et al 2003) after adjustments for 
age, the presence of hypertension, diabetes mellitus and dyslipidaemia. The relationship 
between measures of adiposity and cardiovascular outcomes independent of classical 
cardiovascular risk factors has engendered the notion that obesity could promote 
damage to key cardiovascular organs that is not necessarily mediated through an 
elevated BP, poor blood glucose control or abnormal lipid profiles. The natural extension 
to this argument is that managing hypertension, diabetes mellitus and dyslipidaemias in 
obesity may be insufficient to prevent obesity-induced increases in cardiovascular risk. 
However, there are a number of outstanding questions in this regard and these relate to 
the independent actions of obesity on cardiovascular structure and function. Indeed, the 
major focus of my thesis was to attempt to clarify outstanding issues regarding the 
impact of excess adiposity on cardiovascular target organs either independent of 
conventional cardiovascular risk factors, including BP, or mediated through interactions 
with BP. In the process of addressing these questions, as indicated in the 
aforementioned discussion I nevertheless had to first identify the most appropriate 
adiposity index associated with BP changes. After having completed this aspect of the 
thesis which is described in chapter 2 and published in the Journal of Hypertension 
(Majane et al 2007), with respect to subsequent chapters in my thesis, I performed a 
series of studies that add to our insights into the role of excess adiposity as a potential 
independent predictor of cardiovascular target organ changes. Consequently, in the 
introductory chapter of the present thesis I will also discuss the evidence to indicate that 
cardiac and vascular target organ changes are independent predictors of cardiovascular 
events and subsequently highlight the evidence to suggest that excess adiposity is an 
independent determinant of these cardiovascular changes, and the potential 
mechanisms thereof. In this regard, I will highlight questions that have not been 
adequately addressed and which were subsequently explored in the present thesis. 
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 Before addressing the aforementioned points, it is worth first briefly reviewing the 
changes that occur as a consequence of excessive adipose tissue that may promote 
either increases in BP or cardiovascular target organ changes independent of BP or 
through interactions with BP. The next section is therefore intended to underscore all of 
the potential mechanisms through which an excess adiposity may promote many of the 
adverse cardiovascular effects that will subsequently be discussed. 
 
1.1.1 Insulin resistance in obesity 
 
Insulin resistance may occur as a consequence of excess adiposity (Kahn and 
Flier 2000). This change is thought not only to lead to diabetes mellitus, but also to 
adverse cardiovascular changes independent of diabetes mellitus. At a cellular level, 
insulin binds to its receptor on the surface of target cells, thereby causing tyrosine 
autophosphorylation and consequent intracellular signaling. These events culminate in 
cellular responses, such as the translocation of glucose transporters to the cell surface to 
allow glucose uptake for use or glycogen storage. In obesity, however, insulin signaling 
may be defective. Insulin-stimulated protein kinase activity of the insulin receptor, which 
mediates tyrosine autophosphorylation, is reduced in obese as compared to non-obese 
people, and it is further reduced in patients with obesity-induced type II diabetes mellitus 
(Caro et al 1989). However, euglycaemia is maintained in the initial stages of insulin-
resistance through compensatory hyperinsulinaemia. Indeed, there is considerable 
evidence to suggest that a large proportion of obese individuals are insulin-resistant, but 
that compensatory hyperinsulinaemia maintains fasting blood glucose concentrations 
(Reaven 2003, Keller 2006). Thus, insulin resistance goes undetected in these 
individuals. 
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Insulin resistance will undoubtedly promote adverse cardiovascular effects once 
type II diabetes mellitus develops and the effects of hyperglycaemia are noted (Groop 
2000, Feener and King 1997). However, insulin resistance may also promote adverse 
cardiovascular changes prior to the development of diabetes mellitus and poor blood 
glucose control through a number of mechanisms. In this regard, hyperinsulinaemia, as 
a consequence of insulin insensitivity associated with obesity, could promote obesity-
induced increases in sympathetic nervous system (SNS) activity (Esler et al 2001, Corry 
and Tuck 1999, Landsberg et al 1986, Alonso-Galicia et al 1996, Anderson et al 1991), 
which as shall be discussed below may promote adverse cardiovascular effects. Further, 
hyperinsulinaemia in insulin resistance may induce hypertrophy of the vascular wall 
through an increased synthesis of collagen and proliferation of vascular smooth muscle 
cells (de Fronzo and Ferrannini 1991, Avena et al 1998, King and Wakasaki 1999, Ruiz-
Torres et al 1998), induce increases in arterial stiffness (van Popele et al 2000) and 
promote endothelial dysfunction (Arcaro et al 2002), a change that is considered to 
precede large vessel pathology. 
 
1.1.2 Activation of the sympathetic nervous system in obesity. 
 
There is considerable evidence to suggest that the SNS is activated in obesity 
(Haynes et al 1997 a and b, Haynes et al 1998,  Casto et al 1998, Satoh et al 1999, 
Tentolouris et al 2006, Yang and Barouch 2007, Mark et al 1999, Mark et al 2004, 
Masuo et al 2000). A number of mechanisms could explain this effect, including 
increased circulating concentrations of leptin, an adipokine released from fat tissue in 
excess in obesity (Eikelis et al 2003, Hall et al 2000, Haynes et al 1997 a and b) and as 
discussed above, through hyperinsulinaemia (Esler et al 2001, Corry and Tuck 1999, 
Landsberg et al 1986, Alonso-Galicia et al 1996, Anderson et al 1991) following the 
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development of insulin resistance. With respect to leptin effects, upon leptin release by 
adipocytes, it reaches its receptors in the brain via facilitated passage across the blood-
brain barrier. In addition to reducing appetite and controlling weight gain, leptin activates 
the SNS. The mechanisms of leptin-induced SNS activation in obesity are still unclear 
but this may be via stimulation of neurons within the ventromedial hypothalamus (Satoh 
et al 1999). With regards to hyperinsulinaemia promoting SNS activity, because insulin-
mediated glucose uptake in central hypothalamic neurons regulates SNS activity in 
response to dietary intake, hyperinsulinemia is also thought to provoke SNS stimulation 
(Landsberg 1999). However, there is controversy as to whether increased leptin or 
insulin concentrations in obesity can explain early SNS activation in persons with an 
excess adiposity as indeed, some studies do not support these hypotheses (Masuo et al 
2000, Hall 1995, Hildebrandt et al 1999, Feskens et al 1995). 
It is well accepted that excessive SNS activity may promote increases in BP 
through a number of mechanisms. Indeed, SNS activation may induce adrenergic-
induced vasoconstriction (α-adrenergic receptor effects) which increases peripheral 
resistance. However, as shall be underscored in later discussion, obesity may promote 
decreases rather than increases in vascular resistance in most vascular beds, the 
consequence being an attenuation rather than an increment in total peripheral 
resistance. However, SNS activation increases heart rate and cardiac contractility (β-
adrenergic-induced effects) which enhances cardiac output and hence BP. Further, SNS 
activation induces renal fluid retention (Izzo and Taylor 1999, Sinski et al 2006, Watson 
et al 2006), which also increases cardiac output and hence BP. However, the adverse 
cardiovascular effects of SNS activation may also occur through actions that may be 
unrelated to BP changes. In this regard, left ventricular hypertrophy (LVH) is associated 
with excessive myocardial sympathetic effects (Schlaich et al 2003) and blockade of β-
adrenoreceptors may reduce LVH through effects that cannot be attributed solely to an 
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impact on BP (Roland et al 1997). Moreover, activation of the SNS can promote the 
transition from compensated LVH to heart failure through mechanisms that appear to be 
unrelated to BP changes (Badenhorst et al 2003a, Veliotes et al 2005). 
 
1.1.3 Activation of the renin-angiotensin-aldosterone system in obesity 
 
Another potential mechanism by which obesity may promote adverse 
cardiovascular changes is through activation of the renin-angiotensin-aldosterone 
system (RAAS). In this regard there is considerable evidence to suggest that the RAAS 
is excessively stimulated in obesity. Indeed, angiotensinogen (AGT), a protein 
synthesized principally in the liver and transformed by renin to ultimately produce 
angiotensin II and aldosterone, is also synthesized by adipocytes (Serazin-Leroy et al 
2000, Cassis et al 1988, Campbell et al 1987) and circulating AGT concentrations 
increase in obesity (Cooper et al 1998). Angiotensin-converting enzyme (ACE), an 
enzyme largely derived from endothelial cells in the lung parenchyma, and which is 
responsible for converting inactive angiotensin I to angiotensin II, is also synthesized by 
adipocytes (Jonsson et al 1994) and ACE activity increases in obesity (Cooper et al 
1998) and decreases with weight loss (Harp et al 2002). Moreover, adipocytes are 
capable of producing a lipid substance that is either converted to aldosterone by adrenal 
cortical cells or acts as an adrenal secretagogue and promotes aldosterone release 
(Ehrhart-Bornstein et al 2003). 
The importance of the RAAS in promoting adverse cardiovascular effects has 
been reviewed on a number of occasions (Packer 1992, Mantero and Lucarelli 2000, 
Unger 2002, Nadar 2006, Farmer and Torre-Amione 2001). There is no question as to 
the importance of the RAAS in inducing increases in BP through renal salt and volume 
retention and vasoconstriction. Importantly, however, either angiotensin II or aldosterone 
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may promote cardiovascular fibrosis through direct rather than through haemodynamic 
changes, thus inducing large vessel stiffness (Rocha et al 2002, Mahmud and Feely 
2004, Duprez 2006) or diastolic dysfunction in the heart (Norton et al 1997). Further, 
either angiotensin II or aldosterone can promote cardiomyocyte and vascular smooth 
muscle cell hypertrophy or hyperplasia independent of haemodynamic changes (Tanaka 
et al 2005). Moreover, angiotensin II and aldosterone can promote adverse vascular 
remodeling through inflammatory changes (Rocha et al 2002, Duprez 2006), rather than 
through the aforementioned well-recognized haemodynamic effects. Consequently, 
RAAS activation, such as occurs in obesity, could promote cardiovascular damage 
independent of measurable haemodynamic changes. 
 
1.1.4 Haemodynamic changes in obesity 
 
 What are the potential haemodynamic changes associated with excess adiposity 
that may promote target organ damage through mechanisms that are not necessarily 
mediated by an impact on BP that are measured through conventional methods? 
Because of the high metabolic activity of excessive fat, obesity may result in a decrease 
rather than an increase in total peripheral resistance and an increase in venous return 
with an enhanced stroke volume and cardiac output (Messerli et al 1982, Messerli et al 
1983, Carabello and Gittens 1987). Further, as SNS activity may be enhanced in obesity 
(see above discussion) heart rate and cardiac contractility may also contribute towards 
an increased cardiac output, and as SNS-induced renal fluid retention may occur in 
excess adiposity (Mark et al 1999), this may increase blood volume and hence further 
enhance stroke volume and cardiac output. 
As a consequence of the high cardiac output, systolic BP increases, but this 
increase in BP may be partly offset by a reduced vascular resistance. Nevertheless, 
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irrespective of the effect of obesity on systolic BP, the increased blood volume and blood 
flow may induce an increase in vascular shear stress and promote vascular damage 
independent of BP. Moreover, an increased venous return may increase cardiac preload 
and subsequently induce myocardial damage. Thus, obesity may further haemodynamic-
induced damage to the heart and vessels, through mechanisms that may not necessarily 
be mediated by an increased BP detected from brachial artery or other peripheral artery 
BP measurements. 
An additional haemodynamic change that may also occur with an increased 
adiposity is augmentation of central BP produced by the early return of reflective waves 
in stiffer large arteries (see section on target organ changes in obesity). As will be 
discussed, through this change it is possible that afterload to the left ventricle will 
increase and subsequently induce damage to the heart through changes that are also 
not necessarily reflected by peripheral BP values. 
 
1.2 Excess adiposity and blood pressure. 
 
Based on the neurohumoral and haemodynamic consequences of excess 
adiposity outlined in the aforementioned discussion, it is easy to conceive of the 
possibility that excess adiposity also promotes cardiovascular damage because it is a 
major determinant of increases in BP. There is now substantial evidence from 
population-based studies with large study samples (n=10969-15063) in favour of obesity 
being a major determinant of conventional BP and the development of hypertension 
(Zhu et al 2005; Harris et al 2000). Indeed, the odds of developing hypertension are 
~1.7-3.4 times greater in obese individuals as compared to lean individuals (Harris et al 
2000). Further, there is substantial evidence to indicate that weight reduction results in 
decreases in BP. Indeed, in a meta-analysis of a number of weight reduction studies, 
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with a total sample size of 4874 participants, it was estimated that a ~3.5-4.5 mm Hg 
decrease in BP will occur for every 5.1 kg of weight loss over 16 months (Neter et al 
2003). Moreover, in the Atherosclerosis Risk in Communities (ARIC) study involving 
3245 participants, a ~1.5-2.0 fold chance of hypertension remission was reported to 
occur for every 1 kg decrease in body weight over 9 years (Juhaeri et al 2003). 
The obvious question that arises from association studies between adiposity and 
BP irrespective of whether they are cross-sectional studies or weight reduction studies 
involving lifestyle changes, is whether fat tissue per se mediates the BP effects, or 
whether alternative dietary or exercise-related effects are the main role-players? The 
answer to this question lies in the impact on BP of weight reduction that is not attributed 
to lifestyle modifications. In this regard, in a meta-analysis conducted in a total of 1230 
participants involved in a number of weight reduction studies, where weight reduction 
was achieved with orlistat, a pharmacological agent that specifically targets decreases in 
adipose tissue by decreasing fat absorption in the gastrointestinal tract, provided 
evidence to suggest that for each ~8% reduction in body weight a 8-9 mm Hg decrease 
in BP may occur (Sharma and Golay 2002). Further, in a single study conducted in 531 
participants, a ~5-6% decrease in body weight mediated by orlistat resulted in a ~5-6 
mm Hg reduction in BP (Broom et al 2002). 
Despite the convincing evidence to indicate that excess adiposity mediates 
increases in BP, there is nevertheless some evidence to suggest that these effects are 
not persistent. Indeed, in 343 obese participants, orlistat reduced BP at one year, but 
despite participants largely maintaining weight reduction at two years, BP values 
increased to baseline values (Sjostrom et al 1998). Further, after marked weight 
reduction following gastric banding in obese participants, BP reduction occurred after 
one year, but after 8 years BP levels increased to baseline levels again (Sjostrom et al 
2000). Even studies involving BP measurements that are not prone to observer errors 
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and take into account 24-hour profiles have produced data that suggest that the 
beneficial effects of weight reduction on BP are not sustained. Indeed, although 
ambulatory BP was reduced after two months of a low calorie diet resulting in marked 
weight reduction, after 14 months ambulatory BP values increased to baseline values 
again despite participants largely maintaining weight reduction (Laaksonen et al 2003). 
Thus, further work is still required to understand the apparent non-persistence of the 
effects of weight reduction on BP in some studies. 
 
1.2.1 Fat distribution and blood pressure. 
 
As indicated in the introduction to the present chapter, although the focus of my 
thesis was to attempt to clarify outstanding issues regarding the impact of excess 
adiposity on cardiovascular target organs either independent of conventional 
cardiovascular risk factors, including BP, or mediated through interactions with BP, in the 
process of addressing these questions, I first had to identify the most appropriate 
adiposity index associated with BP changes. In this regard, there is evidence to indicate 
that the distribution of adipose tissue determines the impact of excess adiposity on BP. 
Indeed, the ratio of visceral-to-subcutaneous fat as determined using computer assisted 
tomography (CAT) scans, may account for 50-60% of the variability in BP as compared 
to clinical indexes of adiposity which may account for less than 10% of the variability in 
BP (Kanai et al 1990). Further, in 10,969 nationally representative participants of the 
United States of America, waist circumference, an index of central adiposity, accounted 
for a greater proportion of the variability of BP than BMI (Zhu et al 2005), data which is 
supported by a number of studies assessing the impact of adiposity indexes on BP. 
Indeed, in this regard, present evidence suggests that waist circumference or other 
indexes of central fat appear to be the preferred clinical indexes when relating adiposity 
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to conventional BP (Okosun 1998, Williams et al 1987, Peiris et al 1989, Kanai et al 
1990, Raison et al 1992, Boyko et al 1995, Lerario et al 1997, Ho et al 2001, Okosun et 
al 1999, Hayashi et al 2003, Ding et al 2004). Indexes of central adiposity may show 
either stronger relations with BP than BMI (Zhu et al 2005), or they may show 
relationships with BP independent of BMI (Okosun et al 1998). Importantly, 
subcutaneous liposuction in the abdominal region does not reduce BP in obese 
individuals (Klein et al 2004b) and hence, in support of the strong relationship between 
visceral-to-subcutaneous fat ratios and BP noted in a CAT scan study (Kanai et al 1990), 
it is likely that the visceral fat compartment is responsible for the impact of excess 
adiposity on BP. 
 
1.2.2 Potential explanations for the relationships between indexes of visceral fat 
and blood pressure. 
 
Two possibilities may explain the closer relationship between indexes of central 
as compared to general adiposity and BP. First, an inconsistent relationship between 
BMI and adiposity may occur, particularly in some populations (Luke et al 1997). Thus 
BMI may not be a reliable index of adipose tissue mass. Second, visceral fat mass may 
be more important in mediating BP changes than other fat compartments (Kanai et al 
1990, Williams et al 1987, Peiris et al 1989, Kanai et al 1990, Raison et al 1992, Boyko 
et al 1995, Lerario et al 1997, Okosun et al 1999, Ho et al 2001, Hayashi et al 2003 and 
Ding et al 2004). How could visceral adipose tissue promote increases in BP beyond that 
produced by other fat compartments?   
There are many changes that occur in people with excess adiposity that may 
explain BP effects and these have been discussed in sections 1.1.1-1.1.4. Importantly, 
however, with respect to potential mechanisms that may explain the closer relationship 
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between central as opposed to general adiposity with BP, one potential explanation is 
that visceral fat is more closely associated with SNS activity. Indeed, for the same 
amount of total fat or abdominal subcutaneous fat, basal muscle sympathetic activity 
increases in people with an increased visceral fat content (Alvarez et al 2002). Moreover, 
abdominal fat content is more closely associated with basal muscle sympathetic activity 
than is total fat content or subcutaneous abdominal fat (Alvarez et al 2002).  Evidence in 
support of a contribution of visceral as compared to other fat compartments toward 
increases in SNS activity is that waist-to-thigh ratio is an independent predictor of basal 
muscle sympathetic activity in both males and in females (Jones et al 1996). 
The closer relationship between central as opposed to general adiposity with BP, 
may also be explained by the propensity of visceral fat to promote adrenal 
steroidogenesis. Indeed, the best clinical index of excess adiposity that predicts 
circulating aldosterone concentrations is visceral fat measured by CAT scans and waist-
to-hip ratio (Goodfriend et al 1999). This effect may be mediated by fatty acid-induced 
release of a secretagogue from visceral adipocytes that stimulates aldosterone 
production by adrenal glomerulosa cells or which is converted into aldosterone by the 
adrenal gland (Goodfriend et al 2004, Ehrhart-Bornstein et al 2003).  As it is well 
recognized that aldosterone promotes increases in BP via a number of mechanisms that 
have been extensively reviewed (Rajagopalan and Pitt 2001, Ngarmukos and Grekin 
2001, Funder 1997, Mantero and Lucarelli  2000), it is possible that visceral fat mediates 
increases in BP via excessive aldosterone production. Indeed, aldosterone receptor 
antagonism attenuates obesity-induced hypertension (de Paula et al 2004). 
 A further potential explanation for the closer relationship between central as 
opposed to general adiposity with BP, is that visceral adipocytes tend to produce more 
components of the RAAS than adipose tissue from other fat deposits. In this regard, a 
greater extent of AGT expression may occur in visceral adipocytes as compared to 
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adipocytes from other areas (Wajchenberg 2000). However, to my knowledge as yet 
there is no evidence to indicate that the activity of the circulating RAAS is more closely 
associated with indexes of central adiposity than BMI. Nevertheless, establishing an 
independent relationship between the circulating RAAS and indexes of central adiposity 
was a task that goes beyond the scope of the present thesis. 
 
1.2.3 What is the outstanding evidence with respect to the role of visceral as 
compared to general obesity on blood pressure? 
 
Not all studies support the notion that clinical indexes of central fat are more 
closely associated with BP than indexes of general adiposity. Indeed, in the ARIC study 
conducted in 15,063 partipants, BMI was as closely associated with BP as was waist 
circumference (Harris et al 2000). The ability of BMI to predict BP as closely as waist 
circumference was noted in two ethnic groups (Caucasians and African-Americans) and 
in both women and men (Harris et al 2000). Clearly, clarity on this issue is therefore still 
required. 
One potential method of resolving the conundrum of whether indexes of central 
adiposity promote increases in BP beyond indexes of general adiposity is to evaluate 
this question using ambulatory BP monitoring. Indeed, ambulatory BP monitoring 
eliminates the problems associated with auscultatory BP measurement (observer error, 
observer bias, alerting responses, and an inability to account for BP fluctuations during 
the day, to name a few). Furthermore, 24-hour ambulatory BP is a better index of 
cardiovascular outcomes (Verdecchia et al 1994, Clement et al 2003, Staessen et al 
1999 and Okhubo et al 1998) and target organ effects (Mancia and Parati 2000) than 
conventional BP values. Up until the time of conducting the studies reported on in the 
present thesis, to my knowledge studies that have compared the relative impact of 
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indexes of central fat and BMI on ambulatory BP have either recruited small study 
samples, have been non-random, have focussed on waist-to-hip ratio rather than waist 
circumference as the index of central fat, and have produced ambiguous results 
(Guagnano et al 1994, Guagnano et al 1997, Steptoe et al 1999, Lurbe et al 1998, 
Feldstein et al 2005). In the present thesis I therefore assessed whether any one 
commonly used clinical index of adiposity (waist circumference, waist-to-hip ratio, BMI 
and skin-fold thickness) predicts ambulatory BP independent of the others. This study 
was conducted in a randomly selected population sample, with a high prevalence of 
obesity, living in an urban developing community in South Africa. The results of this 
study are reported on in chapter 2 of the present thesis and have been published in the 
Journal of Hypertension (Majane et al 2007). 
 
1.3 Target organ changes as independent predictors of cardiovascular events. 
 
A number of cardiovascular target organ changes that are influenced by excess 
adiposity have now been established as independent predictors of cardiovascular 
events. The potential impact of adiposity on some of these target organ changes and the 
mechanisms thereof were studied as part of my thesis. These target organ changes that 
I studied include large vessel and cardiac pathology. However, before describing the role 
of excess adiposity as determinants of these cardiovascular target organs I will first 
highlight the evidence to indicate that the pre-clinical cardiac or large vessel pathology 
that may be determined by excess adiposity predicts cardiovascular risk independent of 
conventional cardiovascular risk factors. It is this evidence that has led to the 
recommendation in guidelines for the diagnosis and management of hypertension that 
measurement of some of these target organ changes are incorporated into routine 
clinical practice (Mancia et al 2007). 
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1.3.1 Abnormalities of large vessel function as independent predictors of 
cardiovascular outcomes. 
 
There is now substantial evidence to indicate that increases in the stiffness of the 
wall of large arteries may be a risk factor for cardiovascular events independent of 
classical cardiovascular risk factors (Benetos et al 1997, Blacher et al 1999a, Blacher et 
al 1999b, de Simone et al 1999, Laurent et al 2001, London et al 2001, Guerin et al 
2001, Boutouyrie et al 2002, Safar et al 2002, Blacher and Safar 2005, Dolan et al 2006, 
Sutton-Tyrrell et al 2005, Cruickshank et al 2002, Meaume et al 2001). Indeed, indexes 
of aortic stiffness are independent predictors of cardiovascular events, including stroke 
and myocardial infarction in patients with hypertension (Benetos et al 1997, de Simone 
et al 1999, Laurent et al 2001, Boutouyrie et al 2002), in patients referred to tertiary care 
centres for the management of hypertension (Dolan et al 2006), in patients with end 
stage renal disease (London et al 2001, Guerin et al 2001, Safar et al 2002), in patients 
with diabetes mellitus (Cruickshank et al 2002), in the elderly (Meaume et al 2001) and 
in well functioning older adults (Sutton-Tyrrell et al 2005). These effects of arterial 
stiffness on cardiovascular events are independent of conventional (de Simone et al 
1999, Laurent et al 2001, Guerin et al 2001, London et al 2001, Boutouyrie et al 2002, 
Safar et al 2002, Sutton-Tyrrell et al 2005, Cruickshank et al 2002, Meaume et al 2001) 
or 24-hour ambulatory (Dolan et al 2006) BP. Increases in large artery stiffness not only 
predict vascular events such as stroke and myocardial infarction, but are also associated 
with pump dysfunction in chronic heart failure (Tartiere et al 2006) and with left 
ventricular diastolic dysfunction in hypertension (Palmieri et al 2003), effects that are 
also independent of conventional BP. 
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The explanations for the ability of measurements of large artery stiffness to 
predict cardiovascular outcomes independent of conventional cardiovascular risk factors 
are still uncertain. However, there are three potential theories in this regard. First, large 
artery stiffness may reflect the composite effects of temporal (time-dependent) changes 
in classical cardiovascular risk factors and as such is still dependent on classical risk 
factors, but obviously the sum of their detrimental effects. Second, large artery stiffness 
may contribute toward cardiovascular disease, in-part through the impact of early 
reflective waves on central aortic pressures, a pressure that is not accurately predicted 
by brachial artery BP measurements (Karamanoglu et al 1993, Williams et al 2006). 
Thus, adjustments for brachial artery BP will not eliminate relationships between large 
artery stiffness and cardiovascular outcomes. Third, although an increase in arterial 
stiffness may occur through the deleterious actions of an increased BP (Schiffrin 2004, 
Blacher and Safar 2005), abnormal blood glucose control (Henry et al 2003, Cruickshank 
et al 2002, Cameron and Cruickshank 2007, Schram et al 2004) and abnormal lipid 
profiles (Wilkinson et al 2002), increases in arterial stiffness may also occur through 
factors other than these classical cardiovascular risk factors, such as inflammatory 
mediators in chronic inflammatory diseases (Selzer et al 2001). Thus an increase in 
large artery stiffness may be a good index of the composite of classical and alternative 
cardiovascular changes that lead to cardiovascular morbidity and mortality. In this 
regard, as shall be highlighted in subsequent discussion, a potential source of 
stimulation of increases in large artery stiffness that may not normally be entirely 
accounted for by classical cardiovascular risk assessment may be from adipose tissue.  
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1.3.2 Cardiac hypertrophy as an independent predictor of cardiovascular 
outcomes. 
 
An increased left ventricular mass (LVM) is a relatively common pre-clinical 
complication of poorly managed hypertension. In this regard, many studies have 
reported on the ability of LVM to predict cardiovascular events such as stroke, sudden 
cardiac death and myocardial infarction, independent of classical cardiovascular risk 
factors (Casale et al 1986, Levy et al 1990, Koren et al 1991, Levy et al 1994, 
Verdecchia et al 1996, Ghali et al 1998, Gardin et al 2001, Verdecchia et al 2001). It is 
also now well recognized that reductions in LVM with antihypertensive therapy are 
associated with a reduced risk of cardiovascular morbidity and mortality (Mathew et al 
2001, Okin et al 2004, Devereux et al 2004) and that these effects are partly 
independent of office BP changes (Mathew et al 2001, Okin et al 2004, Devereux et al 
2004). More recently, prospective evidence has also emerged to indicate that LVM is 
associated with a decrease in left ventricular systolic function (left ventricular ejection 
fraction [LVEF]) or left ventricular diastolic function independent of traditional risk factors 
including conventional BP (Drazner et al 2004). 
The relationship between LVM and cardiovascular morbidity and mortality 
independent of conventional cardiovascular risk factors could be explained by three 
hypotheses. First, as with increases in arterial stiffness, LVM may be an index of the 
sum of all BP changes that have occurred over a prolonged time period. Indeed, 
regression of an increased LVM with antihypertensive therapy may take up to two years 
to achieve maximal effects (Devereux et al 2002). Second, an increased LVM (LV 
hypertrophy-LVH) could lead to a number of abnormalities of cardiac function and thus 
predispose to heart failure. These would include an impaired filling of the left ventricle 
through both a decreased early-diastolic relaxation and a reduced late-diastolic 
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compliance (Gradman and Alfayoumi 2006). This, in-turn, may increase cardiac filling 
pressures, augment myocardial transmural pressures during diastole and reduce 
coronary flow (reduced coronary reserve) (Lorell et al 1987). Left ventricular hypertrophy 
could also progress to an impaired left ventricular pump function through a number of 
mechanisms including chamber dilatation (Norton et al 2002) and a decreased 
myocardial contractility (Malik et al 1974). Further, the increased tissue bulk of the 
myocardium may, as previously suggested (Kannel et al 1970, Ghali et al 1991) increase 
myocardial oxygen demand - an effect that may not be accompanied by the expected 
increase in coronary flow because of reductions in coronary reserve. Alterations in 
myocardial oxygen demand-to-supply ratios in LVH could result in programmed cell 
death (apoptosis) (Liu et al 2000, Veliotes et al 2005) and necrosis (Tsotetsi et al 2001). 
It is also possible that increased filling pressures in the left ventricle and hence in the left 
atrium may result in atrial fibrillation and mural thrombus formation, an effect that could 
result in embolic phenomenon and hence strokes. 
A third potential explanation for the ability of LVM to predict cardiovascular 
outcomes independent of conventional risk factors is that an increase in LVM may occur 
through factors other than classical cardiovascular risk factors. These factors may not 
only promote cardiomyocyte growth, but may also contribute toward alternative 
cardiovascular effects that ultimately lead to strokes, myocardial infarcts, sudden cardiac 
death and heart failure. In this regard, as shall be highlighted in subsequent discussion, 
a potential source of stimulation of cardiomyocyte growth that is not normally entirely 
accounted for by classical cardiovascular risk assessment may be from adipose tissue. 
Evidence to support the notion that LVM heralds the onset of alternative vascular effects 
is that there is an association between vascular damage in small resistance arteries and 
the presence of concentric LVH (Treasure et al 1993, Muiesan et al 2002). 
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1.3.3 Preclinical abnormalities of cardiac function as independent predictors of 
cardiovascular outcomes. 
 
Left ventricular systolic or diastolic functional changes are also considered pre-
clinical cardiovascular findings that may be used to predict cardiovascular outcomes. 
Indeed, systolic chamber dysfunction (a reduced ejection fraction) in patients without 
heart failure independently predicts cardiovascular mortality; and the prevention of 
congestive heart failure through the treatment of preclinical systolic dysfunction is 
therefore recommended in guidelines (Hunt et al 2001). Furthermore, a reduced left 
ventricular systolic myocardial function (midwall fractional shortening) despite the 
presence of a normal chamber function (normal ejection fraction) in patients without 
evidence of heart failure, predicts mortality in hypertensives independent of conventional 
cardiovascular risk factors and LVM (de Simone et al 1996). Moreover, a reduced early-
to-late transmitral velocity ratio (E/A), an index of diastolic dysfunction, in patients with a 
largely normal systolic function and without heart failure, predicts cardiovascular 
outcomes in a general population (Bella et al 2002), and cardiovascular events in 
hypertensives (Schillaci et al 2002) independent of conventional cardiovascular risk 
factors. 
 The relationship between preclinical cardiac dysfunction and cardiovascular 
morbidity and mortality independent of conventional cardiovascular risk factors could 
again be explained by a number of hypotheses. First, as with other target organ 
changes, cardiac dysfunction may index the sum of all conventional cardiovascular 
effects that have occurred over prolonged time periods. Second, cardiac dysfunction 
could predispose to heart failure or reflect changes in the heart related to the preclinical 
phase of heart failure. Third, preclinical cardiac dysfunction may reflect adverse effects 
produced by factors other than classical cardiovascular risk factors. These factors may 
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not only promote cardiac dysfunction, but may also contribute toward alternative 
cardiovascular effects that ultimately lead to strokes and myocardial infarcts, as well as 
sudden cardiac death and heart failure. In this regard, as shall be highlighted in 
subsequent discussion, adipose tissue may promote changes that could lead to cardiac 
dysfunction. 
 
1.4 Excess adiposity as an independent cause of target organ changes and the 
potential mechanisms thereof. 
 
 As suggested in the aforementioned discussion, excess adiposity may promote 
cardiovascular target organ changes by inducing hypertension, diabetes mellitus or 
dyslipidaemias. However, as also suggested in the previous discussion, a relationship 
exists between excess adiposity and target organ changes even after adjustments for 
conventional cardiovascular risk factors, such as hypertension, diabetes mellitus and 
dyslipidaemia. Nevertheless, these relationships are not entirely understood. As a clear 
understanding of these relationships is important to be able to design appropriate 
strategies to manage patients with excess adiposity, in this section of the chapter I will 
describe the evidence to show that a relationship may exist between excess adiposity 
and target organ changes even after adjustments for conventional cardiovascular risk 
factors and highlight those areas of understanding in this regard that are particularly 
lacking. I will subsequently describe how, in the present thesis, I have attempted to 
clarify some misunderstandings of these relationships. Importantly, these studies are 
either published in the American Journal of Hypertension (Majane et al 2008) or are 
presently under review for consideration of publication. 
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1.4.1 Excess adiposity as an independent cause of large vessel dysfunction. 
 
A number of studies have demonstrated a relationship between excess adiposity 
and increases in arterial stiffness (Resnick et al 1997, Sutton-Tyrrell et al 2001, Mackey 
et al 2002, Wildman et al 2003, Ferreira et al 2004, Ferreira et al 2004, Snijder et al 
2004) a change which may be noted even in obese children (Tounian et al 2001). 
Despite the consistency in these reports demonstrating relations between excess 
adiposity and arterial stiffness, there is nevertheless controversy as to whether this 
relationship is independent of haemodynamic factors such as BP and heart rate (HR), or 
diabetes mellitus. In this regard, although adiposity is positively correlated with pulse 
wave velocity (PWV), a simple and reliable index of arterial stiffness, some studies have 
(Sutton-Tyrrell et al 2001, Mackey et al 2002, Wildman et al 2003, Ferreira et al 2004), 
whilst most others have not (Ferreira et al  2004, Zebekakis et al  2005, Taquet et al 
1993, Amar et al 2001, Nakanishi et al 2003, Oren et al 2003, Mitchell et al 2004, 
Czernichow et al 2005) been able to demonstrate strong relations between adiposity 
indexes and PWV independent of haemodynamic factors and diabetes mellitus. 
Pre-clinical studies nevertheless suggest that body size is indeed a major 
determinant of PWV independent of BP, HR, and diabetes mellitus (Cosson et al 2007). 
In studies conducted in humans, convincing independent relations between clinical 
indexes of adiposity and PWV have been obtained in elderly populations (Sutton-Tyrrell 
et al 2001, Mackey et al 2002), whilst substantial evidence against a strong independent 
relationship between adiposity and PWV has been noted in samples that are 
predominantly young-to-middle aged (Ferreira et al  2004, Zebekakis et al  2005, Taquet 
et al 1993, Amar et al 2001, Nakanishi et al 2003, Oren et al 2003, Mitchell et al 2004, 
Czernichow et al 2005). Thus, the haemodynamic and glucose control-independent 
effect of adiposity on PWV may be age-dependent. Indeed, adiposity-age interactions 
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have previously been described (Zebekakis et al 2005) which nevertheless only 
achieved significance when assessing associations with measures of arterial stiffness 
other than PWV. However, in that study (Zebekakis et al 2005), an adiposity-age 
interaction was not detected when assessing associations with PWV, although the 
independent effect of adiposity on PWV appeared to be enhanced with increasing age 
(Zebekakis et al 2005). It is possible that the low mean BMI of ~25 kg/m2 in that prior 
study (Zebekakis et al 2005) may have limited the capacity to detect a significant 
adiposity-age interaction for PWV. Further, the use of BMI as an adiposity index, rather 
than indexes of central adiposity, may have limited the sensitivity to detect age-adiposity 
interactive effects on PWV (Zebekakis et al 2005).  
As a consequence of the inconsistencies in the scientific literature regarding the 
potential independent effect of obesity on large artery stiffness, in the present thesis, one 
of my aims was to clarify whether age influences the independent relationship between 
adiposity indexes and PWV or other indexes of large artery dysfunction in a population 
sample of African ancestry with a high prevalence of excess adiposity. These data are 
provided in chapter 3 and have been published in the American Journal of Hypertension 
(Majane et al 2008). The following discussion therefore outlines some of the potential 
non-classical cardiovascular risk factors that could contribute toward PWV in obesity. 
 
1.4.1.1 Potential mechanisms of an independent relationship between adiposity 
and large artery stiffness. 
 
The potential mechanism through which obesity may promote large artery 
dysfunction independent of conventional cardiovascular risk factors is through insulin 
resistance, leptin, or RAAS activation. As indicated in the aforementioned discussion 
insulin resistance may promote adverse effects on large arteries independent of 
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haemodynamic changes by inducing hypertrophy of the vascular wall through an 
increased synthesis of collagen and proliferation of vascular smooth muscle cells (de 
Fronzo and Ferrannini 1991, Avena et al 1998, King and Wakasaki 1999), changes that 
could subsequently increase large artery stiffness. Although, to my knowledge there are 
no studies that have demonstrated any relationship between insulin resistance and large 
artery dysfunction independent of haemodynamic factors or diabetes mellitus, this was 
nevertheless, not a mechanism that I could appropriately explore in the present thesis, 
due to the limited number of participants recruited who had an 8 hour fast at the time of 
blood collection. In this regard, insulin resistance is defined using fasting glucose and 
insulin concentrations rather than post-prandial measurements. 
In contrast to the apparent lack of evidence supporting an independent role for 
insulin resistance as a predictor of large vessel dysfunction, with respect to leptin, there 
is indeed evidence in favour of an independent relationship between circulating leptin 
concentrations and large vessel dysfunction (Singhal et al 2002). However, the exact 
mechanism of this effect has not been identified. Nevertheless, as this independent 
relationship has previously been demonstrated, this was not a mechanism further 
assessed in the present thesis. 
Evidence in favour of RAAS activation contributing to the deleterious effects of 
adiposity on large vessel function is derived from the beneficial effects of ACE inhibition 
on arterial stiffness (Safar et al 1997), an effect that may nevertheless have been 
mediated by BP changes. A BP-independent effect is nonetheless easier to understand 
as it is well recognized that the RAAS promotes vascular hypertrophy, hyperplasia and 
fibrosis (see above discussion). However, there are no convincing studies to my 
knowledge, conducted in large samples of humans that have assessed whether RAAS 
activation is related to large vessel dysfunction beyond conventional risk factors and 
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indexes of adiposity. This was nevertheless, a question that was beyond the scope of 
the present thesis. 
 
1.4.2 Excess adiposity as an independent cause of cardiac hypertrophy. 
 
Although there is no question that body size is the most consistent determinant of 
LVM, there is still no clarity as to why increases in body size produced by excess 
adipose tissue produces pathological effects on the heart whilst normal growth effects 
are physiological in nature. The strong relationship between body size and LVM is 
supported by a number of studies with large sample sizes (Lauer et al 1991, Lauer et al 
1992, de Simone et al 1992, de Simone et al 1994, Gottdiener et al 1994, Urbina et al 
1995, Gardin et al 1995, Sherif et al 2000; Lorber et al 2003, Fox et al 2004). 
Importantly, even in large cohorts of mild-to-moderate hypertensive patients, BMI is the 
strongest predictor of LVM (Lauer et al 1992, Gottdiener et al 1994). The effects of body 
size may be through either the impact of adiposity and muscularity, effects which are 
accounted for by indexing LVM for body surface area, or simply by growth effects, which 
are in-turn, accounted for by indexing LVM for height to appropriate allometric signals 
(growth signals). In support of a pathological role for obesity-induced LVH, LVM indexes 
that incorporate the impact of adiposity on LVM (those indexing LVM for allometric 
signals of height) are associated with a higher proportion of incident cardiovascular 
events than are LVM indexes that discount the impact of adiposity on LVM (those 
indexing LVM for body surface area) (de Simone et al 2005). Consequently, unlike 
normal growth effects on LVM which are physiological in nature, obesity-induced LVH is 
indeed of pathophysiological significance. However, an explanation for the 
pathophysiological significance of adiposity-induced LVH has not been forthcoming. 
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Importantly, recent evidence suggests that severe obesity (BMI>35 kg/m2) 
enhances the impact of BP on LVM (Avelar et al 2007) through an as yet unidentified 
mechanism. These data provide one of the first potential explanations for the 
pathological effects of obesity on LVM as opposed to the physiological effects mediated 
by a normal growth. However, in milder forms of obesity, obesity may not increase the 
impact of BP on LVM (Fox et al 2004, Lauer et al 1992). Nevertheless, in the studies 
conducted in milder forms of obesity, either participants with a narrow range of BP levels 
were evaluated due to exclusion of treated participants (Lauer et al 1992), or analysis 
was conducted in a sample in whom ~50% of participants were receiving 
antihypertensive treatment (Fox et al 2004). The limitations of these studies in milder 
forms of obesity (Fox et al 2004, Lauer et al 1992), therefore prompted me, as one of the 
aims of the present thesis, to assess in a population sample with a high prevalence of 
mild-to-moderate obesity, whether adiposity is associated with an enhanced impact of 
BP on LVMI and wall thickness and the haemodynamic mechanisms thereof. These data 
are described in chapter 4. 
 
1.4.2.1 Potential mechanisms of an independent relationship between adiposity 
and left ventricular mass. 
 
Haemodynamic factors that are not normally measured as part of risk 
assessment may mediate obesity-induced increases in LVM. In this regard, as indicated 
in above discussion, through the high metabolic activity of excessive fat, obesity may 
result in a decrease in total peripheral resistance and an increase in venous return, 
stroke volume and hence cardiac output (Messerli et al 1982, Messerli et al 1983, 
Carabello and Gittens 1987, Paulson and Tahiliani 1992). As a consequence of the high 
stroke volume and cardiac output, systolic BP and pulse pressure as well as cardiac 
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work increase and cardiac hypertrophy may be the consequence. Further, as indicated 
in the aforementioned discussion, obesity promotes increases in large artery stiffness, a 
change that will increase central artery BP, and hence further induce increases in 
cardiac work, and thus cardiac hypertrophy. The impact of changes in large artery 
function on LVM can be independent of BP. Indeed, our group has recently 
demonstrated a strong BP-independent relationship between PWV and LVM and wall 
thickness in women (Libhaber et al 2008). Thus, haemodynamic changes in obesity are 
likely to account for a major portion of adiposity-induced increases in LVM that are not 
incorporated in conventional cardiovascular risk assessment. Therefore, in the study 
described in chapter 4, where I assessed whether adiposity is associated with an 
enhanced impact of BP on LVMI and wall thickness, I not only evaluated interactions 
between BP and adiposity indexes as predictors of LVM, but also interactions between 
PWV, an index of arterial stiffness, and adiposity indexes as predictors of LVM. 
With respect to a potential role of non-haemodynamic factors as mediators of 
obesity-induced increases in LVM, although controversial with respect to the role of 
angiotensin II (Reudelhuber et al 2007), there is some evidence in favor of a contribution 
of the SNS and RAAS to cardiac hypertrophy. Indeed, with respect to the SNS, 
measurements of sympathetic nerve activity to the heart indicate an increased 
myocardial SNS activation in hypertensive patients with LVH as compared to those 
without LVH at similar BP levels (Schlaich et al 2003). With regards to the RAAS, 
inadequate suppression of angiotensin II (Schlaich et al 1998) and angiotensin II in 
relation in salt intake (Schmieder et al 1996) may modulate left ventricular structure in 
humans, blockers of angiotensin II are the only class of antihypertensive agents that 
have been shown to regress LVH beyond that produced by BP effects (Devereux et al 
2004), and genetic variation at the angiotensin II receptor is associated with left 
ventricular structure (Schmieder et al 2001). However, the bulk of evidence in genetically 
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modified experimental animals does not support a direct role for the RAAS in mediating 
cardiac hypertrophy (Reudelhuber et al 2007). Nevertheless this does not rule out a role 
for interactions between the RAAS and other pathological stimuli, such as obesity, in 
mediating LVH. Indeed, although there is no convincing evidence to suggest that SNS or 
RAAS activation mediates obesity-induced increases in LVM independent of 
haemodynamic changes, angiotensin II receptor blockade has been shown to prevent 
obesity-induced increases in LVM (du Toit et al 2005). Although the question of the 
independent role of the RAAS and SNS in mediating increases in LVM is of importance, 
it went beyond the scope of the present thesis. 
 Alternative mechanisms that may also contribute toward obesity-induced LVH 
independent of haemodynamic factors include either a protective effect of leptin on 
cardiac hypertrophy (Barouch et al 2003) or in contrast a hypertrophic action of leptin on 
cardiac myocytes (Rajapurohitam et al 2003). The contrasting outcomes of these studies 
(Barouch et al 2003, Rajapurohitam et al 2003) are nevertheless difficult to explain and 
hence further research is required to evaluate whether leptin either promotes or protects 
cardiac myocytes against hypertrophic effects. 
  
1.4.3 Excess adiposity as an independent cause of abnormalities of cardiac 
function. 
 
A number of pre-clinical studies have provided evidence to suggest that 
cardiomyocyte dysfunction occurs in insulin-resistant or obese states. Indeed, the 
function of the cardiac myocyte sarcoplasmic reticular Ca2+ ATPase enzyme, which is 
responsible for Ca2+ sequestration during relaxation is impaired in insulin resistant 
animals (Wold et al 2005). Further, decreases in myocardial adrenergic-induced 
contractile responsiveness may occur in dietary-induced obese animals (Carroll et al 
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1997), reduced cardiomyocyte contractile function may occur in dietary-induced obese 
animals (Relling et al 2006), and in leptin deficient animals (Dong et al 2006) and a 
decreased cardimoycyte contractile response to insulin and insulin-like growth factor-1 
has been reported on in genetically obese rats (Ren et al 2000). Despite these data, 
there are no studies that have demonstrated a reduced pump function in vivo in 
euglycaemic obese animals. Indeed, when assessed in vivo, euglycaemic animal models 
of obesity have a preserved pump function (Carroll et al 2006, du Toit et al 2008).  
With respect to the conventional cardiovascular risk factor-independent impact of 
excess adiposity on cardiac function in clinical studies, the present scientific literature is 
equally as unclear. In the Multiethnic Study of Atherosclerosis, although obesity was a 
strong predictor of the development of congestive heart failure, this relationship was 
abolished by the inclusion of LV systolic chamber function (LVEF) in the regression 
models (Bahrami et al 2008). These data suggest that obesity mediates the 
development of heart failure in-part through a reduction in LV pump function. However, 
relationships between obesity and LV pump dysfunction independent of conventional 
cardiovascular risk factors have been difficult to identify. In this regard although there are 
consistencies in the literature with respect to the impact of obesity on diastolic function, 
the data is discrepant with respect to systolic dysfunction. The following discussion 
highlights these discrepancies. 
Load-independent tissue Doppler indexes of both systolic and diastolic 
myocardial function are reduced in overweight people even after adjustments for BP, 
age, gender, blood glucose control and LVM (Peterson et al 2004, Wong et al 2004). 
Moreover, weight loss mediated by either gastric bypass surgery (Willens et al, 2005) or 
lifestyle intervention (Wong et al 2006) results in improvements in myocardial diastolic 
function independent of conventional cardiovascular risk factors. However, the 
relationship between excess adiposity and systolic cardiac chamber dysfunction (a 
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reduced pump function) independent of conventional cardiovascular risk factors is not 
that clear. Indeed, previous studies imaging the heart with techniques that assess 
chamber rather than myocardial function have provided contradictory evidence. In this 
regard, the majority of studies have reported on obesity effects on diastolic dysfunction, 
but studies assessing the impact of obesity on systolic chamber function (pump function) 
independent of conventional cardiovascular risk factors have produced conflicting 
outcomes (Peterson et al 2004, Wong et al 2004, Pascual et al 2003, Scaglione et al 
1992, de Divitiis et al 1981, Chakko 1998, Zarich et al 1991, Stoddard et al 1992, de 
Simone et al 1996, Mureddu et al 1996, Iacobellis et al 2002, Karason et al 1998) and 
any improvement in chamber systolic function with weight loss may be related to load-
induced effects (Alpert et al 1995). Moreover, even with the use of load-independent 
tissue Doppler measures of myocardial as opposed to chamber function (Skilton et al 
2007, Wong et al 2006), or with chamber function assessments (Willens et al 2005), 
weight loss produced by either lifestyle modification or gastric bypass does not influence 
left ventricular systolic function. Consequently, clarity is required on the role of obesity as 
a predictor of either myocardial systolic dysfunction or cardiac pump function. From a 
clinical perspective, a reduced cardiac pump function in otherwise well individuals is a 
well established risk factor for the development of heart failure (Hunt et al 2005). 
Consequently, there is an urgent need to assess the importance of obesity as an 
independent risk factor for the development of pump dysfunction. 
Clearly to solve the question of whether or not obesity induces cardiac pump 
dysfunction through non-conventional risk effects, an alternative approach may be 
required. Importantly, as indicated in the aforementioned discussion, neither human 
studies nor animal studies of obesity alone have been able to show an impact of excess 
adiposity on pump function in vivo independent of conventional cardiovascular risk 
factors including glucose control. However, what has not previously been considered is 
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the hypothesis that an interaction between hypertension and obesity may promote the 
progression from compensated cardiac hypertrophy to cardiac dilatation and pump 
dysfunction. What is the evidence to support this hypothesis? 
As shall be described in chapter 4, I was able to show that adiposity interacts 
with BP and arterial stiffness to promote increases in LVM and wall thickness. As LVH is 
a risk factor for pump dysfunction (Drazner et al 2004), it is possible that obesity may 
interact with hypertension to promote not only the development of LVH, but also pump 
dysfunction. Importantly, in studies demonstrating a conventional cardiovascular risk 
factor-independent relationship between obesity and myocardial systolic dysfunction, 
although obese participants may have been normotensive, they nevertheless still had 
higher BP values than lean participants (Skilton et al 2007, Peterson et al 2004, Wong et 
al 2004). In these studies (Skilton et al 2007, Peterson et al 2004, Wong et al 2004) no 
comment was made of potential interactions between adiposity indexes and BP. 
In support of an hypothesis that obesity interacts with BP to promote target organ 
damage is recent data to show that a nonsense mutation in the leptin receptor gene in 
spontaneously hypertensive rats (SHR), which induces marked obesity in these animals, 
results in an early nephropathy despite maintaining euglycaemia (Nagase et al 2006). 
Further, in young adults, although obesity and hypertension separately are associated 
with cardiac dilatation, a combination of obesity and hypertension is clearly required to 
induce marked increases in cardiac cavity dimensions (Haji et al 2006). In this regard, 
cardiac dilatation is now a well recognized determinant of pump dysfunction in pressure 
overload states (Norton et al 2002). Consequently, in the present thesis I hypothesized 
that an interaction between hypertension and obesity may promote the progression from 
compensated cardiac hypertrophy to cardiac dilatation and pump dysfunction. As this is 
not a question that can be answered in human studies in a single centre (it would require 
long-term follow-up and a very large study sample), I assessed this question in an 
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animal model of pressure overload hypertrophy studied in our laboratory over many 
years (Tsotetsi et al 2001, Badenhorst et al 2003b, Veliotes et al 2005). In this regard, 
the SHR is an animal model of compensated cardiac hypertrophy that ultimately 
develops pump dysfunction after many years (Tsotetsi et al 2001) or can be induced to 
develop premature cardiac dilatation and pump dysfunction following SNS and RAAS 
activation (Badenhorst et al 2003a, Veliotes et al 2005). As excess adiposity promotes 
SNS and RAAS activation, as described in chapter 5 of the present thesis I therefore 
assessed whether dietary-induced excess adiposity in SHR can promote the progression 
from compensated cardiac hypertrophy to cardiac dilatation and pump dysfunction and 
the mechanisms thereof. Importantly, this model of dietary-induced excess adiposity 
when studied in isolation does not lead to cardiac pump dysfunction as assessed in vivo 
(du Toit et al 2008). 
 
1.4.3.1 Potential mechanisms of an independent relationship between adiposity 
and cardiac dysfunction. 
 
As with LVM, haemodynamic factors that are not normally measured as part of 
risk assessment may mediate obesity-induced decreases in cardiac systolic or diastolic 
function. Indeed, as previously discussed, obesity may result in a decrease in total 
peripheral resistance and an increase in venous return (Messerli et al 1983, Carabello 
and Gittens 1987). As a consequence of the high venous return, dilatation of the 
chambers may occur, a change that could result in a reduction in pump function (Norton 
et al 2002). Further, as previously discussed, obesity promotes large artery stiffness and 
hence increases in cardiac afterload. The impact of changes in large artery function on 
the heart can be independent of BP as measured using conventional techniques 
(Libhaber et al 2008) as brachial artery BP does not closely reflect central BP. Thus, 
   
 
34 
haemodynamic changes in obesity could still account for a major portion of adiposity-
induced decreases in cardiac function that are not accounted for by conventional 
cardiovascular risk factors. 
With respect to a potential role of non-haemodynamic factors mediating obesity-
induced decreases in cardiac systolic or diastolic dysfunction, one potential mechanism 
is through the adverse effects of insulin on the myocardium or through myocardial insulin 
resistance. Indeed, fasting insulin concentrations are inversely correlated with tissue 
Doppler indexes of both systolic and diastolic myocardial function (Wong et al 2004). 
Furthermore, cardiac dysfunction may be induced by a high fat diet in association with 
alterations in myocardial insulin signalling in rats (Ouwens et al 2005). Second, although 
there is no direct evidence to support this notion, as adipose tissue promotes SNS and 
RAAS activation and both SNS and RAAS activation mediate cardiac dysfunction 
through a number of mechanisms (Veliotes et al 2005), again SNS and RAAS activation 
could mediate cardiac systolic and diastolic dysfunction independent of conventional 
cardiovascular risk factors. Indeed, an increased aldosterone production is thought to 
mediate, in-part, the interaction between obesity and hypertension to promote pre-
clinical renal target organ damage (Nagase et al 2006). Third, a reduced cardiac 
efficiency and an altered myocardial substrate metabolism may accompany obesity 
associated with leptin deficiency or leptin resistance (Buchanan et al 2005). These 
changes in myocardial substrate metabolism may contribute toward an increased 
cardiomyocyte apoptosis in obesity models of leptin deficiency or leptin resistance 
(Barouch et al 2006). The cardiomyocyte apoptosis in leptin resistant or leptin deficient 
animals is thought to occur through a reduced cardioprotection mediated by leptin, 
possibly induced via a resultant increase in ectopic lipid overload in cardiac myocytes 
(lipoapoptosis) (Zhou et al 2000). Cardiomyocyte apoptosis is now considered to be an 
   
 
35 
important pathophysiological process in heart failure (Foo et al 2005, Wencker et al 
2003).  
 
1.5 Summary of problem statements and hypotheses 
 
 The background to the problem statements tested and the hypotheses posed in 
the present thesis has been thoroughly described in the aforementioned discussion. 
However, before describing the studies performed in the present thesis it is worth 
summarizing these problem statements and hypotheses. As previously indicated, the 
present thesis was largely designed to address outstanding issues with respect to the 
role of obesity in promoting target organ changes through mechanisms that cannot be 
attributed soley to conventional cardiovascular risk factors. In this regard, as there is still 
considerable uncertainty as to whether excess adiposity may promote increases in 
arterial stiffness independent of confounders, in the present thesis I hypothesized that 
age may determine whether an excess adiposity promotes increases in arterial stiffness 
independent of confounders. Moreover, as there is still uncertainty as to the mechanism 
by which excess adiposity promotes the development of LVH independent of 
confounders, I also evaluated whether one potential mechanism is by enhancing the 
effects of haemodynamic factors (BP and arterial stiffness) on LVM. Having 
demonstrated a marked interaction between indexes of adiposity and haemodynamic 
factors to promote LVH, I subsequently posed the question as to whether similar 
interactions may promote the transition from compensated hypertensive LVH to cardiac 
decompensation. As it was necessary to account for adiposity-induced effects on BP 
when testing the impact of excess adiposity on arterial stiffness independent of BP and 
when assessing interactions between adiposity and BP to promote increases in LVM, in 
the first part of the thesis I initially identified the most appropriate adiposity index to 
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employ when accounting for adiposity-induced BP effects. This was necessary as it is 
controversial as to whether indexes of central or general obesity are best employed 
when evaluating the impact of adiposity on BP. Thus, the aims of the present thesis may 
be summarized as follows:  
 
 
1.6 Aims 
 
a) To identify whether indexes of central adiposity are associated with both 
conventional and ambulatory BP independent of other indexes of adiposity. 
These data are presented in chapter 2 and have been published in the Journal of 
Hypertension. 
 
b) To clarify whether age influences the independent relationship between adiposity 
and large artery dysfunction in a predominantly young-to-middle aged population 
sample with a high prevalence of excess adiposity. These data are presented in 
chapter 3 and have been published in the American Journal of Hypertension.  
 
c) To determine whether excess adiposity enhances the impact of haemodynamic 
changes on LVM. These data are presented in chapter 4. 
 
d) To determine whether obesity interacts with hypertension to promote the 
development of systolic cardiac dysfunction (pump dysfunction) and the 
mechanisms thereof. These data are presented in chapter 5. 
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CHAPTER 2 
 
The Association of Waist Circumference with Ambulatory Blood 
Pressure is Independent of Alternative Adiposity Indexes. 
 
 
 
Majane et al. Journal of Hypertension. 2007;25:1798-1806. 
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Abstract 
Whether indexes of central adiposity, including waist circumference (WC) or 
waist-to-hip ratio, are associated with BP independent of other clinical indexes of 
adiposity is controversial. As ambulatory BP may offer more prognostic information than 
conventional BP, I aimed to identify whether indexes of central adiposity are associated 
with both conventional and ambulatory BP independent of other indexes of adiposity. 
The relationship between indexes of adiposity (WC, waist-to-hip ratio, body mass index 
(BMI), or skin-fold thickness) and ambulatory (Spacelabs model 90207) or conventional 
BP was determined in 300 randomly selected subjects of African descent living in an 
urban developing community in South Africa. Relationships were determined with 
multiple indexes of adiposity in the same regression model and after adjusting for age, 
gender, alcohol and tobacco intake, the presence or absence of diabetes mellitus or 
inappropriate blood glucose control (HbA1c), antihypertensive therapy and menopausal 
status. 65% of subjects were overweight or obese. With respect to the relationships 
between indexes of adiposity, BMI and WC showed the strongest correlation (r=0.84, 
p<0.0001). After including all indexes of adiposity and confounders in the model, WC 
was the only clinical index of adiposity which independently predicted 24-hour (partial 
r=0.15, p<0.005) and conventional (partial r=0.14, p<0.005) systolic BP and 24-hour 
(partial r=0.13, p<0.02) and conventional (partial r=0.40, p<0.0001) diastolic BP. After 
adjusting for other adiposity indexes and confounders, every 1 SD (15 cm) increase in 
WC was associated with a 4.04 mm Hg increase in 24-hour systolic BP and a 4.33 mm 
Hg increase in 24-hour diastolic BP. In conclusion, WC is the only clinical index of 
adiposity that is associated with 24-hour BP independent of other adiposity indexes in a 
community with a high prevalence of obesity.  
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2.1        Introduction 
There is now substantial evidence from large-population-based studies in favour 
of excess adiposity being a major determinant of blood pressure (BP) and the 
development of hypertension (Zhu et al 2005, Okosun 1998 and Harris et al 2000). In 
this regard, present evidence suggests that waist circumference appears to be the 
preferred clinical index when relating adiposity to conventional BP (Zhu et al 2005, 
Okosun 1998, Harris et al 2000, Luke et al 1997, Williams et al 1987, Peiris et al 1989, 
Kanai et al 1990, Raison et al 1992, Boyko et al 1995, Lerario et al 1997, Ho et al 2001, 
Okosun et al 1999, Hayashi et al 2003 and Ding et al 2004). However, this has not, to 
my knowledge, been reproduced in all studies (Harris et al 2000). Moreover, studies that 
have compared the relative impact of indexes of central fat and body mass index (BMI) 
on ambulatory BP have either recruited small study samples, have been non-random, 
have focussed on waist-to-hip ratio rather than WC as the index of central fat, and have 
produced ambiguous results (Guagnano et al 1994, Guagnano et al 1997, Steptoe et al 
1999, Lurbe et al 1998 and Feldstein et al 2005). As twenty four-hour (24-hour) 
ambulatory BP is a better index of cardiovascular outcomes (Verdecchia et al 1994, 
Clement et al 2003, Staessen et al 1999 and Okhubo et al 1998) and target organ effects 
(Mancia and Parati 2000) than conventional BP values, the relative impact of indexes of 
central and general adiposity on ambulatory BP requires elucidation. In the present 
study I therefore assessed whether any one commonly used clinical index of adiposity 
(waist circumference, waist-to-hip ratio, BMI and skin-fold thickness) predicts 
conventional and ambulatory BP independent of the others. This study was conducted in 
a randomly selected population sample, with a high prevalence of obesity, living in an 
urban developing community in South Africa. 
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2.1 Methods 
Study participants. The study was approved by the University of the 
Witwatersrand Committee for Research in Human Subjects (approval number: M02-04-
72) and conducted according to the principles outlined in the Declaration of Helsinki. 
Participants gave informed, written consent. This study is part of the ongoing African 
Project on Genes in Hypertension which has previously been described (Shiburi et al 
2006, Maseko et al 2006). South Africans of black African ancestry from nuclear families 
of the predominant chiefdoms (tribes) of the area (Nguni, Sotho and Venda) with 
common ancestral backgrounds were randomly recruited from a metropolitan area of 
Johannesburg (South Western Townships-SOWETO). Nuclear families were recruited if 
at least one or two offspring of at least 17 years of age and one or both parents were 
available for examination. The analysis for the study was conducted in 2006 and was 
derived from the data base available at the end of 2005. Of the 496 South Africans of 
African ancestry randomly recruited by the end of 2005, 395 subjects had all clinical 
data. Of these participants 300 had more than 20 hours of ambulatory BP recordings 
and more than 10 and 5 readings for the computation of daytime and night-time means 
respectively.  
Clinical, demographic and anthropometric measurements. A standardized 
questionnaire was administered to obtain demographic data and information on each 
participant’s medical history, smoking habits, intake of alcohol, use of medication and 
menopausal status. The questionnaire was explained to families at an initial home visit 
and then subsequently completed in the presence of trained study assistants at an office 
visit where questions could be answered. At a second home visit, medications, and 
alcohol and tobacco in the household were compared against those reported on in the 
questionnaire. Menopause was confirmed with measurements of follicle stimulating 
hormone concentrations (Bayer, Leverkusen, Germany). 
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Height and weight were measured with the participants standing and wearing 
indoor clothes with no shoes. Body mass index (BMI) was calculated as weight in 
kilograms divided by the square of height in meters. Waist circumference was measured 
at the end of gentle expiration, at the point midway between the lowest rib and the iliac 
crest with the subject standing. Hip circumference was measured using a standard 
approach and waist-to-hip ratio calculated. Triceps and subscapular skin-fold thickness 
were determined using a Harpenden skin-fold callipers and the mean of these values 
obtained for statistical analyses. Participants were identified as being overweight if their 
BMI was ≥25 kg.m2 and obese if their BMI was ≥30 kg.m2. Standard laboratory blood 
tests of renal function, liver function, haematological parameters, blood glucose, lipid 
profiles and glycated haemoglobin (HbA1C) were performed. Diabetes mellitus or 
inappropriate blood glucose control was defined as the use of insulin or oral 
hypoglycaemic agents or a percentage HbA1C (Roche Diagnostics (Mannheim, 
Germany)>7.0% (Peters et al 1996). 
Conventional blood pressure (BP) measurements and heart rate. Trained 
observers measured brachial artery BP using a mercury sphygmomanometer as well as 
heart rate (HR) from the radial artery pulse. The participants were seated and asked to 
rest for 5 minutes. The observers measured the participants’ sitting BP and HR five 
consecutive times. Systolic and diastolic (phase V) BP were determined to the nearest 2 
mm Hg according to the recommendations of the European Society of Hypertension 
(O’Brien et al 2003). Standard cuffs with an inflatable bladder with a length of 22 cm and 
a width of 12 cm were used unless the arm circumference exceeded 31 cm, when larger 
cuffs with a 31 x 15 cm bladder were employed. The five readings were averaged to 
obtain a single systolic, diastolic and mean arterial BP reading and HR. 0.76% of visits 
had fewer than the planned conventional BP recordings. The frequency of identical 
consecutive conventional BP recordings was 0.25%. The occurrence of conventional BP 
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values recorded as an odd number was 0% and of the 3936 systolic and diastolic 
conventional BP readings, 27.8% ended on a zero (expected =20%). 
24-hour urine assessments. To determine 24-hour urine Na+ excretion (an index 
of Na+ intake), timed urine samples were obtained over a period of at least 24 hours after 
discarding urine excreted immediately prior to the start of the collection period. Urine Na+ 
concentrations were measured and 24-hour urine Na+ excretion rate calculated from the 
product of urine volume and urine Na+ concentration. The quality of the urine samples 
was determined as previously described (Maseko et al 2006 and Staessen et al 1988). 
Briefly, I constructed regression relations between 24-hour urine creatinine and body 
weight and 24-hour urine volume and age in gender-specific groups. Based upon the 
95% confidence intervals for each group, a 24-hour urine sample was considered 
acceptable if 24-hour urine creatinine (mmol) was >3.5 and <35 for males and >3.5 and 
<30 for females. Samples with urine volumes <300 mls/day were also assumed to be 
incomplete urine collections. These approaches are standard approaches and have 
been published by other groups (Stolartz et al 2004, Kuznetsova et al 2004). 
Ambulatory blood pressure measurements. Twenty four-hour ambulatory BP 
monitoring was performed using oscillometric monitors (Spacelabs, model 90207) 
performed on the same day as the conventional BP measurements. The size of the cuff 
was the same as that which was used for conventional BP measurements. The accuracy 
of ambulatory monitors was checked monthly against a mercury manometer. If the 
monitors recorded pressure values that deviated from a mercury reading by more than 4 
mm Hg, monitors were recalibrated by the commercial suppliers. The monitors were 
programmed to measure BP at 15-minute intervals from 06:00 to 22:00 and then 30-
minute intervals from 22:00 to 06:00. Subjects kept a diary card for the duration of the 
recordings to note the time of going to bed in the evening and getting up in the morning. 
From the subject’s diary card data we determined the awake and asleep periods. 
   
 
43 
Considering the patterns of daily activities, the daytime and night-time intervals were 
defined as time intervals ranging from 09:00 h to 19:00 h and from 23:00 h to 05:00 h 
respectively. These fixed clock-time intervals (Thijs et al 1992, Fagard et al 1996, Fagard 
et al 1997) were defined in order to eliminate the transition periods (evening and 
morning) during which BP changes rapidly in most subjects. Intra-individual means of the 
ambulatory measurements were weighted by the time-interval between successive 
recordings (Thijs et al 1992, Fagard et al 1996, Fagard et al 1997). Ambulatory BP data 
were expressed as 24-hour, daytime and night-time average systolic and diastolic BP. 
The average (±SD) number of BP recordings obtained was 63.4±10.6 (range=31–80)       
for the 24-hour period, 29.7±6.6 (range=11–41) for the fixed clock-time day interval, and   
9.5±0.9 (range=6 –10) for the fixed clock-time night interval. 
 Data analysis. Database management and statistical analyses were performed 
with SAS software, version 9.1 (The SAS Institute Inc., Cary, North Carolina, USA). Data 
from individual subjects were averaged and expressed as mean±SD. Proportions were 
compared with Х2 analysis. Linear regression analysis was used to determine 
relationships. Stepwise regression analysis was performed to determine independent 
effects of indexes of adiposity on BP. Included in the regression model were age, 
gender, alcohol and tobacco intake (defined as the presence or absence of daily tobacco 
or alcohol ingestion), postmenopausal status (confirmed with follicle stimulating hormone 
measurements), the presence or absence of diabetes mellitus or inappropriate blood 
glucose control (considered as a single covariate) and the use of antihypertensive 
therapy (either receiving therapy or not receiving therapy). Further adjustments of 
probability values were made for non-independence of family members using non-linear 
models (mixed procedure as described in the SAS software). To identify those indexes 
of adiposity associated with BP independent of other indexes of adiposity, indexes of 
adiposity were considered together in the regression model. In addition to including 
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antihypertensive therapy as a covariate in the regression analysis, sensitivity analyses 
were repeated in a subgroup of participants who were not receiving antihypertensive 
therapy (n=273). 
 
2.2 Results 
Characteristics of the participants. Table 2.1 gives the demographic and clinical 
characteristics of the participants. More women than men participated. Sixty five percent 
of subjects were overweight or obese, with 27.6% being overweight and 37.7% being 
obese. In the group 42% were hypertensive, 20% were receiving therapy for 
hypertension, and 8% had diabetes mellitus. A relatively small percentage of the group 
were smokers (12%), mostly due to lack of affordability and also due to the greater 
proportion of women (who traditionally don’t smoke in this population) compared to men. 
24-hour urine Na+ excretion rates (an index of Na+  intake) despite being high, were not 
associated with indexes of obesity (r values: BMI=0.05; waist circumference=0.003; skin-
fold thickness=0.003; waist-to-hip ratio=0.11; p>0.1 for all). The mean age (41.4±17.9 
years) and BMI (28.9±7.3 kg/m2) and the percentage women (63%) in all subjects 
recruited was the same as that for subjects with all clinical data (Table 2.1). The 
demographic and clinical characteristics of the subjects with ambulatory BP 
measurements that met pre-specified quality control criteria were similar to those of 
subjects with all clinical data (Table 2.1). In addition, although they were younger 
(38.1±16.5 years), fewer individuals had hypertension (26%), and there were fewer 
postmenopausal women (29%), the other demographic and clinical characteristics in the 
participants not receiving antihypertensive therapy (n=237) did not differ from those of 
either the participants with ambulatory BP measurements or those with all clinical data 
(data not shown). Average conventional systolic and diastolic BP values were higher  
than average 24-hour, day or night-time systolic and diastolic BP values (Table 2.1). 
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Association between indexes of adiposity. As with the data described in chapters 
2 and 3, BMI and waist circumference showed the strongest relationship in the cohort 
described in the present study (Table 2.2). The weakest relationship was noted between  
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Table 2.1. Demographic, anthropometric and clinical characteristics of study subjects. 
                        All subjects         Subjects with ambulatory BP  
______________________________________________________________________ 
Sample number    395   300 
% Female     63   63    
Age (years)     41.8±18.1  43.0±17.9  
Height (cm)      161±9   161±9  
Weight (kg)     75±19   75±19  
BMI (kg/m2)     28.8±7.4  29.0±7.4  
Waist circumference (cm)   89±15   89±15  
Hip circumference (cm)    107±15  106±15   
WHR      0.84±0.10  0.84±0.10 
% Overweight/obese    65   66 
Skin-fold thickness (cm)  
Subscapular    2.41±1.37  2.47±1.36  
   Triceps    1.90±1.20  2.01±1.25 
Mean     2.15±1.16  2.24±1.19 
Urine Na+ excretion (mmol/day)  113.9±53.5  110.4±48.1 
% smokers     12.2   12.7 
% alcohol*     21.2   22.3 
% with hypertension    42.0   41.7 
% treated for hypertension   20.3   21.0 
% with DM     8.2   8.1  
HbA1C (%)     6.02±1.07  6.04±1.07 
n (%) postmenopausal   98 (25)   78 (27) 
Clinic SBP/DBP (mm Hg)    130±23/84±12  131±23/84±12 
Ambulatory BP (mm Hg) 
24 hour SBP/DBP (mm Hg)    -   119±16/73±11 
Daytime SBP/DBP (mm Hg)     -   123±16/78±11 
Night-time SBP/DBP (mm Hg)   -   112±18/65±12 
BMI, body mass index; WHR, waist-to-hip ratio; DM, diabetes mellitus; HbA1C, glycated 
haemoglobin; SBP, systolic BP; DBP, diastolic BP; * refers to % who consume alcohol 
on a daily basis. 
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Table 2.2. Correlation matrix between indexes of adiposity in the present study group 
(n=300). 
 
                                                WC (cm)     WHR    Mean skin-fold thickness 
______________________________________________________________________ 
Body mass index (kg/m2)  0.84**       0.18*        0.66** 
Waist circumference (WC) (cm)  -       0.58**        0.58** 
Waist-to-hip ratio (WHR)  -         -         0.11† 
______________________________________________________________________ 
WC, waist circumference, WHR, waist-to-hip ratio. Numbers are correlation coefficients 
(r). *p<0.01, **p<0.0001 for the relationships. †p=0.058.  
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waist-to-hip ratio and BMI. Furthermore, only a trend effect was noted between waist-to-
hip ratio and skin-fold thickness (Table 2.2). 
Unadjusted associations between indexes of adiposity and BP. Body mass index, 
waist circumference, waist-to-hip ratio and skin-fold thickness were all correlated with 
conventional systolic BP (Figure 2.1). However, BMI, waist circumference and waist-to-
hip ratio, but not skin-fold thickness, were correlated with 24-hour systolic BP (Figure 
2.2). Significant correlations between either BMI (r=0.35, p<0.0001), waist circumference 
(r=0.41, p<0.0001), waist-to-hip ratio (r=0.27, p<0.0001) or skin-fold thickness (r=0.25, 
p<0.0001) and conventional diastolic BP were also noted before adjustments. However, 
BMI (r=0.17, p=0.0031), waist circumference (r=0.28, p<0.0001), and waist-to-hip ratio 
(r=0.23, p<0.0001), but not skin-fold thickness (r=0.09, p=0.14) were correlated with 24-
hour diastolic BP. Significant unadjusted correlations were noted between body weight 
and conventional BP (SBP: r=0.29, p<0.0001, DBP: r=0.32, p<0.0001), 24-hour BP 
(SBP: r=0.20, p=0.0005, DBP: r=0.16, p=0.0052), daytime BP (SBP: r=0.20, p=0.0005, 
DBP: r=0.15, p=0.011), and night-time BP (SBP: r=0.18, p=0.0016, DBP: r=0.18, 
p=0.0019). The unadjusted associations between indexes of adiposity and BP in the 
subgroups of participants who were not receiving antihypertensive therapy (data not 
shown) were similar to those in the group of participants with ambulatory BP. 
Conventional and ambulatory BP and indexes of adiposity in separate models. 
When considering indexes of adiposity in separate regression models, but adjusting for 
other confounders, BMI, waist circumference and skin-fold thickness were independent 
predictors of conventional systolic and diastolic BP; whereas waist-to-hip ratio was only 
associated with conventional diastolic BP (Table 2.3). Waist circumference was the only 
index of adiposity associated with 24-hour systolic and diastolic BP after adjustments for 
other covariates (Table 2.3). Nevertheless, the relationship between BMI and 24-hour 
systolic BP was close to significant (Table 2.3). Analyses of daytime and night-time  
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Figure 2.1. Relationships between indexes of adiposity and conventional systolic blood 
pressure (SBP) in study subjects (n=300). BMI, body mass index; WHR, waist-to-hip 
ratio. 
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Figure 2.2. Relationships between indexes of adiposity and 24-hour ambulatory systolic 
blood pressure (SBP) in study subjects (n=300). BMI, body mass index; WHR, waist-to-
hip ratio. 
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Table 2.3. Partial correlation coefficients (r) for the relationship between indexes of adiposity considered separately in the regression 
model and systolic (SBP) or diastolic blood pressure (DBP) in the study group (n=300). 
  
                                        Partial r * p value*     Partial r*   p value*  Partial r*   p value* Partial r*   p value* 
              Conventional SBP (mm Hg)  24 hour SBP (mm Hg)   Daytime SBP (mm Hg)  Night-time SBP (mm Hg) 
Waist circumference (cm)       0.13 <0.005                  0.14       0.009  0.14     0.009    0.11     0.031 
Body mass index (kg/m2)       0.13  <0.01        0.10       0.054  0.09     0.098    0.09     0.088  
Waist-to-hip ratio        0.05  0.255              0.08       0.107  0.10     0.055    0.08     0.151  
Mean skin-fold thickness (cm)     0.12  <0.01         0.05       0.373  0.05     0.332    0.03     0.606 
         Conventional DBP (mm Hg)   24 hour DBP (mm Hg)   Daytime DBP (mm Hg) Night-time DBP (mm Hg) 
Waist circumference (cm)       0.41          <0.0001               0.12       0.033  0.13     0.018   0.11     0.048 
Body mass index (kg/m2)       0.21          <0.0001        0.06       0.231             0.06     0.314   0.06     0.237 
Waist-to-hip ratio        0.12   0.029        0.08       0.162  0.10     0.062   0.09     0.115 
Mean skin-fold thickness (cm)     0.17   0.002        0.02       0.675             0.03     0.637   0.03     0.584 
_________________________________________________________________________________________________________ 
The p values indicated in bold are significant. * from stepwise regression analysis including indexes of adiposity considered 
separately and age, gender, alcohol and tobacco intake, postmenopausal status (confirmed with follicle stimulating hormone 
measurements), the presence or absence of diabetes mellitus or inappropriate blood glucose control, and the use of antihypertensive 
therapy in the regression model. 
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systolic and diastolic BP revealed similar results, with waist circumference being the only 
index of adiposity associated after adjustments for other covariates (Table 2.3). Similar 
results were observed in the subgroup of participants not receiving antihypertensive 
therapy (data not shown) 
Although, body weight was associated with conventional BP (systolic BP: partial 
r=0.10, p=0.03; diastolic BP: partial r=0.21, p<0.0001), no associations with 24-hour, 
daytime or night-time systolic and diastolic BP were noted after adjustments for other 
covariates. 
Conventional and ambulatory BP and indexes of adiposity in the same model. The 
independent relationship between waist circumference and either conventional or 24-hour 
BP (Table 2.3) persisted after BMI, waist-to-hip ratio and skin-fold thickness were included 
in the model (Figure 2.3, left panels). In contrast, neither BMI nor skin-fold thickness were 
associated with clinic or 24-hour BP after adjusting for waist circumference and waist-to-
hip ratio (Figure 2.3, left panels). Similarly, in the subgroup of participants not receiving 
antihypertensive therapy, waist circumference was independently related to either 
conventional or 24-hour BP after BMI, waist-to-hip ratio and skin-fold thickness were 
included in the model (Figure 2.3, right panels). In contrast, neither BMI, nor skin-fold 
thickness were significantly associated with either clinic or 24-hour BP after adjusting for 
waist circumference and waist-to-hip ratio (Figure 2.3, right panels). In addition, the 
independent relationship between waist circumference and either day or night BP 
persisted after BMI, waist-to-hip ratio and skin-fold thickness were included in the model 
(in all participants with ambulatory BP data the partial correlation coefficients for waist 
circumference and daytime SBP were: r=0.16, p=0.025; daytime DBP: r=0.15, p=0.009; 
night-time SBP: r=0.10, p=0.058; night-time DBP: r=0.12, p=0.027; in participants not 
receiving antihypertensive therapy, the partial correlation coefficients for waist 
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Figure 2.3. Partial correlation coefficients (r) and 95% confidence intervals for the 
relationship between indexes of obesity and conventional (BPc) or 24-hour (BP24) systolic 
and diastolic blood pressure after including all indexes of adiposity together in the 
regression equation. Partial correlation coefficients are after adjustments for other 
confounders (see Table 2.3 for additional confounders) in the study group (n=300, left 
panels) and in the subgroup not receiving antihypertensive therapy (untreated subjects, 
n=237, right panels). BMI, body mass index; skin-fold, skin-fold thickness; WC, waist 
circumference; WHR, waist-to-hip ratio. p values are for significant independent 
relationships. 
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circumference and daytime SBP were: r=0.18, p=0.002; daytime DBP: r=0.14, p=0.018; 
night-time SBP: r=0.17, p=0.005; night-time DBP: r=0.14, p=0.015). 
Predicted size effects of indexes of adiposity on ambulatory BP. The size effects of 
waist circumference on 24-hour ambulatory systolic BP associated with a 15cm (~1 SD) 
increase in waist circumference were partially improved on after further adjusting for skin-
fold thickness, waist-to-hip ratio and BMI (Figure 2.4A). Before adjusting for BMI, waist-to-
hip ratio and skin-fold thickness, every 1 SD (15 cm) increase in waist circumference was 
associated with a 2.46 mm Hg increase in 24-hour systolic BP (Figure 2.4A). In 
comparison, after adjusting for skin-fold thickness, BMI and waist-to-hip ratio, every 1 SD 
(15 cm) increase in waist circumference was associated with a 4.04 mm Hg increase in 
24-hour systolic BP (Figure 2.4A). In contrast, the size effects of BMI on 24-hour 
ambulatory systolic BP associated with a 7.4 kg/m2 (~1 SD) increase in BMI were 
considerably reduced after adjusting for WC and waist-to-hip ratio (Figure 2.4B). Similarly, 
before adjusting for BMI, waist-to-hip ratio and skin-fold thickness, every 1 SD (15 cm) 
increase in waist circumference was associated with a 1.55 mm Hg increase in 24-hour 
diastolic BP (Figure 2.4C); whereas, after adjusting for skin-fold thickness, BMI and waist-
to-hip ratio, every 1 SD (15 cm) increase in waist circumference was associated with a 
4.33 mm Hg increase in 24-hour diastolic BP (Figure 2.4C). In contrast, the size effects of 
BMI on 24-hour ambulatory diastolic BP associated with a 7.4 kg/m2 (~1 SD) increase in 
BMI were considerably reduced after adjusting for waist circumference and waist-to-hip 
ratio (Figure 2.4D). 
 The analyses in the group not receiving antihypertensive therapy were similar, with 
every 1 SD (14.7 cm) increase in waist circumference was associated with a 2.69 and 1.57 
mm Hg increases in 24-hour systolic and diastolic BP, respectively, compared to increases 
of 4.74 and 4.62 mm Hg in 24-hour systolic and diastolic BP, respectively after adjusting 
for BMI, waist-to-hip ratio and skin-fold thickness. In contrast, the effects of BMI on 24-
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hour ambulatory systolic (1.96 mm Hg) and diastolic (0.98 mm Hg) BP associated with a 
6.8 kg/m2 (~1 SD) increase in BMI were considerably reduced after adjusting for WC and 
waist-to-hip ratio (-2.01 and 2.42 for systolic and diastolic BP, respectively). 
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Figure 2.4. Unadjusted (unadj.) and adjusted differences in 24-hour systolic (SBP) and 
diastolic (DBP) blood pressure associated with one standard deviation (SD) increase in 
waist circumference (WC) - panels A and C, SD~15cm) or body mass index (BMI – panels 
B and D, SD~7 kg/m2) in the study group (n=300). Alcoh., alcohol intake; Smoke, tobacco 
intake; Menop, menopausal status; DM, presence or absence of diabetes mellitus or 
inappropriate blood glucose control; HT-Trt, hypertension treatment; Skin-fold, skin-fold 
thickness; WHR, waist-to-hip ratio. *p<0.05, ** p<0.005. 
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2.4 Discussion 
The main findings of the present study are that waist circumference is the only 
clinical index of adiposity that was associated with an increased ambulatory systolic and 
diastolic BP independent of other indexes of adiposity. 
 A recent large study conducted in a European population in which abdominal fat 
effects were not assessed, has demonstrated convincingly that BMI is associated with 
ambulatory BP (Kotsis et al 2005). However, the present study is the first conducted in a 
relatively large, randomly selected population sample that has explored whether the 
relationship between ambulatory BP and indexes of central adiposity (waist circumference 
and waist-to-hip ratio) are independent of other indexes of adiposity. In this regard, the 
relationship between WC and 24-hour BP was independent of BMI and skin-fold thickness, 
whereas the relationship between BMI and 24-hour BP was masked by adding waist 
circumference to the regression equation. As ambulatory BP is a better index of 
cardiovascular outcomes (Verdecchia et al 1994, Clement et al 2003, Staessen et al 1999 
and Okhubo et al 1998) and target organ effects (Mancia et al 2000) than conventional BP 
values, these data support an important role for the use of waist circumference when 
predicting the BP that is more closely associated with cardiovascular outcomes and target 
organ damage than conventional BP. 
Prior studies conducted in small, non-random samples have explored whether 
waist-to-hip ratio is associated with ambulatory BP independent of BMI (Guagnano et al 
1994, Guagnano et al 1997, Steptoe et al 1999, Lurbe et al 1998 and Feldstein et al 
2005). Some of these studies have suggested that waist-to-hip ratio is independently 
related to ambulatory BP in both adults (n=51-97) (Guagnano et al 1994, and Guagnano 
et al 1997) and in 140 children (Lurbe et al 1998), findings not supported by the present 
study. On the other hand, consistent with the present study, some previous studies have 
demonstrated that waist-to-hip ratio is not independently associated with ambulatory 
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systolic or diastolic BP in 156 school-teachers (Steptoe et al 1999)  and 357 untreated 
hypertensives (Feldstein et al 2005). The lack of consistent relationship between waist-to-
hip ratio and ambulatory BP may be explained by the poor relationship between visceral 
fat mass and waist-to-hip ratio (Kvist et al 1988, Seidell et al 1988, Pouliot et al 1994, 
Wajchenberg et al 2000 and Stewart et al 2003). In this regard, some studies have 
highlighted the critical role of visceral fat mass in mediating BP changes (Williams et al 
1987, Peiris et al 1989, Kanai et al 1990, Raison et al 1992, Boyko et al 1995, Lerario et al 
1997, Okosun et al 1999, Ho et al 2001, Hayashi et al 2003, Ding et al 2004). 
Three possibilities may explain the independent relationship between waist 
circumference, but not BMI with BP in the present and in previous (Zhu et al 2005 and 
Okosun et al 1998) studies. First, an inconsistent relationship between BMI and adiposity 
may occur, particularly in populations of African descent (Luke et al 1997). Thus BMI may 
not be a reliable index of adipose tissue mass in some populations. Second, as visceral fat 
mass may be important in mediating BP changes (Williams et al 1987, Peiris et al 1989, 
Kanai et al 1990, Raison et al 1992, Boyko et al 1995, Lerario et al 1997, Okosun et al 
1999, Ho et al 2001, Hayashi et al 2003 and Ding et al 2004), it is also possible that BMI is 
not that closely related to the fat compartment that contributes to BP. However, in the 
present study the correlation coefficient between waist circumference and BMI was 
remarkably strong (r=0.84). Third, the association between BMI and BP could be 
tempered by the presence of a genotype that moderates the relationship (Tiago et al 2003) 
or a genotype that increases the association between waist circumference and BP. 
 The lack of independent relationship between skin-fold thickness and BP in the 
present study may also be explained by the close relationship between visceral fat and BP 
(Williams et al 1987, Peiris et al 1989, Kanai et al 1990, Raison et al 1992, Boyko et al 
1995, Lerario et al 1997, Okosun et al 1999, Ho et al 2001, Hayashi et al 2003 and Ding et 
al 2004). Skin-fold thickness is an index of subcutaneous peripheral fat and as indicated in 
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the present study, has a poor correlation with indexes of central fat. Interestingly, when 
indexes of adiposity were considered separately in the regression model, skin-fold 
thickness and conventional systolic and diastolic BP were correlated, whereas skin-fold 
thickness and ambulatory BP were not. These data would suggest that although 
peripheral/subcutaneous fat is associated with resting BP, it is not associated with 
ambulatory BP. 
 As compared to ambulatory BP, conventional BP is more likely to reflect an 
increased sympathetic activity associated with the alerting reaction (Weber et al 1994), 
and sympathetic overactivation has been shown to be associated with obesity (Tentolouris 
et al 2006). Thus, the closer relationship between skin-fold thickness and conventional BP 
as compared to skin-fold thickness and ambulatory BP in the present study may be 
explained by an increase in sympathetic activity associated with the measurement of 
conventional BP (alerting reaction). Similarly, the colser relationship between waist 
circumference asnd conventional diastolic BP as compared to waist circumference and 
ambulatory diastolic BP in the present study may also be explained by an increase in 
sympathetic activity associated with the measurement of conventional diastolic BP.  
 The limitations of the present study include the cross-sectional design. Moreover, 
more direct measures of visceral fat (such as computed tomography) were not employed. 
However, the present study was not designed to determine the impact of visceral fat on 
ambulatory BP, but rather to identify which clinical index of adiposity is independently 
associated with ambulatory BP. The relatively lower proportion of males as compared to 
females recruited in the present study also raises the question as to whether the outcomes 
of the present study may only apply to females. The lower sample of males prevented us 
from performing gender-specific analysis with confidence in the outcomes. However, it is 
well recognised that obesity in males is more frequently accompanied by central rather 
than peripheral fat accumulation. Hence, the outcomes of the present study are unlikely to 
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be through an effect noted only in females. As this study was performed in a population 
sample of African ancestry with a high prevalence of hypertension (42%) and a high 
proportion of participants who were overweight or obese (66%), these data may not be 
applicable to other populations with a different prevalence of hypertension or obesity. 
In conclusion, the present study indicates that waist circumference is the only 
clinical index of adiposity that is associated with ambulatory systolic and diastolic BP 
independent of other indexes of adiposity. Therefore, the present data suggest that waist 
circumference is the index of adiposity to use when assessing the impact of excess 
adiposity on ambulatory BP, a BP measurement that is more closely associated with 
cardiovascular outcomes than is conventional BP. 
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Abstract 
There is uncertainty as to whether age influences the independent relationship 
between adiposity and pulse wave velocity (PWV). I therefore explored the impact of age 
on the independent relations between indexes of central (waist circumference [WC] and 
waist-to-hip ratio [WHR]), general (body mass index) or subcutaneous (skin-fold thickness) 
adiposity and PWV, or augmentation index (AI) in 508 randomly selected subjects greater 
than 16 years of age in a population sample of African ancestry with a high prevalence of 
excess adiposity (~63% overweight or obese). Applanation tonometry was performed at 
the radial, carotid and femoral arteries, from which PWV, and central (AIc) or peripheral 
(AIp) AI were derived. Multivariate relations were determined in sex-specific groups with 
confounders. ~22% of the sample were receiving antihypertensive therapy and ~8% had 
diabetes mellitus or an HbA1c>7.0%. In women a strong interaction between age and 
either WC or WHR was associated with log PWV independent of confounders and the 
individual terms (r=0.68, p<0.0001). This translated into a markedly greater increase in 
logPWV with increases in either WHR or WC in women older as compared to women 
younger than the median age (slopes of WHR-logPWV relations=0.37±0.13 vs -0.16±0.11, 
p<0.005; slopes of WC-logPWV relations=0.0030±0.0009 vs -0.0009±0.0007, p<0.002). In 
women older than the median age for the group, one SD increase in WC (12.8 cm) 
translated into a 0.69 m/sec increase in PWV as compared to a 0.16 m/sec decrease in 
PWV for each one SD increase in WC (13.0 cm) in women younger than the median age. 
No index of adiposity was independently associated with the log of AIc, or AIp. In 
conclusion, in women of African ancestry, age has a marked effect on the independent 
relationship between indexes of central adiposity and PWV, with a greater independent 
effect of adiposity noted in older as compared to younger women. 
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3.1 Introduction 
As underscored in chapter 1 of the present thesis, excess adiposity contributes to 
adverse cardiovascular outcomes (Kurth et al 2002, Wilson et al 2002, National Task 
Force on the Prevention and Treatment of Obesity 2000) not only by promoting the 
development of conventional cardiovascular risk factors (National Task Force on the 
Prevention and Treatment of Obesity 2000), but also through alternative effects. One such 
effect may be through an increase in arterial stiffness (Sutton-Tyrrell et al 2001, Ferreira et 
al 2004, Mackey et al 2002, Wildman et al 2003, Czernichow et al 2005, Ferreira et al 
2004, Snijder et al 2004, Zebekakis et al 2005, Cosson et al 2007, Toto-Moukouo et al 
1986), a change that augments central artery systolic blood pressure (BP) through early 
wave reflections and hence increases cardiac and large vessel loads. Importantly, arterial 
stiffness determines cardiovascular outcomes independent of conventional BP (de Simone 
et al 1999, Laurent et al 2001, Boutouyrie et al 2002, London et al 2001, Safar et al 2002, 
Guerin et al 2001) as conventional BP measurements do not accurately reflect central 
artery BP values (Karamanoglu et al 1993, Williams et al 2006). 
Despite the consistency in the reports demonstrating relations between indexes of 
adiposity and arterial stiffness, there is controversy as to whether this relationship is 
independent of factors such as BP, heart rate (HR), and diabetes mellitus. In this regard, 
although adiposity is associated with pulse wave velocity (PWV), a simple and reliable 
index of arterial stiffness that is a strong independent predictor of cardiovascular outcomes 
(Blacher et al 1999a, Laurent et al 2001, London et al 2001, Guerin et al 2001, 
Cruickshank et al 2002, Boutouyrie et al 2002, Sutton-Tyrrell et al 2005), some studies 
have (Sutton-Tyrrell et al 2001, Mackey et al 2002, Wildman et al 2003, Ferreira et al 
2004), whilst most others have not (Ferreira et al 2004, Zebekakis et al 2005, Taquet et al 
1993, Amar et al 2001, Nakanishi et al 2003, Oren et al 2003, Mitchell et al 2004, 
Czernichow et al 2005) been able to demonstrate strong relations between adiposity 
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indexes and PWV independent of haemodynamic factors and diabetes mellitus. 
Nevertheless, convincing independent relations between clinical indexes of adiposity and 
PWV have been obtained in elderly populations (Sutton-Tyrell et al 2001, Mackey et al 
2002), whilst substantial evidence against a strong independent relationship between 
adiposity and PWV has been noted in samples that are predominantly young-to-middle 
aged (Ferreira et al 2004, Zebekakis et al 2005, Taquet et al 1993, Amar et al 2001, 
Nakanishi et al 2003, Oren et al 2003, Mitchell et al 2004, Czernichow et al 2005). Thus, 
the haemodynamic and glucose control-independent effect of adiposity on PWV may be 
age-dependent. Consequently, in the present study I sought to determine whether age 
influences the independent relationship between adiposity indexes and PWV or other 
indexes of large artery dysfunction. 
3.2 Methods 
Study participants, demographic and clinical data. The study design and most of 
the methodology for the present study, including the questionnaire, blood measurements 
and BP measurements, has been described in chapter 2 (section 2.2). Importantly, the 
analysis for the present study was conducted in 2007 on 671 participants recruited up until 
November 2006. Pulse wave velocity could not be determined on 163 participants, 110 of 
whom were women, because they were either too obese or had a bradycardia. I discarded 
73 (38 were women) because the recorded peripheral (AIp) or central (AIc) AI was of 
insufficient quality. Therefore, the overall number of participants statistically analyzed 
totalled 508 (310 women) for the carotid-femoral PWV and 598 (388 women) for AIc, AIp, 
and central systolic and diastolic BP and pulse pressure (PP). 
With respect to conventional BP measurements, in the present study 2% of visits 
had fewer than the planned BP recordings. The frequency of identical consecutive 
recordings was 1.58% for systolic BP and 2.96% for diastolic BP. The occurrence of BP 
values recorded as an odd number was 0%. Of the 4988 systolic and diastolic BP 
  
65 
readings, 28.3 % ended on a zero (expected =20%). 
 Pulse wave analysis. Details of the technique employed to determine carotid-
femoral PWV, AIc and AIp have previously been published (Shiburi et al 2006). All 
measurements were made by a single experienced observer unaware of the clinical 
history of the participants. Briefly, after subjects rested for 15 minutes in the supine 
position, the radial waveform at the dominant arm was recorded by applanation tonometry 
during an 8-second period using a high-fidelity SPC-301 micromanometer (Millar 
Instrument, Inc., Houston, Texas) interfaced with a computer employing SphygmoCor, 
version 6.21 software (AtCor Medical Pty. Ltd., West Ryde, New South Wales, Australia) 
(Figure 3.1). Recordings where the systolic or diastolic variability of consecutive 
waveforms exceeded 5% or the amplitude of the pulse wave signal was less than 80 mV 
were discarded. The pulse wave was calibrated by manual measurement (auscultation) of 
BP immediately before the recordings. From the radial signal, SphygmoCor software 
calculates the aortic pulse wave by means of a validated and population-based 
generalized transfer function. The radial (peripheral arterial) AI (AIp) was defined as the 
ratio of the second to the first peak of the pressure wave expressed as a percent. The AIc 
was determined from the difference between the second and the first systolic peak given 
as a percentage of the aortic pulse pressure (Figure 3.2).  
Peripheral (PPp) and central (PPc) pulse pressures (PP) were defined as the 
difference between systolic and diastolic BP derived from the brachial or central BP 
respectively. The central systolic and diastolic BP were obtained from the aortic pulse 
wave. Central mean arterial pressure (MAPc) was calculated from central diastolic BP + 
[(central systolic BP-central diastolic BP)/3]. Pulse wave velocity (PWV) was determined 
from carotid and femoral waveform measurements. The distance travelled by the pulse 
wave was measured over the body surface as the distance between the recording sites at 
the femoral artery to the suprasternal notch minus the distance from the  
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A         Applanation tonometer to derive pulse waves. 
   B ECG electrodes to determine the timing of pulse waves. 
    C SphygmoCor device used to amplify pulse waves. 
                            D         Computer showing arterial pulse waves. 
 
Figure 3.1 Hardware used to perform pulse wave analysis. A is placed over either radial, 
femoral or carotid arteries and via C derives pulse waves shown in D. Further analysis is 
determined from a simultaneous electrocardiogram (ECG) obtained from B and this 
analysis is explained in the text and in Figure 3.2.  
A 
C 
B 
D 
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Figure 3.2. Shows the derivation of pulse transit time and central augmentation index 
(AIc) obtained from pulse wave analysis performed at the carotid, femoral and radial 
arteries. 
Femoral pulse wave 
Carotid pulse wave 
A 
B 
Carotid femoral pulse transit time=B-A 
Radial pulse wave 
Radial pulse wave is converted to an 
aortic pulse wave via a population-based 
transfer function 
C 
D 
AIc=C/D x 100 
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recording site at the carotid artery to the suprasternal notch (D). The time (t) taken for the 
pulse wave to travel from the carotid to the femoral site (pulse transit time) was 
determined from the differences in the times taken to generate the femoral and carotid 
pulse waveforms (Figure 3.2). To assess time differences in the generation of carotid and 
femoral waveforms, these waveforms were matched to a simultaneous electrocardiograph 
recording (B in Figure 3.1). Pulse transit times were determined from an average of 10 
consecutive beats. Aortic PWV was calculated as PWV = D/t. 
 Intra-observer variability was assessed on 25 participants on who repeat pulse 
wave analysis was performed within a two week period of the initial measurements. The 
Pearson’s correlation coefficients for carotid-femoral PWV, AIc, AIp, central systolic BP 
and central PP were 0.86, 0.81, 0.89, 0.92 and 0.75 (all p<0.0001) respectively, and the 
variances (mean % difference ± SD) were 2.66±10.54%, 0.49±33.01%, 1.37±10.28%, 
1.48±5.81% and 1.35±23.02% respectively. In addition, no significant differences between 
repeat measurements were evident on paired t-test analysis (p=0.14, p=0.58, p=0.38, 
p=0.25 and p=0.86 respectively). 
Data analysis. Database management and statistical analyses were performed with 
SAS software, version 9.1 (The SAS Institute Inc., Cary, North Carolina, USA). Data from 
individual participants were averaged and expressed as mean±SD. The X2-statistic was 
used to compare proportions. Stepwise regression analysis was performed to determine 
the contribution of indexes of adiposity and other factors to PWV, or AI. Again this analysis 
was conducted in sex-specific groups as previous studies have shown that adiposity 
indexes may be related to PWV and AI in a sex-specific manner (Mackey et al 2002, 
Zebekakis et al 2005, Protogerou et al 2007). In the present analysis, as PWV, AIc or AIp 
were not normally distributed, they were log-transformed. Included in the regression 
models were those adjustors described in chapter 2 including indexes of adiposity, age, 
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antihypertensive therapy, height (except when using BMI in the model), regular tobacco 
and alcohol use, menopausal status, and oral contraceptive use. However, in addition, to 
assess whether adiposity indexes are associated with indexes of large artery dysfunction 
independent of haemodynamic factors and glucose control, included as adjustors in the 
regression models were MAPc, HR, and the presence or absence of diabetes mellitus or 
an abnormal blood glucose control. In secondary analysis in 440 participants whom had 
complete lipid profiles, total/HDL cholesterol was included as an additional confounder in 
the model. Further adjustments of probability values were made for non-independence of 
family members using non-linear models (mixed procedure as described in the SAS 
software). To determine whether age influences the independent relationship between 
adiposity indexes and PWV, I tested for an interaction between age and indexes of 
adiposity as independent predictors of PWV in sex-specific groups. In this analysis the 
same aforementioned factors were included in the regression relations as well as the 
independent terms for age and adiposity indexes.  
3.3       Results 
Characteristics of the participants. Table 3.1 gives the demographic and clinical 
characteristics of the participants. More women than men participated. A high proportion of 
participants were overweight or obese, with excessive adiposity noted more frequently in 
women than in men and with women having greater values for all indexes of adiposity 
except for waist-to-hip ratio which was higher in men. Of the women 112 (~36%) were 
postmenopausal as confirmed with follicle stimulating hormone measurements. 7.1% of 
women were receiving oestrogen contraception, but none were receiving hormone 
replacement therapy. A greater proportion of women than men were hypertensive. On 
average 22% of participants were receiving antihypertensive therapy with a greater 
proportion of women than men receiving antihypertensive medication. On average ~8% 
were either receiving therapy for diabetes mellitus or had an HbA1c >7.0%, with 
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Table 3.1. Demographic, anthropometric and clinical characteristics of study subjects with 
pulse wave velocity measurements.  
              Women      Men 
____________________________________________________________________ 
Number      310      198   
Age (years)            42.0±17.8   41.3±19.4  
Height (cm)           157.2± 6.8   168.5±7.5* 
Weight (kg)           74.7± 18.8   71.3±15.0* 
Body mass index (kg/m2)          30.4± 7.2   25.1±5.0*  
Waist circumference (cm)         90.0± 15.4   85.4±14.0* 
Hip circumference (cm)        110.6± 14.6   97.0±10.9*  
Waist-to-hip ratio         0.81± 0.09   0.86±0.10* 
Skin-fold thickness (cm) Subscapular      2.1± 1.1   1.2±1.0* 
         Triceps       2.7± 1.4   1.9±1.2* 
                            Mean       2.4± 1.1   1.6±1.0* 
% overweight/obese               24/49       30/18* 
% regular tobacco use     3.2        31.9* 
% regular alcohol consumption   14.2        36.4* 
% postmenopausal     36           - 
% oestrogen contraceptives    7.1           - 
% with hypertension     33.7        20.0* 
Antihypertensive medication (%)   26.8        14.0* 
% diabetes mellitus or HbA1c>7.0%   8.5         7.2 
HbA1C (%)           6.11± 1.16   5.98±1.21 
Glucose (mmol/l)          5.49± 3.24   5.37±2.66 
Total cholesterol (mmol/l)          4.60± 1.15 (n=268)    4.35±1.01 (n=172) 
HDL cholesterol (mmol/l)          1.47± 0.37 (n=268)    1.35±0.48 (n=172) 
Total/HDL cholesterol          3.32± 1.20 (n=268)    3.52±1.27 (n=172) 
Peripheral hemodynamic measurements 
SBP/DBP (mm Hg)     130± 23/84±13          132±24*/84±11 
Pulse pressure (mm Hg)            46±14      49±20* 
Augmentation index (%)        84.9±22.2   79.2±18.5* 
Heart rate (beats/min)         66±10.9    59.5±11.2* 
Central hemodynamic measurements 
SBP/DBP (mm Hg)     121± 23/85±13        123±24*/85±12 
MAP (mm Hg)        97± 15.97    97±14.29 
Pulse pressure (mm Hg)                   37±14        38±18 
Augmentation index (%)      27.8± 13.3     24.5±12.4* 
Aortic PWV (m/sec)      6.76± 2.93      6.85±3.31 
HbA1C, glycated haemoglobin; HDL, high density lipoprotein; SBP, systolic BP; DBP, 
diastolic BP; MAP, mean central artery pressure, PWV, pulse wave velocity. * p<0.05 
versus women. 
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marginally more women than men either receiving glucose lowering agents or with an 
abnormal blood glucose control. No participants were receiving statin therapy. On average 
a low proportion of subjects either regularly smoked or consumed alcohol, but the 
percentage was far greater in men than in women. Men had marginally higher mean 
peripheral and central systolic BP values and a higher PPp, but not PPc than women. Men 
had a lower pulse rate on average than women. Men had a lower peripheral and central AI 
than women, but PWV was similar between the two genders. 
Association between indexes of obesity. As with the data shown in chapter 2, in the 
sample analyzed for the present study, all indexes of adiposity were strongly associated 
with each other in both gender groups, with the closest relationships noted between waist 
circumference and BMI in both women and in men (Table 3.2). However, the relationship 
between waist-to-hip ratio and both BMI and skin-fold thickness was markedly lower in 
women than in men (Table 3.2). 
Relationship between adiposity and either age, haemodynamic factors or diabetes 
mellitus. All adiposity indexes were correlated with age (r=0.28-to-0.56, p<0.0001), MAPc 
(r=0.26-to-0.45, p<0.001), HR (r=0.15-to-0.21, p<0.001), and the presence of diabetes 
mellitus or an HbA1c >7.0% (r=0.10-to-0.25, p<0.001). Waist-to-hip ratio (r=0.18, 
p<0.0005) and waist circumference (r=12, p<0.02), but neither BMI, mean skin-fold 
thickness nor hip circumference were associated with total/HDL cholesterol. 
Univariate relations between adiposity indexes and indexes of arterial stiffness or 
wave reflection. On univariate analysis, all indexes of adiposity were correlated with PWV 
(Figures 3.3 and 3.4) and with AIc (Table 3.3). In women, the relationship between BMI 
and PWV was similar to those between indexes of central adiposity and PWV (Figure 3.3) 
and AIc (Table 3.3). However, in women the relationship between skin-fold thickness and 
PWV tended to be lower than those for the other relationships (Figure 3.3). In men, the  
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Table 3.2 Correlation matrices between indexes of adiposity in gender-specific groups. 
 
                                                WC (cm)     WHR    Mean skin-fold thickness 
______________________________________________________________________ 
     Women (n=310) 
Body mass index (kg/m2)  0.76**       0.09**        0.37** 
Waist circumference (WC) (cm)  -       0.41**        0.28** 
Waist-to-hip ratio (WHR)  -         -         0.04* 
     Men (n=198) 
Body mass index (kg/m2)  0.76**       0.30**        0.46** 
Waist circumference (WC) (cm)  -       0.61**        0.36** 
Waist-to-hip ratio (WHR)  -         -         0.18** 
WC, waist circumference; WHR, waist-to-hip ratio. Numbers are correlation coefficients 
(r2). * p<0.001, ** p<0.0001 for the relationships. 
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Figure 3.3. Relationship between indexes of adiposity and pulse wave velocity (PWV) in 
310 women. WHR, waist-to-hip ratio; WC, waist circumference; BMI, body mass index; 
skinfold, skin-fold thickness. 
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Figure 3.4 Relationship between indexes of adiposity and pulse wave velocity (PWV) in 
198 men. WHR, waist-to-hip ratio; WC, waist circumference; BMI, body mass index; 
skinfold, skin-fold thickness. 
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Table 3.3 Correlation coefficients (unadjusted) for the relationships between indexes of 
adiposity and central augmentation index in gender-specific groups. 
       Women (n=387)            Men (n=212) 
    Correlation p value  Correlation p value 
               coefficient (r)    coefficient (r) 
Body mass index   0.25  <0.0001  0.097        =0.16 
Waist circumference  0.25  <0.0001  0.24          =0.0005 
Waist-to-hip ratio  0.14  =0.005   0.30           <0.0001 
Skin-fold thickness  0.17  =0.0008  0.14  =0.04 
______________________________________________________________________ 
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relationships between BMI and PWV and between skin-fold thickness and PWV were 
markedly lower than those between indexes of central adiposity and PWV (Figure 3.4). 
Furthermore, in men, there was no significant relationship between BMI and AIc and the 
relationship between skin-fold thickness and AIc was lower than those relations noted 
between indexes of central adiposity and AIc (Table 3.3). 
Factors associated with PWV, or AI. Tables 3.4 and 3.5 show the contribution of 
factors associated with indexes of arterial stiffness to log PWV in stepwise regression 
models in women and in men. Table 3.4 shows models with BMI and skin-fold thickness 
and Table 3.5 shows models with waist-to-hip ratio, waist circumference, and hip 
circumference. In both gender groups, the factor that contributed the most to the variability 
in log PWV was age, accounting for 39-44% of the variability in log PWV. The relationship 
between age and log PWV was similar irrespective of whether a linear (r=0.65), 
exponential (r=0.65) or power (0.64) function was used to fit the relationship. Additional 
factors that contributed to log PWV included MAPc, which accounted for ~5% of the 
variability of log PWV in women and ~2.7% of the variability in men; HR which accounted 
for ~4.6% of the variability in log PWV in men, but not in women; antihypertensive 
treatment which accounted for ~1-2% of the variability of PWV in men, but not in women, 
and indexes of adiposity. With respect to the contribution of indexes of adiposity to log 
PWV, in neither sex was BMI, skin-fold thickness (Table 3.4) or hip circumference (Table 
3.5) independently associated with log PWV. In women, waist-to-hip ratio and waist 
circumference accounted for only ~1% of the variability of log PWV respectively (Table 
3.5). Neither waist circumference, nor waist-to-hip ratio were independently associated 
with log PWV in men (Table 3.5). Regular alcohol intake was associated with log PWV in 
men, but not in women. Regular tobacco use was not independently associated with log 
PWV in either men or women. The presence or absence of diabetes mellitus or an  
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Table 3.4. The results of stepwise regression analysis showing factors associated with log 
pulse wave velocity in study participants. Significant associations are highlighted in bold. 
    Women (n=310)        Men (n=198) 
       Partial correlation    p value*        Partial correlation    p value* 
                          coefficient (r)*              coefficient (r)* 
     Model with body mass index 
   (Model r2=0.50, adjusted r2= 0.48)  (Model r2=0.50, adjusted r2= 0.47) 
Body mass index   0.05  =0.26      -0.08     =0.14 
Age    0.66  <0.0001      0.63     <0.0001  
MAPc    0.23  <0.0001      0.16     <0.01 
Heart rate   0.03  =0.45       0.22     <0.001 
DM or HbA1c>7.0%             0.08  =0.08       0.02     =0.72 
Antihypertensive therapy 0.000  =0.88       0.11      <0.05 
Postmenopausal             0.03  =0.43         -        - 
Oestrogen contraception      0.03  =0.52         -        - 
Regular alcohol             0.01  =0.85       0.11      <0.05 
Regular tobacco use  0.000  =0.98      -0.05      =0.39 
         Model with mean skin-fold thickness 
       (Model r2=0.50, adjusted r2= 0.49)       (Model r2=0.49, adjusted r2= 0.47) 
Mean skin-folds   0.07  =0.08      -0.05     =0.36 
Height              -0.08  =0.06      -0.02     =0.77 
Age    0.66  <0.0001      0.63     <0.0001  
MAPc    0.23  <0.0001      0.16     <0.01 
Heart rate   0.08  =0.54       0.22     <0.001 
DM or HbA1c>7.0%             0.08  =0.07       0.02     =0.71 
Antihypertensive therapy 0.000  =0.95       0.11      <0.05 
Postmenopausal  0.03  =0.39         -        - 
Oestrogen contraception        0.08  =0.57         -        - 
Regular alcohol            0.02  =0.71       0.11      <0.05 
Regular tobacco use             0.000  =0.92      -0.04      =0.43 
___________________________________________________________________ 
MAPc, mean central artery pressure; DM, treatment for diabetes mellitus. *From stepwise 
regression analysis with further adjustments of probability values made for non-independence of 
family members. 
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Table 3.5. The results of stepwise regression analysis showing factors associated with log 
pulse wave velocity in study participants. Significant associations are highlighted in bold. 
 
    Women (n=310)        Men (n=198) 
       Partial correlation    p value*        Partial correlation    p value* 
                          coefficient (r)*              coefficient (r)* 
     Model with waist-to-hip ratio  
      (Model r2=0.51, adjusted r2= 0.49) (Model r2=0.49, adjusted r2= 0.47) 
Waist-to-hip ratio  0.10  <0.05       0.01     =0.85 
Height              -0.08  =0.08      -0.01     =0.78 
Age    0.66  <0.0001      0.63     <0.0001  
MAPc    0.23  <0.0001      0.16     <0.01 
Heart rate   0.01  =0.74       0.22     <0.001 
DM or HbA1c>7.0%             0.07  =0.11       0.01     =0.78 
Antihypertensive therapy 0.000  =0.97       0.11     <0.05 
Postmenopausal  0.04  =0.37        -         - 
Oestrogen contraception        0.04  =0.34        -         - 
Regular alcohol             0.02  =0.68       0.11      <0.05 
Regular tobacco use  0.000  =0.97      -0.03      =0.54 
     Model with waist circumference 
    (Model r2=0.51, adjusted r2= 0.49) (Model r2=0.49, adjusted r2= 0.47) 
Waist circumference   0.09  <0.05      -0.03     =0.52 
Height              -0.08  =0.06       0.000     =0.96 
Age    0.66  <0.0001      0.63     <0.0001  
MAPc    0.23  <0.0001      0.16     <0.01 
Heart rate   0.02  =0.62       0.22     <0.001 
DM or HbA1c>7.0%             0.08  <0.05       0.02     =0.74 
Antihypertensive therapy 0.000  =0.88       0.11      <0.05 
Postmenopausal  0.03  =0.42         -         - 
Oestrogen contraception        0.04  =0.36         -         - 
Regular alcohol             0.02  =0.68       0.11      <0.05 
Regular tobacco use             0.000  =0.89      -0.04      =0.49 
     Model with hip circumference  
        (Model r2=0.50, adjusted r2= 0.49) (Model r2=0.49, adjusted r2= 0.47) 
Hip circumference   0.02  =0.61      -0.05     =0.36 
Height              -0.08  =0.06       0.000     =0.99 
Age    0.66  <0.0001      0.63     <0.0001  
MAPc    0.23  <0.0001      0.16     <0.01 
Heart rate   0.03  =0.53       0.22     <0.001 
DM or HbA1c>7.0%             0.08  <0.05       0.02     =0.75 
Antihypertensive therapy        0.000  =0.93       0.11     <0.05 
Postmenopausal  0.03  =0.52         -         - 
Oestrogen contraception        0.03  =0.44         -         - 
Regular alcohol             0.01  =0.72       0.11      <0.05 
Regular tobacco use             0.000  =0.96      -0.04      =0.49 
MAPc, mean central arterial pressure; DM, treatment for diabetes mellitus. *From stepwise 
regression analysis with further adjustments of probability values made for non-
independence of family members. 
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abnormal blood glucose control was only independently associated with log PWV in 
women in the models including either waist or hip circumference (Table 3.5). 
In multivariate regression models, no single index of adiposity was independently 
associated with either AIc, AIp, or the log or square root of these variables in either men or 
women (data not shown).  
In secondary analysis with total/HDL cholesterol included in the regression models, 
similar outcomes were noted as those in the whole group. Indeed, with respect to the 
impact of adiposity indexes, waist-to-hip ratio (partial r=0.12, p<0.01) and waist 
circumference (partial r=0.10, p<0.05) were independently associated with log PWV in  
women, but not in men, whilst neither BMI, skin-fold thickness nor hip circumference were 
independently associated with log PWV in either gender group. In these models, total/HDL 
cholesterol was not an independent positive predictor of log PWV in any model (p=0.80-
0.96 in the models with waist-to-hip ratio and waist circumference in women).  
Age-adiposity interactions as predictors of PWV. Although waist-to-hip ratio and 
waist circumference made only a minor contribution to the overall variation in PWV in 
women (Table 3.5), after adjustments for all potential confounders including the individual 
terms for age and adiposity indexes, marked interactions between age and waist-to-hip 
ratio (r=0.68, p<0.0001) and between age and waist circumference (r=0.68, p<0.0001) 
were significant independent predictors of log PWV. Secondary analysis with total/HDL 
cholesterol forced into the model, resulted in similar outcomes (data not shown). In 
contrast, in men no interactions between age and adiposity indexes were independently 
associated with log PWV. 
The interactions between age and adiposity indexes as predictors of PWV in 
women, translated into a major impact of age on the effect of waist-to-hip ratio and waist 
circumference on PWV in women. The effect of age on the relationships between indexes 
of central adiposity and log PWV in women are illustrated in Figures 3.5 and 3.6 and the  
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Figure 3.5. Impact of age on waist-to-hip ratio (WHR)-log pulse wave velocity (PWV) 
relations. Upper panel shows relations between WHR and log PWV in women older 
(closed dots) than the median age (41.8 years) and women younger (open dots) than the 
median age. The lower panels compare the multivariate adjusted slopes (β-coefficients) of 
the relations. The lower left panel shows slopes with adjustments for age, antihypertensive 
therapy, mean central artery pressure, heart rate, height, regular tobacco and alcohol use, 
the presence or absence of diabetes mellitus or an abnormal blood glucose control, 
menopausal status, and oestrogen contraception. The lower right panel shows slopes with 
adjustments for the same potential confounders and with total/HDL cholesterol forced into 
the regression models. Probability values were further adjusted for non-independence of 
family members. *p<0.01 ** p<0.005 versus younger women. 
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Figure 3.6. Impact of age on waist circumference (WC)-log pulse wave velocity (PWV) 
relations. Upper panel shows relations between WC and log PWV in women older (closed 
dots) than the median age (41.8 years) and women younger (open dots) than the median 
age. The lower panels compare the multivariate adjusted slopes (β-coefficients) of the 
relations. The lower left panel shows slopes with adjustments for age, antihypertensive 
therapy, mean central artery pressure, heart rate, height, regular tobacco and alcohol use, 
the presence or absence of diabetes mellitus or an abnormal blood glucose control, 
menopausal status, and oestrogen contraception. The lower right panel shows slopes with 
adjustments for the same potential confounders and with total/HDL cholesterol forced into 
the regression models. Probability values were further adjusted for non-independence of 
family members. *p<0.005 versus younger women. 
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factors associated with log PWV in women younger as compared to older than the median 
age are shown in Table 3.6. In women younger than the median age (41.8 years), no 
univariate relationships between either waist-to-hip ratio and log PWV (Figure 3.5, upper 
panel) or between waist circumference and log PWV (Figure 3.6, upper panel) were noted 
and no independent relationships between waist-to-hip ratio and log PWV or between 
waist circumference and log PWV were noted in multivariate models (Table 3.6). However, 
in women older than the median age, strong univariate correlations between waist-to-hip 
ratio and log PWV (Figure 3.5, upper panel) and between waist circumference and log 
PWV (Figure 3.6, upper panel) and a positive independent association between waist-to-
hip ratio and log PWV and between waist circumference and log PWV was noted in a 
multivariate models (Table 3.6). In contrast to the ~1% contribution of either waist-to-hip 
ratio or waist circumference to the variation in PWV in all women (Table 3.4), waist-to-hip 
ratio contributed ~5.6% to the variability of log PWV and waist circumference contributed 
~6% to the variability of log PWV in women older than the median age (Table 3.6), 
whereas waist-to-hip ratio and waist circumference made no significant positive 
contribution to the variation in log PWV in women younger than the median age (Table 
3.6). 
Figures 3.5 and 3.6, lower left panels, show the multivariate adjusted slopes (β-
coefficients) of the waist-to-hip ratio-log PWV (Figure 3.5) and waist circumference-log 
PWV (Figure 3.6) relations in women older as compared to those younger than the median 
age. Age produced a marked effect on the multivariate adjusted slope of the wasit-to-hip 
ratio-log PWV (Figure 3.5) and the waist circumference-log PWV (Figure 3.6) relationship 
in women. A greater effect of either waist-to-hip ratio or waist circumference on log PWV 
was noted in women older as compared to those younger than the median age. Indeed, 
the adjusted slopes showed a positive effect of waist-to-hip ratio on log PWV in women 
older than the median age (β-coefficient=0.37±0.13), whilst a trend for a negative  
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Table 3.6. Factors associated with log pulse wave velocity in women younger and older 
than the median age for the study group (41.8 years). Significant associations are 
highlighted in bold.                 
Older (n=155)   Younger (n=155)  
       Partial correlation    p value*        Partial correlation    p value* 
                     coefficient (r)*        coefficient (r)* 
     Model with waist-to-hip ratio  
   Model r2=0.33           Model r2=0.35 
Waist-to-hip ratio  0.24  <0.01      -0.11     =0.13 
Height              -0.11  =0.13       0.000     =0.94 
Age    0.45  <0.0001      0.10     =0.14  
MAPc    0.20  <0.01       0.57     <0.0001 
Heart rate   0.03  =0.68       0.01     =0.84 
DM or HbA1c>7.0%             0.05  =0.46          -         - 
Antihypertensive therapy 0.02  =0.77       0.07     =0.33 
Postmenopausal  0.07  =0.36         -         - 
Oestrogen contraception        0.04  =0.56       0.03     =0.65 
Regular alcohol  0.08  =0.29      -0.02     =0.78 
Regular tobacco use            -0.04  =0.61       0.03     =0.67 
     Model with waist circumference 
   Model r2=0.34             Model r2=0.35 
Waist circumference   0.24  <0.01      -0.09     =0.20 
Height              -0.17  <0.05       0.000     =0.94 
Age    0.45  <0.0001      0.10     =0.14  
MAPc    0.18  <0.05            0.57     <0.0001 
Heart rate   0.03  =0.67       0.000     =0.98 
DM or HbA1c>7.0%             0.10  =0.14          -          - 
Antihypertensive therapy 0.000  =0.97       0.07      =0.35 
Postmenopausal  0.01  =0.90         -         - 
Oestrogen contraception        0.05  =0.45       0.03      =0.65 
Regular alcohol             0.08  =0.24      -0.02      =0.78 
Regular tobacco use            -0.02  =0.77       0.02      =0.75 
______________________________________________________________________ 
MAPc, mean central arterial pressure; DM, treatment for diabetes mellitus. *From stepwise 
regression analysis with further adjustments of probability values made for non-
independence of family members. No younger subjects had DM or an HbA1c>7.0%.
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relationship was noted in women younger than the median age (β-coefficient=-0.16±0.11) 
(Figure 3.5). The adjusted slope of the waist-to-hip ratio-log PWV relationship in the older 
group was statistically greater (p<0.005) than that in the younger group (Figure 3.5). 
Moreover, the adjusted slopes showed a positive effect of waist circumference on log 
PWV in women older than the median age (β-coefficient=0.0030±0.0009), whilst a trend 
for a negative relationship was noted in women younger than the median age (β-
coefficient=-0.0009±0.0007) (Figure 3.6). The slope of the waist circumference-log PWV 
relationship in the older group was also statistically greater (p<0.005) than that in the 
younger group (Figure 3.6). 
Figures 3.5 and 3.6, lower right panels, show the outcomes of secondary analysis 
with total/HDL cholesterol forced into the models in participants with these data. The 
multivariate adjusted slopes of the waist-to-hip ratio-log PWV and waist circumference-log 
PWV relationships were similarly greater in older as compared to younger women (waist-
to-hip ratio-log PWV: β-coefficients: older women =0.36±0.15, younger women=-
0.07±0.10, p<0.01: waist circumference-log PWV:  β-coefficients: older women 
=0.0031±0.0010, younger women=-0.0007±0.0006, p<0.005) even after adjustments for 
total/HDL cholesterol. 
Size effects of indexes of adiposity on PWV in younger versus older women. In 
women older than the median age for the group a one SD increase in waist-to-hip ratio 
(0.096) translated into a 0.58 m/sec increase in PWV as compared to a 0.16 m/sec 
decrease in PWV for each one SD increase in waist-to-hip ratio (0.076) in women younger 
than the median age (p<0.001). In women older than the median age for the group a one 
SD increase in waist circumference (12.8 cm)  translated into a 0.69 m/sec increase in 
PWV as compared to a 0.16 m/sec decrease in PWV for each one SD increase in waist 
circumference (13.0 cm) in women younger than the median age (p<0.001). 
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3.4 Discussion 
The main finding of the present study is that in a predominantly young-to-middle 
aged population sample of African ancestry with a high prevalence of excess adiposity, 
age markedly influenced the independent relationship between indexes of central adiposity 
(waist-to-hip ratio and waist circumference) and PWV in women. In women older than the 
median age of the sample (~42 years), waist-to-hip ratio and waist circumference were 
strongly and independently associated with PWV, whereas in women younger than the 
median age a trend for a negative relationship was noted. Moreover, in women older than 
the median age of the sample, the quantitative effect of waist-to-hip ratio or waist 
circumference on PWV was ~5-fold greater than in women younger than the median age 
of the sample. Further, in older women, the contribution of waist-to-hip ratio or waist 
circumference to the variation in log PWV was at least as much as mean central arterial 
BP. 
The age effect on adiposity-PWV relations noted in present study provides insight 
into discrepancies in studies assessing relations between adiposity and PWV. In this 
regard, a number of studies with study sample sizes ranging from 336-to-2431 participants 
have failed to show strong independent relations between adiposity and PWV in 
predominantly young-to-middle aged groups (Ferreira et al 2004, Zebekakis et al 2005, 
Taquet et al 1993, Amar et al 2001, Nakanishi et al 2003, Oren et al 2003, Mitchell et al 
2004, Czernichow et al 2005). However, consistent with the impact of age on adiposity-
PWV relations, marked independent relations have been reported on in 2488 participants 
aged 70-79 years (Sutton-Tyrrell et al 2001) and in 356 participants aged 70-90 years 
(Mackey et al 2002). In support of an age-dependent effect of excess adiposity on PWV 
noted in the present study, adiposity-age interactions have been described in another 
study (Zebekakis et al 2005) which nevertheless only achieved significance when 
assessing associations with measures of arterial stiffness other than PWV. However, in 
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that study (Zebekakis et al 2005), an adiposity-age interaction was not detected when 
assessing associations with PWV, although the independent effect of adiposity on PWV 
appeared to be enhanced with increasing age (Zebekakis et al 2005). It is possible that the 
low mean BMI of ~25 kg/m2 in that prior study (Zebekakis et al 2005) may have limited the 
capacity to detect a significant adiposity-age interaction for PWV. Further, as suggested by 
the present study, where interactions between central adiposity and age, but not between 
BMI and age were noted, the use of BMI as an adiposity index may limit the sensitivity to 
detect age-adiposity interactive effects on PWV. 
In all prior studies demonstrating either a lack of independent relationship (Ferreira 
et al 2004, Taquet et al 1993, Amar et al 2001, Nakanishi et al 2003, Oren et al 2003, 
Mitchell et al 2004) or only a weak independent relationship (Zebekakis et al 2005, 
Czernichow et al 2005) between adiposity indexes and PWV, the mean BMI ranged from 
~23-to-26 kg/m2, suggesting a low prevalence of excess adiposity, a characteristic of 
these populations that may have limited the strength of the independent relationship 
between adiposity and PWV. In contrast, in the present study ~63% of the sample were 
either overweight (~26%) or obese (~37%), and hence the outcomes are unlikely to be 
limited by a low prevalence of excess adiposity in the study sample. 
The present study is in apparent contrast to a previous study conducted in 186 
younger subjects, 21-26% of whom were obese, where adiposity indexes were strongly 
associated with PWV independent of age, gender and BP (Wildman et al 2003) However, 
in contrast to this prior study (Wildman et al 2003) where the relations between adiposity 
indexes and PWV were not adjusted for HR, in the present study we adjusted for HR. As 
indicated in the present and a prior study (Mackey et al 2002) HR is strongly associated 
with both adiposity indexes and PWV. 
 The potential mechanisms that may explain the independent relationship between 
adiposity and PWV in older women are numerous, have been discussed in the 
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introductory chapter and may be summarized as follows: First, increased insulin 
concentrations, without overt diabetes mellitus, may accompany obesity and insulin could 
promote vascular changes that result in increases in large vessel stiffness (King et al 
1999). However, to my knowledge there are no studies that have demonstrated a 
relationship between insulin resistance and large artery dysfunction independent of 
haemodynamic factors or diabetes mellitus. Second, the adipokine leptin may 
independently promote increases in arterial stiffness (Singhal et al 2002). However, the 
exact mechanism of this effect has not been identified. Third, activation of the RAAS may 
contribute to large vessel dysfunction. Indeed, ACE inhibition reduces arterial stiffness 
(Safar et al 1997). However, there are no large studies that have been conducted to date 
that have assessed whether RAAS activation is indeed related to large vessel dysfunction 
beyond conventional risk factors and indexes of adiposity. Fourth, adipose tissue secretes 
pro-inflammatory substances and obesity is associated with increases in circulating C-
reactive protein concentrations (Visser et al 1999, Berg and Scherer 2005). In this regard, 
C-reactive protein concentrations are associated with an increased arterial stiffness in 
apparently healthy individuals (Yasmin et al 2004).    
 It is unclear why a gender-specific independent relationship between adiposity and 
PWV was noted in the present study. Nevertheless, in support of the present study, in 
previous studies (Mackey et al 2002, Zebekakis et al 2005, Protogerou et al 2007) 
adiposity was independently associated with PWV in women, but not in men. It is possible 
that independent relationships between adiposity and PWV are sensitive to the prevalence 
of obesity in the population sampled. In this regard, in the present study fewer men were 
obese than women. 
 In the present study, although indexes of adiposity were independently associated 
with PWV, there was no independent relationship between indexes of adiposity and AI. 
The lack of effect of adiposity indexes on AI might relate to the dependence of AI, but not 
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PWV, on ventricular ejection time (Wilkinson et al 2002). Moreover, AIc, but not PWV, 
depends on the distance of the reflection points from the heart. It is possible that in a large 
population sample, subjects with a higher PWV might have reflection points further from 
the heart. Irrespective of the mechanism responsible for the lack of independent 
relationship between indexes of adiposity and AIc despite the relationship between central 
adiposity and PWV, our data are consistent with an alternative study similarly showing a 
lack of independent relationship between adiposity and AI (Vergnaud et al 2007). 
The limitations of the present study are again the cross-sectional nature of the 
study design and the lack of more direct measures of body fat, particularly visceral or trunk 
fat. However, visceral (Sutton-Tyrrell et al 2001) or trunk (Ferreira et al 2004) fat is more 
closely associated with PWV than other fat compartments. Hence, if anything I may have 
underestimated the independent relationship between adiposity indexes and PWV in the 
present study. Further, as a considerable number of participants older than the median 
age for the group were receiving antihypertensive therapy, I was not statistically powered 
to perform sensitivity analysis in only untreated women or men. However, I did adjust for 
antihypertensive treatment and the inclusion of treated participants in the analysis is more 
likely to have biased against the outcomes by reducing the sensitivity to show an 
interactive effect between age and adiposity indexes. 
In conclusion, in a predominantly young-to-middle-aged population sample of 
African ancestry with a high prevalence of excess adiposity, age modified the independent 
relationship between indexes of central adiposity and PWV in women. In this regard, 
waist-to-hip ratio and waist circumference accounted for a significant proportion of the 
variability of PWV in older, but not younger women independent of other confounders. 
Moreover, the effect of waist-to-hip ratio and waist circumference on increases in PWV 
was ~5-fold higher in older than in younger women after adjustments for confounders. 
Thus, although in younger women the impact of adiposity on PWV is likely to be mediated 
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principally through conventional haemodynamic factors such as BP, the effect of adiposity 
in older persons may be mediated by additional factors not normally included in 
cardiovascular risk assessment. 
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CHAPTER 4 
 
 
Adiposity Enhances the Impact of Arterial Stiffness and Hence 
Blood Pressure on Left Ventricular Mass. 
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Abstract 
Although normal growth effects on left ventricular mass (LVM) are of physiological 
relevance, obesity-induced LV growth may have pathophysiological significance. However, 
an explanation for the pathophysiological effects of adiposity-induced LV growth has not 
been provided. I determined, in 399 randomly recruited participants in the community 
(~68% with excess adiposity), whether excess adiposity enhances the impact of 
haemodynamic changes on LVM. I determined LVM indexed for height2.7 (LVMI) and 
mean wall thickness (MWT) from echocardiography; blood pressure (BP) from 
conventional and 24-hour ambulatory measurements; and carotid-femoral pulse wave 
velocity (PWV) from applanation tonometry. After adjustments for appropriate 
confounders, including the individual terms, interactions between adiposity indexes (waist 
circumference [WC] or mean skin-fold thickness) and conventional systolic BP (SBP), 24-
hour SBP, PWV, conventional pulse pressure (PP), or 24-hour PP were independently 
associated with LVMI and MWT (p<0.001). The adiposity index-haemodynamic interaction 
translated into a greater impact of BP on LVMI and MWT in obese as compared to lean 
participants. Every one SD increase in conventional SBP (~22 mm Hg) was associated 
with a 1.61 g/m2.7 increase in LVMI in participants with a normal WC, in comparison to a 
5.24 g/m2.7 increase in those with an increased WC (p<0.0001). In conclusion, adiposity-
induced increases in LVM are of pathophysiological significance in-part because they 
reflect an enhanced impact of arterial stiffness and hence SBP on LV growth. 
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4.1 Introduction 
Excess adiposity predicts adverse cardiovascular outcomes independent of 
conventional cardiovascular risk factors (Kurth et al 2002, Wilson et al 2002, National Task 
Force on the Prevention and Treatment of Obesity 2000). In this regard, a potential 
mechanism through which obesity may mediate independent effects on cardiovascular 
outcomes is by promotiong left ventricular hypertrophy (LVH) (de Simone et al 1992, de 
Simone et al 1994, Lauer et al 1991, Lorber et al 2003, Messerli et al 1982, Messerli et al 
1983, Urbina et al 1995), which is a strong independent predictor of cardiovascular events 
(Casale et al 1986, Devereux et al 2004, Ghali et al 1998, Koren et al 1991, Levy et al 
1990, Levy et al 1994, Verdecchia et al 1996). Left ventricular mass (LVM) indexes that 
incorporate the impact of adiposity on LVM are associated with a higher proportion of 
incident cardiovascular events than are LVM indexes that discount the impact of adiposity 
on LVM (de Simone et al 2005). Consequently, unlike normal growth effects on LVM which 
are physiological in nature, obesity-induced LVH may be of pathophysiological 
significance. However, an explanation for the pathophysiological significance of adiposity-
induced LVH has not been forthcoming. 
One potential mechanism that may explain the potential pathological effects of 
obesity-induced increases in LVM is through an enhanced impact of blood pressure (BP) 
on LVM as demonstrated in severe obesity (body mass index>35 kg/m2) (Avelar et al 
2007). However, obesity may not increase the impact of BP on LVM in milder forms of 
obesity (Fox et al 2004, Lauer et al 1992). Nevertheless, in these studies only participants 
with a narrow range of BP levels (Lauer et al 1992) or where ~50% of the sample were 
receiving antihypertensive treatment at the time (Fox et al 2004) were studied. Therefore, 
in the present study I assessed in a population sample with a high prevalence of mild-to-
moderate obesity (Shiburi et al 2006, chapters 2-3) whether adiposity is associated with an 
enhanced impact of BP or arterial stiffness on LVMI and wall thickness. 
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4.2 Methods 
Study participants. The study design has been described in detail in chapter 2. The 
analysis for this component of the thesis was undertaken in early 2007 in the database 
available at the end of 2006. Of the 671 participants enrolled in the study up until 
November 2006, 418 (62%) agreed to echocardiograph assessments. Of these, 19 were 
discarded because of poor quality echocardiograph assessments. Thus, in total 399 
subjects were assessed in this study. For statistical analysis with ambulatory BP, data 
from 297 participants with high quality echocardiograms who also had ambulatory BP 
recordings that met with pre-specified quality criteria (longer than 20 hours and more than 
10 and 5 readings for the computation of daytime and night-time means, respectively) 
were assessed. Pulse wave velocity (PWV) could not be measured in 71 subjects because 
they had a bradycardia or were too obese and hence the overall number of participants 
statistically analyzed totaled 328 for PWV. 
The techniques employed to obtain clinical, demographic and anthropometric data, 
conventional BP and pulse wave data have been described in chapter 2. As with other 
chapters, participants were identified as being overweight if their body mass index (BMI) 
was ≥25 kg/m2 and obese if their BMI was ≥30 kg/m2. In addition however, as I have 
demonstrated (in chapter 2) that waist circumference was the most appropriate index of 
adiposity for predicting BP effects, I also defined excess adiposity from waist 
circumference thresholds in the present study. An enlarged waist circumference was 
defined as >88 cm in women and >102 cm in men (Third report of the National Cholesterol 
Education Program 2002). As the present analysis was conducted in 2007, and based on 
a new meta-analysis published in 2007, where revised thresholds for the use of HbA1c as 
a diagnositic tool for diabetes mellitus have been described (Bennett et al 2007), diabetes 
mellitus or abnormal blood glucose control was defined as the use of insulin or oral 
hypoglycaemic agents or an HbA1c value greater than 6.1% in the present study. 
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In the cohort of participants with appropriate echocardiography, the frequency of 
identical consecutive conventional BP recordings was 3.01%. No BP values were 
recorded as an odd number. Of the 3990 systolic and diastolic BP readings, 28.7% ended 
on a zero (expected =20%). The technique employed for 24-hour ambulatory BP 
monitoring has been described in chapter 2. The average (±SD) number of BP recordings 
obtained in the cohort with appropriate echocardiography and 24-hour BP recordings was 
62.8±11.4 (range=24-81) for the 24-hour period. 
 Echocardiography. Echocardiographic measurements were performed using 
previously described methods performed by our group (Skudicky et al 2002) (see Figure 
4.1 for a representative two-dimensional guided M-mode echocardiogram from which LV 
dimensions were determined). Briefly, two-dimensional guided M-mode echocardiography 
was performed using a pulse color Doppler Hewlett Packard model 5500 recorder coupled 
to a 2.5 MHz transducer. Data obtained in the short axis view were analyzed according to 
the American Society of Echocardiography convention (Sahn et al 1978). During 
recordings the transducer was placed perpendicular to the chest wall or pointed slightly 
inferiorly and laterally at the end of the long axis (Sahn et al 1978). All measurements 
were recorded on videotape and analyzed off-line by an experienced investigator (Dr. 
Carlos Libhaber), who was unaware of the clinical condition of the subjects. The 
interventricular septal wall thickness (IVS) at end diastole and end systole, the posterior 
wall thickness (PWT) at end diastole and end systole and the end diastolic and end 
systolic internal dimensions of the left ventricle were measured only when appropriate 
visualization of both the right and the left septal surfaces was obtained (Sahn et al 1978). 
Figure 4.1 shows echocardiography being performed and a representative M-mode image. 
Left ventricular mass was derived according to an anatomically validated formula: LVM = 
0.8 x [1.04 (LVEDD + IVS +PWT) 3 – (LVEDD) 3] + 0.6g, where LVEDD = LV internal 
diameter, IVS =LV septal thickness,  
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Figure 4.1. Upper panel illustrates the Hewlett Packard model 5500 utilised to assess left 
ventricular dimensions in the study sample. The lower panel shows an M-Mode image 
(courtesy of Dr. Carlos Libhaber). 
 
A-Left ventricular end diastolic (LVED) diameter 
B-Left ventricular end systolic (LVES) diameter 
C-LVED posterior wall thickness. 
D-LVES posterior wall thickness. 
E-LVED septal wall thickness. 
F-LVES septal wall thickness 
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PWT = posterior wall thickness, all measured at diastole in centimeters (Devereux et al 
1986). 
Intra-observer variability was assessed on 29 subjects in whom repeat 
echocardiographic measurements were performed within a two week period of the initial 
measurements. The Pearson’s correlation coefficients for LV end diastolic diameter, septal 
wall thickness and posterior wall thickness were 0.76, 0.94 and 0.89 (all p<0.0001) 
respectively, and the variances (mean % difference ± SD) were 0.12±5.95%, -0.77±4.47% 
and 0.67±5.57% respectively. In addition, no significant differences between repeat 
measurements were evident on paired t-test analysis (p=0.99, p=0.42 and p=0.48 
respectively).To adjust for the influence of growth on LVM without eliminating the impact of 
excess adiposity, LVM was indexed to height2.7 (LVMI). Left ventricular mean wall 
thickness (MWT) was calculated as the mean of LV posterior and LV septal wall thickness 
at end diastole. Left ventricular hypertrophy was defined as an LVMI>51g/m2.7 in both men 
and women (Nunez et al 2005). 
Data analysis. Database management and statistical analyses were performed with 
SAS software, version 9.1 (SAS Institute Inc., Cary, NC, USA). Descriptive data are 
reported as mean±SD and β coefficients (slopes) of relations as the mean±SEM. As 
neither waist circumference, nor the mean of triceps and sub-scapular skin-fold thickness 
(mean skin-fold thickness) were positively associated with height (p>0.30); when 
assessing the effect of adiposity on LVMI or MWT, waist circumference and mean skin-
fold thickness were used as indexes of adiposity. Independent relationships between 
interactive terms and either LVMI or MWT were determined by multivariate regression 
analysis with adjustments for the individual components of the interactive terms (or the 
individual components2) as well as age (or age2), sex, height (for MWT only), diabetes 
mellitus or an HbA1c>6.1%, antihypertensive treatment, regular tobacco or alcohol intake, 
total/HDL cholesterol, and pulse rate. Probability values were further adjusted for non-
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independence of family members in non-linear models (Mixed procedure as defined in the 
SAS package). To assess the extent to which adiposity enhances the impact of 
haemodynamic factors on LVMI or RWT, the β-coefficient (slope) of the adjusted 
relationship (adjusted for aforementioned confounders) between haemodynamic factors 
and either LVMI or MWT was compared between subjects with either an increased or a 
normal waist circumference. An unpaired Student’s t-test was used to compare the slopes 
of regression relations. Sensitivity analysis was performed in subjects not receiving 
antihypertensive therapy.  
4.3 Results 
Characteristics of the participants. Table 4.1 gives the demographic and clinical 
characteristics, and the haemodynamic values of the study group and the group never 
having received antihypertensive therapy. More women than men participated. In general 
the group had a high BMI, with ~68% of subjects being either overweight (~26%) or obese 
(~43%) and ~43% having central obesity. More women than men were obese with 55% of 
women and 22% of men being obese and 58% of women and 15% of men having central 
obesity. ~41% of subjects were hypertensive, ~23% of participants had diabetes mellitus 
or an impaired blood glucose control. A relatively low proportion of subjects reported 
smoking or a regular intake of alcoholic beverages. No differences were noted in the 
demographic and clinical characteristics between all participants recruited and those with 
high quality echocardiograms (data not shown). Similarly, no differences were noted in 
demographic and clinical characteristics between all participants and never-treated 
participants.  
Table 4.2 shows the left ventricular dimensions and mass of the study group and 
the group never having received antihypertensive therapy. Left ventricular dimensions 
were larger in men than in women (data not shown). However, LVMI was similar between 
the genders (data not shown). ~29% of men and ~27% of women had LVH. 
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Table 4.1. Demographic, anthropometric, clinical and haemodynamic characteristics of 
study participants. 
                    All participants     Never-treated participants
  
Number (%female)                399 (63.9)              309 (61.2) 
Age (years)                  44±18      39±17  
Height (m)                161.8±8.7  162.8±8.7 
Weight (kg)               76.7±18.7  75.1±18.6  
Body mass index (kg/m2)              29.4±7.4   28.5±7.2  
Waist circumference (cm)              90.4±15.5  87.9±15.2  
Subscapular skin-fold thickness (cm)            2.47±1.29  2.35±1.26 
Triceps skin-fold thickness (cm)             1.83±1.15  1.81±1.18 
Mean skin-fold thickness (cm)             2.15±1.10  2.08±1.11 
% overweight/obese                25.8/42.6  24.9/38.2 
% with central obesity                    42.9       35.9  
% with hypertension                    41.0       24.3 
% with DM or HbA1c>6.1%                             22.8       17.2 
Regular smoking (%)        11.5       13.6 
Regular alcohol (%)        21.8       23.6 
Haemodynamics 
Conventional SBP/DBP         131±22/85±12  128±21/84±12  
Conventional PP (mm Hg)            46.3±14.7     43.9±13.7 
24-hour SBP/DBP (mm Hg) (n)          119±15/73±10 (n=297)   118±15/72±10 (n=231) 
24-hour PP (mm Hg) (n)       45.9±8.2 (n=297)         45.5±8.0 (n=231) 
Pulse wave velocity (m/sec) (n)      6.82±3.23 (n=328)         6.32±3.05 (n=254) 
DM, diabetes mellitus; HbA1C, glycated hemoglobin; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; PP, pulse pressure. 
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Table 4.2. Left ventricular dimensions and mass of study participants. 
 
                    All participants      Never-treated participants  
________________________________________________________________________ 
Number (%female)               399 (63.9)              309 (61.2) 
LVED diastolic diameter (cm)   4.74±0.51  4.75±0.50 
LVED septal thickness (cm)             1.03±0.17  1.01±0.15  
LVED posterior wall thickness (cm)          0.99±0.15  0.97±0.13 
LVED mean wall thickness (cm)          1.01±0.16  0.99±0.14   
LV mass (g)               172±52    168±48   
LV mass indexed for BSA (g/m2)          95.4±25.3  93.7±23.1   
LV mass indexed for height2.7 (g/m2.7)         47.1±14.3  45.2±12.6 
LVED. left ventricular end diastolic; BSA, body surface area. 
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Relationships between indexes of adiposity and haemodynamic factors. As 
described in previous chapters, waist circumference was strongly and positively 
associated with conventional systolic BP (SBP), 24-hour SBP, conventional diastolic BP, 
24-hour diastolic BP, PWV, conventional pulse pressure (PP), and 24-hour PP (p<0.0001 
for all). In addition, waist circumference was associated with pulse rate (p<0.002). 
Likewise, mean skin-fold thickness was associated with conventional systolic and diastolic 
BP (p<0.0001 for all), 24-hour SBP (p=0.035), conventional PP (p=0.002), 24-hour PP 
(p<0.03), PWV (p<0.0001), but not with pulse rate (p=0.07). Similar univariate relations 
were noted in untreated subjects. 
Individual factors associated with LVMI or wall thickness. With respect to adiposity 
indexes, waist circumference was associated with LVMI (r=0.40, p<0.0001), and MWT 
(r=0.42, p<0.0001); and mean skin-fold thickness was associated with LVMI (r=0.24, 
p<0.0001) and MWT (r=0.16, p<0.002). With respect to haemodynamic effects, the factors 
positively correlated with LVMI were conventional SBP (r=0.47) and 24-hour SBP (r=0.35), 
conventional diastolic BP (r=0.29) and 24-hour diastolic BP (r=0.21), PWV (r=0.42), 
conventional PP (r=0.46), and 24-hour PP (r=0.38) (p<0.001 for all). Similar relations were 
noted between haemodynamic factors and MWT (data not shown). Pulse rate was not 
associated with either LVMI or MWT. Age, hypertension treatment and DM/HbA1c>6.1% 
were all associated with both LVMI and MWT (p<0.0001 for all). Male gender was 
associated with MWT (p<0.001), but not LVMI. Neither regular tobacco, regular alcohol 
consumption, nor total/HDL cholesterol were associated with LVMI and MWT. Similar 
relationships were noted in untreated subjects. 
Interactions between adiposity and haemodynamic factors as predictors of LVMI or 
geometry. Table 4.3 shows the multivariate adjusted association of haemodynamic factor-
adiposity index interactions with either LVMI or MWT. After multivariate adjustments 
including the individual terms for adiposity indexes and haemodynamic factors in the  
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Table 4.3. Multivariate adjusted correlation coefficients (partial r) and 95% confidence 
intervals (CI) for independent relations between haemodynamic factor-adiposity index 
interactions and left ventricular mass index (LVMI) or mean wall thickness (LV MWT). 
 
                                                          All participants  Never-treated participants 
Interactive term                            partial r*      CI      p value*       partial r*      CI      p value*        
 
Interactions with waist circumference (WC) 
LVMI vs 
Conventional SBP X WC       0.17     0.06-0.27   <0.003       0.21     0.10-0.32  <0.0005 
24-hour SBP X WC        0.15     0.03-0.27   <0.02        0.25     0.11-0.37   <0.001 
Conventional PP X WC       0.19     0.08-0.28   <0.001       0.20     0.09-0.31   <0.001 
24-hour PP X WC        0.14     0.02-0.26   <0.03        0.27     0.13-0.39  =0.0002 
Pulse wave velocity x WC       0.17     0.05-0.28   =0.003       0.23     0.10-0.35   <0.001 
LV MWT vs 
Conventional SBP X WC      0.17     0.06-0.27   <0.002        0.21     0.09-0.32  =0.0005 
24-hour SBP X WC       0.14     0.02-0.26   <0.02        0.19     0.05-0.32   <0.01 
Conventional PP X WC      0.18     0.08-0.28   <0.001        0.22     0.10-0.33  =0.0003 
24-hour PP X WC       0.13     0.01-0.25   <0.05        0.20     0.06-0.33   =0.005 
Pulse wave velocity x WC      0.17     0.05-0.28   =0.003        0.19     0.06-0.31   <0.004 
 
Interactions with skin-fold thickness (SK) 
LVMI vs 
Conventional SBP X SK      0.17     0.06-0.27   <0.003        0.21     0.10-0.32  <0.0005 
24-hour SBP X SK       0.15     0.03-0.27   <0.02         0.25     0.11-0.37   <0.001 
Conventional PP X SK      0.19     0.08-0.28   <0.001         0.20     0.09-0.31   <0.001 
24-hour PP X SK       0.14     0.02-0.26   <0.03         0.27    0.13-0.39  =0.0002 
Pulse wave velocity x SK      0.17     0.05-0.28   =0.003         0.23     0.10-0.35   <0.001 
LV MWT vs 
Conventional SBP X SK      0.17     0.06-0.27   <0.002        0.21     0.09-0.32  =0.0005 
24-hour SBP X SK       0.14     0.02-0.26   <0.02          0.19     0.05-0.32   <0.01 
Conventional PP X SK      0.18     0.08-0.28   <0.001        0.22     0.10-0.33  =0.0003 
24-hour PP X SK       0.13     0.01-0.25   <0.05          0.20     0.06-0.33   =0.005 
Pulse wave velocity x SK      0.17     0.05-0.28   =0.003        0.19     0.06-0.31   <0.004 
________________________________________________________________________ 
See Table 4.1 for abbreviations. *Multivariate adjusted correlation coefficients with 
adjustments for haemodynamic factors (individual terms), adiposity index (individual term), 
age, sex, diabetes mellitus or an HbA1c>6.1%, antihypertensive treatment (in all 
participants), regular tobacco or alcohol intake, total/HDL cholesterol, and pulse rate. 
Probability values were further adjusted for non-independence of family members.  
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models, statistically significant interactions between adiposity indexes and either SBP, 
PWV, or PP were noted as independent predictors of LVMI and MWT. However, no 
interactions between adiposity indexes and diastolic BP were noted as independent 
predictors of LVMI. Moreover, no interactions between adiposity indexes and diastolic BP 
were noted as independent predictors of MWT (data not shown). Adjusting for adiposity 
index2, haemodynamic factor2 and age2 in the regression models did not affect the main 
outcomes. 
Impact of an increased waist circumference on the relations between 
haemodynamic factors and LVMI or MWT. Figures 4.2 and 4.3 show the impact of an 
increased waist circumference on the univariate relations (left and middle panels) and the 
multivariable adjusted slopes (β-coefficients) (right panels) of the relations between 
haemodynamic factors and LVMI. For comparable increases in either SBP (Figure 4.2), or 
PWV and PP (Figure 4.3), participants with a high waist circumference had a greater 
increase in LVMI as compared to participants with a normal waist circumference. Indeed, 
the multivariate adjusted slopes of the relations between haemodynamic factors and LVMI 
were considerably greater in participants with an increased waist circumference as 
compared to participants with a normal waist circumference. Adjusting for adiposity index2 
and age2 in the regression models did not affect the main outcomes. 
Impact of an increased waist circumference on the effect of haemodynamic factors 
on LVMI or MWT. Figure 4.4 summarizes the impact of an increased waist circumference 
on the multivariate adjusted increase in LVMI and MWT for every one SD increase in 
either conventional or 24-hour SBP or PP, or PWV. In participants with an increased waist 
circumference, conventional SBP, PP, 24-hour SBP and PP and PWV were associated 
with a greater increase in LVMI or MWT. Importantly, every one SD increase in 
conventional systolic BP (~22 mm Hg) translated into a 5.24 g/m2.7 increase in LVMI in  
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Figure 4.2. Impact of an increased waist circumference (WC) on the associations between 
conventional systolic blood pressure (SBPconv.) and left ventricular mass index (LVMI) in 
all and never-treated participants. Left and middle panels show univariate relations in 
participants with a normal and an increased WC and right panel shows comparisons of the 
multivariate adjusted slopes (β-coefficient) of relations between participants with a normal 
and an increased WC. Adjustments were for WC, age, sex, diabetes mellitus or an 
HbA1c>6.1%, antihypertensive treatment (in all participants), regular tobacco or alcohol 
intake, total/HDL cholesterol, and pulse rate. Probability values were further adjusted for 
non-independence of family members.  *p<0.05, **p<0.001 compared to normal WC. 
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Figure 4.3. Impact of an increased waist circumference (WC) on the associations between 
indexes of large artery dysfunction (pulse wave velocity [PWV] and conventional pulse 
pressure [PPconv]) and left ventricular mass index (LVMI). Left and middle panels show 
univariate relations in participants with a normal and an increased WC and right panels 
show comparisons of the multivariate adjusted slopes (β-coefficient) of relations between 
participants with a normal and an increased WC. Adjustments are as in Figure 1. *p<0.01, 
** p<0.001 compared to normal WC. 
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Figure 4.4. Impact of an increased waist circumference (WC) on the multivariate adjusted 
change in left ventricular mass index (LVMI) or mean wall thickness (MWT) (±95% 
confidence intervals) for every 1 SD increase in systolic blood pressure (SBP), pulse 
pressure (PP) or pulse wave velocity (PWV). Adjustments were for age, WC, sex, height 
(for mean wall thickness only), diabetes mellitus or an HbA1c>6.1%, antihypertensive 
treatment, regular tobacco or alcohol intake, total/HDL cholesterol, and pulse rate. 
Probability values were further adjusted for non-independence of family members. conv., 
conventional; 24, 24-hour. *p<0.0001 vs normal WC. 
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participants with an increased waist circumference, but only a 1.61 g/m2.7 increase in LVMI 
in participants with a normal waist circumference. Thus, an increased adiposity was 
associated with a 3.26 times greater impact of BP on LVMI. 
 4.4    Discussion 
The main findings of the present study are as follows. In a population sample with 
a high prevalence of excess adiposity (~68% overweight or obese and ~43% with central 
obesity) and untreated hypertension (~19%), synergy between indexes of adiposity (waist 
circumference and skin-fold thickness) and either conventional or 24-hour SBP, or indexes 
of large artery dysfunction (PWV and PP) were independently associated with LVMI and 
MWT after multivariate adjustments including the individual adiposity indexes and 
haemodynamic variables. The synergistic effects between indexes of adiposity and 
haemodynamic variables translated into a greater impact of these haemodynamic factors 
on LVMI and MWT in participants with an increased as compared to a normal waist 
circumference. For example, for comparable increases in SBP, participants with an excess 
adiposity (a high waist circumference) had a ~3-4 times greater increase in LVMI after 
adjustments for confounders. 
The present study provides the first evidence to indicate that mild-to-moderate 
forms of excess adiposity not only promote the development of increases in BP as is well 
recognized (Majane et al 2007, chapter 2 and as summarized in chapter 1), but also 
enhance the impact of BP on LVMI. In this regard the present study results agree with the 
finding that severe obesity (BMI>35 kg/m2) is associated with an enhanced effect of 
hypertension on LVM (Avelar et al 2007). However, in contrast to the present study, in a 
predominantly middle-aged population sample (Fox et al 2004), and in a randomly 
selected Framingham sample (Lauer et al 1992), interactions between discrete categories 
of BMI (lean, overweight and obese) and BP (normal, high-normal and hypertensive) failed 
to predict LVMI. In this regard the assessment of BP as a discrete trait could potentially 
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reduce the sensitivity of detecting an interactive effect. Furthermore, in contrast to the 
present study where ~17% of subjects were receiving antihypertensive therapy and ~24% 
were hypertensive but not receiving therapy, in one study (Fox et al 2004) ~50% of 
subjects (the majority of hypertensives) were receiving antihypertensive therapy, thus 
potentially modifying the effects of BP on LVMI. Further in the Framingham Heart Study, 
by excluding treated hypertensives from the analysis a very narrow range of BP values 
was obtained in the participants (Lauer et 1992), thus potentially limiting the sensitivity of 
detecting an interactive effect. Last, the use of BMI as an index of adiposity as previously 
studied (Lauer et al 1992, Fox et al 2004), which may not closely reflect the degree of 
adiposity in some populations (Luke et al 1997), could confound the interpretation of these 
data.  
In the present study, interactions between adiposity indexes and SBP, PP and 
PWV were independently associated with LVMI and MWT. As SBP, PP and PWV are all 
affected by large artery dysfunction, these data suggest that excess adiposity not only 
promotes large artery dysfunction (see chapter 3), but also enhances the impact of large 
artery dysfunction on LV growth via systolic BP effects. This synergy between adiposity 
and large artery dysfunction to promote LV growth clearly represents a pathological 
afterload effect on the LV. This finding may therefore provide insight into why adiposity-
induced increases in LVM are associated with deleterious cardiovascular outcomes 
independent of conventional risk factors (de Simone et al 2005), in direct contrast to 
normal growth-induced increases in LVM that are considered to be entirely benign. 
The strengths of the present study are as follows. I analysed haemodynamic 
factors and indexes of adiposity as continuous and not as discrete variables in a random 
population sample of subjects with a high prevalence of hypertension (~41%), but in whom 
antihypertensive use was limited (~17%). Using this approach the interactive effects 
between haemodynamic factors and indexes of adiposity as predictors of LVMI were 
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remarkably robust even after multiple adjustments, and striking increases in the slopes of 
the relations in subjects with an increased as compared to a normal waist circumference 
were noted. Moreover, these interactive effects were confirmed on sensitivity analysis in 
never-treated subjects. In the present study I also examined two adiposity indexes (waist 
circumference and skin-fold thickness) that were unrelated to height and I did not rely on 
BMI, which is well recognized to be a poor index of excess adiposity in some populations 
(Luke et al 1997). Last, I confirmed the interactive effects with a number of measurements 
including pulse wave analysis, conventional SBP and PP measurements and ambulatory 
SBP and PP measurements. In this regard 24-hour BP is more closely associated with 
LVMI than conventional BP measurements (Mancia and Parati 2000). 
As this was a cross-sectional study, further prospective studies are still required to 
determine whether adipose tissue loss or gain modifies the impact of haemodynamic 
changes on LVM. Further, in the present study I did not evaluate the potential cellular 
mechanisms of the effects of interactions between BP and body size on LVMI. In this 
regard, cardiomyocytes may respond to tension transduction as well as circulating factors 
released from adipocytes through common downstream pathways. 
The potential mechanisms that may explain the interaction between BP and excess 
adiposity to promote increases in LVM warrant consideration. In this regard, although 
controversial with respect to a role for angiotensin II (Reudelhuber et al 2007), the renin-
angiotensin system, which is activated in obesity (Serazin-Leroy et al 2000, Cassis et al 
1988, Campbell et al 1987, Cooper et al 1998, Jonsson et al 1994, Harp et al 2002)     
may contribute toward obesity-induced increases in LVM. Indeed, angiotensin II receptor 
blockade has been shown to prevent obesity-induced increases in LVM (du Toit et al 
2005). Alternatively, either a protective effect of leptin on cardiac hypertrophy (Barouch et 
al 2003) or in contrast, a hypertrophic action of leptin on cardiac myocytes (Rajapurohitam 
et al 2003) may contribute toward cardiac growth effects. 
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The potential clinical implications of the present study are underscored by 
comparing the increase in LVMI produced by an equivalent change in BP in subjects with 
as compared to those without an increased waist circumference. As compared to subjects 
with a normal waist circumference where a 22 mm Hg increase in systolic BP (~one SD) 
was associated with a 1.61 g/m2.7 increase in LVMI, in subjects with an increased waist 
circumference, a 22 mm Hg increase in systolic BP (~one SD) was associated with a 5.24 
g/m2.7 increase in LVMI. Thus for an equivalent increase in systolic BP, participants with 
an increased waist circumference have a three-four times greater increase in LVMI. 
In conclusion, the present study indicates that obesity-induced increases in LVM 
are characterized in-part by a considerably enhanced impact of arterial stiffness and 
hence systolic BP on LVM and wall thickness. The results of the present study therefore 
provide unique insights into why, as opposed to normal growth effects on LVM which have 
no pathological relevance, adipose tissue-induced effects on cardiac growth may be of 
pathophysiological relevance.  
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CHAPTER 5 
 
Dietary-Induced Obesity Promotes the Progression From 
Compensated Cardiac Hypertrophy to Cardiac Dilatation and 
Pump Dysfunction in Hypertensive Rats. 
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Abtsract 
The role of obesity in the development of cardiac pump dysfunction is uncertain. I 
explored whether excess adiposity can promote the transition from compensated cardiac 
hypertrophy to pump dysfunction in spontaneously hypertensive rats (SHR) and the 
mechanisms thereof. After feeding rats a diet for 4-5 months that resulted in an increased 
energy intake, obesity was induced in SHR and Wistar Kyoto (WKY) control rats at an age 
when cardiac pump function is maintained. Dietary-induced obesity was not associated 
with abnormal blood glucose control (HbA1c) or with increases in systolic blood pressure. 
However, dietary-induced obesity resulted in a reduced left ventricular (LV) endocardial 
fractional shortening (echocardiography) and LV end systolic elastance (isolated perfused 
heart studies) in SHR, but not in WKY controls. The reduced LV systolic chamber function 
in SHR was associated with a marked increase in LV end diastolic diameter (LVEDD) and 
a right shift of the LV diastolic pressure-volume relation in obese SHR, but not in obese 
WKY. Moreover, LV intrinsic myocardial systolic function, as determined from the slope of 
the linearized LV systolic stress-strain relationship, was markedly reduced in obese as 
compared to lean SHR, whilst intrinsic myocardial systolic function was maintained in 
obese as compared to lean WKY rats. Obese SHR had a greater increase in LV weight as 
compared to obese WKY rats and cardiomyocyte apoptosis (TUNEL) and the activity of 
myocardial matrix metalloproteinases (zymography) was enhanced in obese SHR, but not 
in obese WKY rats. As compared to lean rats, obesity in either SHR or in WKY failed to 
alter either total or cross-linked LV collagen concentrations. In conclusion, these data 
suggest that in hypertension, obesity may promote the progression from compensated LV 
hypertrophy to pump dysfunction independent of further BP changes or alterations in blood 
glucose control, changes that may be mediated through both cardiomyocyte apoptotic-
induced decreases in myocardial function and activation of myocardial collagenases to 
promote cardiac dilatation. 
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5.1 Introduction 
Obesity is risk factor for heart failure and this effect may be independent of other 
conventional cardiovascular risk factors (Bahrami et al 2008, Ingelsson et al 2005, 
Kenchaiah et al 2002, Kenchaiah et al 2004, Poirier et al 2006, Wong and Marwick 2007, 
Contaldo et al 2002). As adjustments for baseline cardiac systolic chamber function 
abolish the independent relationship between obesity and heart failure (Bahrami et al 
2008), it is possible that heart failure in obesity is mediated by pump dysfunction. 
Nevertheless, whether obesity is associated with cardiac pump (chamber) dysfunction 
independent of conventional cardiovascular risk factors is controversial (Peterson et al 
2004, Wong et al 2004, Pascual et al 2003, Scaglione et al 1992, de Divitiis et al 1981, 
Chakko 1998, Zarich et al 1991, Stoddard et al 1992, de Simone et al 1996, Mureddu et al 
1996, Iacobellis et al 2002, Karason et al 1998, Carroll et al 2006, du Toit et al 2008). 
Although sensitive myocardial tissue Doppler techniques indicate that obesity is 
associated with myocardial systolic abnormalities independent of BP, age, gender, blood 
glucose control and left ventricular mass (LVM) (Peterson et al 2004, Wong et al 2004); 
weight loss produced either by lifestyle modification or gastric bypass does not influence 
myocardial systolic function of the LV (Skilton et al 2007, Wong et al 2006). Moreover, 
although animal models of obesity without diabetes mellitus are associated with a 
reduction in isolated cardiomyocyte contractile function (Carroll et al 1997, Relling et al 
2006, Dong et al 2006, Ren et al 2000), euglycaemic animal models of obesity have a 
preserved pump function (Carroll et al 2006, du Toit et al 2008). As a reduced cardiac 
pump function is a well recognized feature of the development of heart failure (Hunt et al 
2005), clarity on the role of obesity in the development of pump dysfunction independent 
of conventional risk factors is required. 
In studies demonstrating a relationship between obesity and myocardial systolic 
dysfunction, BP was greater in obese as compared to lean participants (Skilton et al 2007, 
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Peterson et al 2004, Wong et al 2004). It is therefore possible that obesity may promote 
the development of myocardial systolic and hence pump dysfunction through an 
interaction with BP effects. As obesity may enhance the impact of BP on LV hypertrophy 
(LVH) (see preceding chapter, Avelar et al 2007) and an increased LV mass is a risk factor 
for the development of pump dysfunction (Drazner et al 2004), I therefore hypothesized 
that one potential mechanism that may explain the relationship between obesity and the 
development of heart failure (Kenchaiah et al 2002) is that obesity may enhance the 
detrimental effects of blood pressure (BP) on the heart. To test this hypothesis I assessed 
whether dietary-induced obesity promotes the development of LV systolic chamber and 
myocardial dysfunction in spontaneously hypertensive rats (SHR) as compared to 
normotensive Wistar Kyoto control (WKY) rats and the mechanisms thereof. 
5.2       Methods 
This study was conducted in accordance with the Principles of Laboratory Animal 
Care of the National Society for Medical Research and the Guide for the Care and use of 
Laboratory Animals of the National Academy of Sciences (NIH publication no 80-23, 
revised 1985) and was approved by the Animal Ethics Screening Committee of the 
University of the Witwatersrand (Approval number: 2006/99/3). Eight month old SHR (an 
age when compensatory LVH occurs)(Tsotetsi et al 2001) and age-matched WKY rats 
were assigned to receive an obesity-inducing or control diet for 5 months (du Toit et al 
2008). 
The experimental diet contained elevated carbohydrates and fats and resembles a 
Western-type diet (Pickavance et al 1999). The experimental diet consisted of 65% 
carbohydrate, 19% protein, and 16% fat in comparison to that of a control group which 
consisted of 60% carbohydrate, 30% protein, and 10% fat (du Toit et al 2008). As the diet 
is designed to induce hyperphagia (Pickavance et al 1999), the experimental groups 
consumed a greater quantity of food and consequently, energy intake was enhanced in 
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the experimental groups (570±23 kJ/day) as compared to the control group that consumed 
371±18 kJ/day). Our group has previously shown that differences in micronutrient 
(vitamins and minerals) intake, produced by dilution of the diet by addition of 
carbohydrates and fats, does not modify either body size or cardiac function (du Toit et al 
2008). 
Assessment of dietary-induced effects on adipose tissue. To identify an impact of 
the diet on adipose tissue, body weights were measured weekly and visceral fat was 
weighed at the end of the study. Visceral fat included retroperitoneal and omental fat. 
Blood pressure. Tail cuff systolic BP was determined on three separate occasions 
(beginning, middle and end of dietary period) during the study using a photoelectric diode 
to detect tail pulses (Figure 5.1). Rats were housed in restrainers for approximately 20 
minutes and a lamp placed over the tail to dilate the tail artery in order to assist with the 
detection of the tail pulse (Figure 5.1). Once a pulse was detected with a photoelectric 
diode, a cuff placed proximal to the photoelectric diode was inflated until the pulse 
disappeared. The cuff was then allowed to slowly deflate until the pulse was detected 
again. The cuff pressure at which the pulse was detected on deflation of the cuff was 
considered systolic BP (Figure 5.1). Prior to the first measurement, rats were placed for 
two hours a day over two days in restrainers, and the tail cuff inflated to 200 mm Hg 5 
times for 30 seconds each time to habituate rats to the procedure. 
Echocardiography. Left ventricular systolic function and chamber dimensions were 
determined in vivo using two-dimensional targeted M-mode echocardiography performed 
using a 7.5 MHz transducer and a Hewlett Packard Sonos 2500 sector scanner according 
to the American Society of Echocardiography convention and as previously described 
(Norton et al 2002). Echocardiography was performed under anaesthesia induced by the 
administration of 50 mg/kg of ketamine and 3 mg/kg of xylazine (Norton et al 2002). Left 
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Figure 5.1. Photograph of the experimental apparatus used to measure tail artery systolic 
blood pressures in rats (left panel) and an example of a recording obtained (right panel). 
Systolic blood pressure was determined by inflating the tail cuff to pressures above that 
which abolished the pulse in the tail artery and then slowly releasing the tail cuff pressure 
until the pulse returned (see right panel). Systolic blood pressure was taken as the 
pressure in the tail cuff at which the pulse was first detected. 
A = Syringe coupled to pressure transducer and to tail cuff. The syringe is used to inflate or 
deflate the tail cuff 
 
B = Casing containing the photoelectric diode which is used to detect tail pulses (upper right 
recording) and the tail cuff used to occlude the tail artery.  
 
C = Pressure transducer used to record the pressures in the tail cuff as depicted in the lower 
right recording. 
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ventricular end-diastolic (LVEDD) and end-systolic (LVESD) internal diameter and end-
diastolic (ED PWT) and end-systolic posterior wall thickness (ES PWT) were measured 
using the leading edge technique (Norton et al 2002) (Figure 5.2). 
Left ventricular systolic chamber function (pump function) was determined from LV 
endocardial fractional shortening (LV FSend)(Norton et al 2002). Left ventricular FSend 
was determined from the equation (LVEDD-LVESD)/LVEDD x 100 (Norton et al 2002). LV 
remodelling was determined from LV EDD and ED PWT measurements as well as LV 
relative wall thickness values calculated from ED PWT/0.5 x LVEDD. 
Isolated, perfused heart preparations. Following echocardiography, LV systolic 
function and LV remodelling was assessed ex vivo in isolated perfused heart preparations 
as previously described (Woodiwiss et al 2001, Norton et al 2002). To undertake these 
measurements, whilst rats were still anaesthetized hearts were removed from the thoracic 
cavity and placed in an ice-cold physiological saline solution until they were mounted on a 
perfusion apparatus illustrated in Figure 5.3. Hearts were perfused retrogradely via the 
aorta at a constant flow (12 ml.min-1.g wet heart weight) with 37°C physiological saline  
solution consisting of (in mM) 118.0 NaCl, 4.7 KCl, 2.5 CaCl2, 25.0 NaHCO3, 1.2 KH2PO4, 
1.2 MgSO4 and 10.0 glucose with a pH of 7.4. The solution was saturated with 95% O2 
and 5% CO2 gas and filtered through a size 0.45µm Millipore Durapore membrane filter. 
Hearts were paced at 360 beats.min-1 with platinum electrodes attached to the left atrium 
and the apex of the heart. An empty latex balloon with a known wall volume, coupled to a 
Statham P23 pressure transducer and a micromanipulator (see Figure 5.3) via a 
polyethylene catheter, was inserted through the mitral valve into the LV lumen. A thin-
walled latex balloon with zero pressure at filling volumes beyond maximum LV lumen 
capacities was selected for this study to avoid the stiffness of the balloon wall contributing 
to LV pressure at higher filling volumes. The volume of the balloon wall was assessed with 
a water-displacement technique, and the same balloon was used 
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 A = Left ventricular end diastolic diameter 
B = Left ventricular end systolic diameter 
C = Left ventricular end diastolic posterior wall thickness 
D = Left ventricular end systolic posterior wall thickness 
 
 
 
 
 
                          
 
 
 
 
 
 
 
 
 
 
 
A = Left ventricular end systolic diameter 
B = Left ventricular end systolic posterior wall thickness 
C = Left ventricular end diastolic diameter 
D = Left ventricular end diastolic posterior wall thickness 
E = Calibration showing 1 cm  
 
Figure 5.2. Echocardiogram used to assess cardiac structure and function in rats. The 
figure shows internal dimensions and posterior wall thickness of the left ventricle recorded 
over ~three beats from an ultrasonic image obtained in the short axis of the heart. The 
lines (A-D) show where recordings of internal dimensions at end diastole and peak systole 
were obtained in order to determine systolic pump function and the degree of chamber 
dilatation (see text). 
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Systolic pressure 
 
 
 
 
 
 
 
 
Figure 5.3. Experimental apparatus for the isolated, perfused heart apparatus (upper panel) and 
typical recordings obtained (lower panel). See text for description. The left ventricular diastolic and 
developed (systolic) pressures are recorded at incremental volumes in the left ventricle (0.01 
increments in volume). 
Left ventricular diastolic pressure Left ventricular developed 
(systolic) pressure 
20 mm Hg 
0 mm Hg 
0 mm Hg 
120 mm Hg 
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throughout each of the studies. A micromanipulator was used to gradually increase LV 
volumes to values that resulted in no further change in LV developed pressure. LV 
pressures were determined at as many multiple small increments in volume as were 
practically possible to improve on the accuracy of curve fitting during analysis (Figure 5.3). 
Load-independent LV systolic chamber performance (a measure of systolic pump 
function) was determined in vitro from the slope (Ees) of the linear portion of the LV peak 
systolic pressure-volume relation. Intrinsic myocardial systolic performance (a load- 
independent measure of intrinsic myocardial contractility) was assessed in vitro from the 
slope (En) of the systolic stress (σ)-strain relation (Norton et al 2002). Systolic σ and strain 
were calculated using previously described formulae (Weber et al 1988) assuming a thick-
walled, spherical model of LV geometry as follows: 
 
σ = [1.36 P V2/3]/[(V+Vm)2/3-V2/3] 
strain = {[V1/3+(V+Vm)1/3]/[V01/3+(V0+Vm)1/3]} – 1 
 
where P=pressure, V=volume, Vm=left ventricular muscle volume, V0=unstressed left 
ventricular volume 
LV remodelling was assessed in isolated, perfused heart preparations from the 
volume intercept (V0) of the LV diastolic P-V relation (Woodiwiss et al 2001, Norton et al 
2002). 
Cardiomyocyte necrosis. A longitudinal slice of the LV from the apex to the base 
through the LV free wall was obtained from all rats for histology. LV tissue was stored in 
formalin for subsequent histology. LV tissue was processed routinely for light microscopy 
and 50 µm-thick sections of the long axis circumference were cut through the full thickness 
of the LV wall. Ten slices were obtained at 1-mm intervals and stained with van Gieson’s 
stain. After staining a pathological grade was assigned, where 0 indicates no damage; 1 
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and 2, patchy fibrosis in less than or more than 20% of the field respectively; 3 and 4, 
diffuse contiguous subendocardial fibrosis in less than or more than 50% of the field 
respectively and 5 and 6, full thickness fibrosis in less than or more than 50% of the field 
respectively (Teerlink et al 1994; Woodiwiss et al 2001). Representative slides are 
illustrated in Figure 5.4. 
Cardiomyocyte apoptosis. The degree of apoptosis was quantified on myocardial 
tissue sections obtained from the same tissue blocks used to assess the pathological 
score. For each tissue block, 5 µm thick sections were stained and evaluated. Nuclear 
deoxyribonucleic acid (DNA) fragments in the tissue sections were detected using a non-
radioactive in situ apoptotic cell death detection kit (DeadEndTM Colorimetric TUNEL 
system, Promega, Madison, WI, USA), where terminal deoxynucleotidyl transferase (TdT) 
was used to incorporate biotinylated nucleotide at the 3’-OH DNA ends. Using this 
technique horseradish-peroxidase-labeled streptavidin binds to biotinylated nucleotides, 
which subsequently stain dark brown in response to hydrogen peroxide and 
diaminobenzidine (Agarwala and Kalil 1998) (Figure 5.4). Both positive (DNase treated) 
and negative (no addition of TdT) control tissue sections were incorporated into each 
assay (Figure 5.5). The number of apoptotic cardiomyocyte nuclei and the total number of 
cardiomyocyte nuclei (haematoxylin and eosin stain) in each slide were counted on ten 
evenly spaced fields from the apex to the base using a computer-based image acquisition 
and analysis system at 400 times magnification (Axiovision 3, Carl Zeiss, Gottingen, 
Germany). Apoptotic cardiomyocyte nuclei were expressed as a percentage of the total 
number of cardiomyocyte nuclei. Representative examples of stained sections for the 
samples assessed and from positive and negative controls and from an SHR are 
illustrated in Figure 5.5. 
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Figure 5.4. Histological images obtained using light microscopy from cross-sections of 
myocardial tissue stained with van Gieson’s stain. The slides show portions of the heart 
with evidence of tissue necrosis and fibrosis following cell death (upper panel) as 
compared to normal portions of the heart (lower panel). 
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Figure 5.5. Histological sections of the myocardium stained for apoptotic nuclei. The 
upper panels illustrate sections obtained from a positive (left) and a negative (right) control 
and the lower panel a section from the myocardium of a heart showing apoptotic 
cardiomyocyte nuclei (arrows). Note the numerous apoptotic nuclei in the positive control 
section.  
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Matrix metalloproteinase activity. To avoid a potential impact of prolonged 
anaesthesia and perfusion of the myocardium with artificial solutions on MMP activity, 
gelatin zymography was performed on tissue collected from rats that had not undergone 
echocardiography or isolated, perfused heart studies. Gelatin zymography was performed 
as previously described (Tyagi et al 1993) in order to determine the activity of the 
gelatinase, MMP-2. For this purpose, tissue from the lateral wall of the LV was analyzed. 
Tissue samples used were frozen in liquid nitrogen within 5 minutes of removing hearts 
from the thoracic cavity and then stored at -70°C u ntil analysis. To extract cardiac tissue 
protein, tissue was ground to a powder under liquid nitrogen using a mortar and pestle. 
The ground tissue was weighed and 100 µl extraction buffer (50 mM Tris, 0.1% SDS) 
added per 100 mg tissue powder. The samples were incubated for 18 h at 4°C and 
thereafter the samples were centrifuged at 12 000 rpm for 10 minutes and the supernatant 
containing the soluble extracted protein was decanted and stored at -70°C. The protein 
concentrations of the supernatants were estimated using a modified Lowry/Folin technique 
(Lowry et al 1951). In order to determine the relative activity of MMP-2 in each sample, 20 
µg of protein was loaded into each well of a 10% polyacrylamide gel containing 1mg.ml-1 
of type A gelatin. The proteins were separated electrophoretically over 1.5 hours at 30 mA. 
A single standard of rat MMP-2 (Sigma, purity >95% by SDS-PAGE visualized by silver 
staining) was included on each gel to locate the MMP-2 bands. The gels were then 
incubated overnight in substrate buffer (Tris 50 mM pH 8, CaCl2 5 mM) to allow 
degradation of gelatin. The gels were then stained for protein with Coomassie blue dye 
resulting in a gel with a dark background and light bands (Figure 5.6 upper panel), the 
intensity of which indicate the activity of MMP. The gels were scanned using a flat bed 
transmission scanner (Cano Scan 4200 F, Cannon Solutions, China). Images were 
inverted (Figure 5.6 lower panel) and the density of the MMP band analyzed compared to  
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Figure 5.6. A representative example of a normal (A) and inverted (B) image of a 
zymogram illustrating banding patterns obtained for matrix metalloproteinase (MMP) 2 
activity. Lanes 1-6 represent samples.  
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a standard extract MMP sample using digital densitometry with LabWorks Software 
Version 4.5 (UVP, Upland, USA). 
Myocardial collagen. Samples of LV tissue were weighed and stored at -70°C prior 
to tissue analysis. Myocardial hydroxyproline concentration ([HPRO]) was determined after 
acid (HCl) hydrolysis (Norton et al 1997, Tsotetsi et al 2001, Woodiwiss et al 2001, Norton 
et al 2002, Badenhorst et al 2003b).  Myocardial collagen was also extracted and digested 
with cyanogen bromide (CNBr) (Norton et al 1997; Tsotetsi et al 2001; Woodiwiss et al 
2001; Badenhorst et al 2003b). A portion of the CNBr digested collagen sample was 
subjected to acid hydrolysis and [HPRO] determination. The amounts of non-cross-linked 
(soluble) and cross-linked (insoluble) collagen in the myocardium were ascertained based 
on the solubility of myocardial collagen to CNBr digestion (Norton et al 1997, Tsotetsi et al 
2001, Woodiwiss et al 2001, Badenhorst et al 2003b). 
Blood analysis To determine the impact of the model of obesity on percentage 
glycosylated haemoglobin (HbA1c), blood samples were obtained from the thoracic cavity 
immediately after extirpation of the heart. HbA1c measurements were determined using 
HBA1C II Tina-quant kit (Cobas – Roche Diagnostics). 
Data analysis. Regression analysis was used to determine the lines of best fit for 
the cardiac function relations. All data are presented as mean±SEM. Comparisons 
between groups were made with a two way ANOVA. 
5.3 Results 
Characteristics of the obesity model. Table 5.1 shows the effect of the 
experimental diet on body weights, visceral fat weight, systolic BP, and percentage HbA1c 
in SHR and WKY rats. At the initiation of the study, WKY rats were markedly heavier than 
SHR, but otherwise body weights were similar between groups of animals assigned to 
dietary groups (SHR assigned to control diet=360±17.9 g, SHR assigned to experimental  
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Table 5.1. Effect of an obesity-inducing diet (Experimental [Exp] diet) on morphological, 
blood and haemodynamic characteristics in spontaneously hypertensive (SHR) and Wistar 
Kyoto control (WKY) rats.  
 
                                                                WKY                   SHR 
                                            Control (n=10)  Exp diet (n=9)  Control (n=10)  Exp diet (n= 10)       
  
Final body weight (BW)(g)            484±9              527±8**         362±5†         400±6**† 
Tibial length (cm)                  4.61±0.12        4.39±0.12       4.68±0.17         4.37±0.12 
Body weight/tibial length (/10)    10.6±0.3           12.2±0.5**       7.6±0.3†             8.7±0.2**† 
Visceral fat (g)                  19.4±1.5          29.4±1.3**       9.6±0.7†            17.2±0.7**† 
Systolic BP (mm Hg)                  124±4              122±4       184±5†               186±3† 
Glycated haemoglobin (%)          4.61±0.22         4.42±0.06       4.78±0.08          4.66±0.09 
Heart weight (g)                  1.41±0.15        1.52±0.07       1.52±0.07        1.70±0.23# 
LV weight (g)                   1.17±0.15        1.23±0.05       1.22±0.08        1.34±0.14# 
Heart weight/BW (X100)             2.91±0.004      2.88±0.005    4.24±0.004†        4.52±0.002†           
LV weight/BW (X100)                  2.40±0.003      2.33±0.004   3.41±0.004†        3.55±0.002† 
LV weight/tibial length (x10)        2.53±0.10         2.82±0.11       2.63±0.008       3.08±0.15†* 
BP, blood pressure; LV, left ventricle. * p<0.05 ** p<0.005 vs SHR Control diet group or 
WKY Control diet group, † p<0.001 vs respective WKY group, # p<0.05 vs WKY Control 
group.    
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diet=361±19.0 g, WKY assigned to control diet=427±21.5 g, WKY assigned to 
experimental diet=414±19.1 g). The diet produced a modest increase in body weight in 
both SHR and WKY groups (Table 5.1), but almost doubled visceral fat content (Table 
5.1). At the initiation of the study, systolic BP values were higher in SHR as compared to 
WKY rats. However, systolic BP values were otherwise similar between groups of animals 
assigned to dietary groups (SHR assigned to control diet=179±21.6 mm Hg, SHR 
assigned to experimental diet=177±20.5 mm Hg, WKY assigned to control diet=14±14.2 
mm Hg, WKY assigned to experimental diet=111±11.7 mm Hg). The experimetal diet 
failed to modify systolic BP in either group either during the course of the study (data not 
shown) or at the termination of the study (Table 5.1). Furthermore, blood glucose control, 
as indexed by HbA1c measurements, was unchanged in either SHR or WKY rats receiving 
the experimental diet (Table 5.1). 
Cardiac weight. Table 5.1 also shows the effect of the experimental diet on heart 
and LV weights in SHR and WKY rats. Despite SHR having increased systolic BP values, 
as SHR were considerably smaller than WKY rats, they had similar absolute heart and LV 
weights as compared to WKY rats. However, when normalised for body weight 
differences, SHR had marked increases in heart and LV weights as compared to WKY 
rats. The experimental diet increased LV weight in SHR, with this effect achieving 
statistical significance when LV weights were normalised for growth effects as determined 
from tibial length measurements (p<0.05 for the interaction between the presence of 
hypertension and the diet). However, the diet failed to significantly increase either heart or 
LV weights in WKY rats even after normalising LV weight for tibial length. 
 Left ventricular pump function. Figure 5.7 shows the effect of the experimental diet 
on LV systolic chamber function in SHR and WKY rats. In keeping with concentric LV 
remodelling (see data on LV remodelling below), SHR receiving the control diet had a 
greater FSend (Figure 5.7 left lower panel) and a left shift in the LV systolic pressure-
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volume relationship (Figure 5.7-upper panel) as compared to WKY rats receiving the 
control diet. However, pump function, as assessed using the load and heart rate 
independent index of function, LV Ees (Figure 5.7-right lower panel), was unchanged in 
SHR as compared to WKY rats receiving a control diet. The experimental diet given to 
SHR resulted in a decrease in LV systolic chamber function as indicated by a decline in 
both FSend, and a right shift in the LV systolic pressure-volume relationship (upper panel 
of Figure 5.7), a change attributed to a decrease in the slope of this relationship (LV Ees). 
However, the experimental diet failed to modify LV systolic chamber function in WKY rats. 
Indeed, neither FSend nor the LV systolic pressure-volume relationship or its slope (LV 
Ees) was altered by feeding the experimental diet to WKY rats. 
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Figure 5.7. Effect of an obesity-inducing diet (Experimental [Exp] diet) on left ventricular 
(LV) pump function in spontaneously hypertensive (SHR) and Wistar Kyoto control (WKY) 
rats as determined ex vivo from LV systolic pressure-volume relations (upper panel) and 
the slope of these relations (LV Ees) (lower left panel) and in vivo from LV endocardial 
fractional shortening (FSend) measurements (lower right panel). * p<0.05 for an 
interaction between the presence of hypertension (SHR vs WKY) and diet category. 
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Left ventricular instrinsic myocardial systolic function. Figure 5.8 shows the effect 
of the experimental diet on intrinsic myocardial systolic function in SHR and WKY rats as 
indexed by LV systolic stress-strain relations and their load, heart rate and LV geometry- 
independent slope (LV En). SHR and WKY rats receiving the control diet had a similar 
intrinsic myocardial systolic function (systolic stress-strain relationships and LV En were 
comparable). The experimental diet given to SHR produced a striking decrease in intrinsic 
myocardial systolic function as indicated by right shift in the LV systolic stress-strain 
relation, an effect that was attributed to a decrease in the slope of this relationship (LV 
En). However, the experimental diet failed to modify intrinsic myocardial systolic function in 
WKY rats. 
Left ventricular chamber remodelling. Figure 5.9 shows the effect of the obesity-inducing 
diet on LV diastolic pressure-volume relations assessed ex vivo, the volume intercept at a 
diastolic pressure of 0 mm Hg (LV V0) of the LV diastolic pressure-volume relationship, 
and LV chamber dimensions assessed in vivo using echocardiography in SHR and WKY 
rats. Consistent with either concentric LV remodelling in SHR or with a smaller body size, 
despite having similar LV weights as WKY rats (Table 5.1), SHR had a left shift in the LV 
diastolic pressure-volume relationship, and a decrease in LV V0, and LV EDD. Moreover, 
also consistent with concentric LV remodelling in SHR, despite having similar LV weights 
as age-matched WKY rats, SHR had increased LV end diastolic posterior and relative wall 
thickness values. The experimental diet given to SHR resulted in a right shift in the LV 
diastolic pressure-volume relationship, an increase in LV V0 and LV EDD and a decrease 
in LV posterior and relative wall thickness. In contrast, the experimental diet given to WKY 
rats had no effect on the LV diastolic pressure-volume relationship, LV V0, LV EDD, or LV 
posterior and relative wall thickness. 
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Figure 5.8. Effect of an obesity-inducing diet (Experimental [Exp] diet) on left ventricular 
(LV) intrinsic myocardial systolic function in spontaneously hypertensive (SHR) and Wistar 
Kyoto control (WKY) rats as determined ex vivo from LV systolic stress-strain relations 
(upper panel) and the slope of these relations (LV En) (lower panel). * p<0.005 for an 
interaction between the presence of hypertension (SHR vs WKY) and diet category. 
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Figure 5.9. Effect of an obesity-inducing diet (Experimental [Exp] diet) on left ventricular 
(LV) diastolic pressure-volume relations (upper panel), the volume intercept of these 
relations (lower panel) and LV dimensions determined using echocardiography (lower 
panels) in spontaneously hypertensive (SHR) and Wistar Kyoto control (WKY) rats. * 
p<0.005 for an interaction between the presence of hypertension (SHR vs WKY) and diet 
category. EDD, end diastolic diameter; LV PWT, LV end diastolic posterior wall thickness; 
LV RWT, LV end diastolic relative wall thickness. 
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 To assess whether the degree of adverse LV remodelling in SHR exceeded that 
which would be expected to occur with increases in body weight, LV diastolic pressure-
volume relations were also constructed after normalizing all LV volumes to 100 g body 
weight (Figure 5.10). After adjustments of LV volumes for body weight, SHR receiving the 
control diet had similar LV diastolic pressure-volume relations and LV V0 values as WKY 
rats (Figure 5.10). The experimental diet given to SHR resulted in a right shift in the LV 
diastolic pressure-volume relationship, and an increase in LV V0. In contrast, the 
experimental diet given to WKY rats had no effect on the LV diastolic pressure-volume 
relationships or LV V0  (Figure 5.10). 
Myocardial apoptosis, necrosis and interstitial changes. Figure 5.11 shows the effect of the 
experimental diet on cardiomyocyte apoptosis and matrix metalloproteinase 2 activity in 
SHR and WKY rats. Table 5.2 shows the effect of the experimental diet on cardiomyocyte 
necrosis (pathological score), myocardial hydroxyproline concentrations and the degree of 
myocardial collagen cross-linking in SHR and WKY rats. SHRs receiving a control diet had 
a similar percentage cardiomyocyte apoptotic nuclei as WKY rats receiving a control diet. 
Administration of the experimental diet to SHR however produced an increase in 
cardiomyocyte apoptosis as compared to SHR receiving the control diet (Figure 5.11). In 
contrast, the experimental diet failed to modify the degree of cardiomyocyte apoptosis in 
WKY rats (Figure 5.11). In contrast to effects on the index of cardiomyocyte apoptosis, the 
experimental diet failed to influence the myocardial pathological score in either SHR or 
WKY rats (Table 5.2). 
SHRs receiving a control diet had a similar myocardial MMP-2 activity as WKY rats 
receiving a control diet. Administration of the experimental diet to SHR however also 
produced an increase in MMP-2 activity as compared to SHR receiving the control diet 
(Figure 5.11). In contrast, the experimental diet failed to modify myocardial MMP-2 activity 
in WKY rats (Figure 5.11). 
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SHRs receiving a control diet had a marked increase in myocardial collagen 
concentrations, as indexed by HPRO measurements, as compared to WKY rats receiving 
a control diet (Table 5.2). The increase in myocardial collagen concentrations in SHR as 
compared to WKY rats receiving control diets was of the cross-linked form as indicated by 
an increased insoluble HPRO concentration (Table 5.2). The preferential accumulation of 
cross-linked myocardial collagen in SHR was attributed to an increase in myocardial 
collagen cross-linking as detected by a marked decrease in myocardial collagen solubility 
to digestion by cyanogen bromide (Table 5.2). As a consequence of a decrease in 
myocardial collagen solubility in SHR, the non-cross-linked form of HPRO was unchanged 
in SHR as compared to WKY rats receiving the control diet (Table 5.2). Administration of 
the experimental diet to either SHR or WKY rats failed to modify HPRO concentrations or 
to alter the degree of myocardial collagen cross-linking (Table 5.2). 
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Figure 5.10. Effect of an obesity-inducing diet (Experimental [Exp] diet) on left ventricular 
(LV) diastolic pressure-volume relations (upper panel), and the volume intercept of these 
relations (lower panel) after normalising LV volumes to 100 g body weight, in 
spontaneously hypertensive (SHR) and Wistar Kyoto control (WKY) rats. * p<0.005 for an 
interaction between the presence of hypertension (SHR vs WKY) and diet category.  
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Figure 5.11. Effect of an obesity-inducing diet (Experimental [Exp] diet) on left ventricular 
cardiomyocyte apoptosis (TUNEL) (upper panel) and myocardial matrix metalloproteinase 
2 activity (lower panel) in spontaneously hypertensive (SHR) and Wistar Kyoto control 
(WKY) rats. * p<0.005 for an interaction between the presence of hypertension (SHR vs 
WKY) and diet category. 
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Table 5.2. Effect of an obesity-inducing diet (Experimental [Exp] diet) on left ventricular 
(LV) necrosis (pathological score) and interstitial characteristics in spontaneously 
hypertensive (SHR) and Wistar Kyoto control (WKY) rats.  
 
                                                           WKY        SHR 
                                             Control (n=10)  Exp diet (n=9)  Control (n=10) Exp diet (n=10)       
 
Pathological score         0.88±0.26      0.50±0.18      0.94±0.18   0.88±0.19                   
[HPRO] (µg.mg-1 dry LV)              3.33±0.21      3.16±0.31      8.04±0.54†   9.22±0.43† 
% CNBr solubility         28.6±4.33      35.4±4.8      12.3±1.5†  11.0±1.2† 
Soluble HPRO (µg.mg-1 dry LV)    0.95±0.12      1.08±0.11   0.96±0.12  0.98±0.09 
Insolube HPRO(µg.mg-1 dry LV)    2.37±0.20      2.07±0.28   7.16±0.56†  8.23±0.43† 
________________________________________________________________________             
[HPRO], myocardial hydroxyproline concentration; % CNBr solubility, solubility of 
myocardial collagen to cyanogens bromide digestion. † p<0.001 vs respective WKY 
groups. 
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5.4 Discussion 
The main findings of the present study are as follows: Predominantly visceral 
obesity induced by feeding a diet designed to produce an increased caloric intake, was 
associated with the premature progression from compensated LVH to LV pump 
dysfunction in SHR, but not in WKY rats. The dietary-induced change in pump function in 
SHR occurred in the absence of further peripheral systolic BP changes or changes in 
blood glucose control (HbA1c). Dietary-induced pump dysfunction in SHR was noted both 
in vivo (endocardial fractional shortening) and ex vivo using a load-independent 
assessment of chamber function (end systolic chamber elastance). Further, dietary-
induced pump dysfunction in SHR was associated with excessive LVH, a reduced intrinsic 
myocardial contractile function (end systolic myocardial elastance) and marked LV 
dilatation (increased chamber diameters and a right shift in the LV diastolic pressure-
volume relationship), changes that were associated with increases in cardiomyocyte 
apoptosis and myocardial MMP-2 activation in SHR, but not in WKY rats. However, 
dietary-induced pump dysfunction in SHR was not associated with excessive myocardial 
necrosis, changes in myocardial collagen concentrations, or alterations in the quality of 
myocardial collagen. 
The present study provides insight into the potential mechanisms that may explain 
the relationship between obesity and the development of heart failure even after 
adjustments for the presence of diabetes mellitus (Bahrami et al 2008, Ingelsson et a 
2005, Kenchaiah et al 2002, Kenchaiah et al 2004, Poirier et al 2006, Wong and Marwick 
2007, Contaldo et al 2002). The present study is the first prospective study to show that 
dietary-induced obesity, in the absence of hyperglycaemia, can promote myocardial 
contractile disturbances which translate into pump dysfunction. Although sensitive 
myocardial tissue Doppler techniques conducted in case-control studies indicate that 
obesity is associated with myocardial systolic abnormalities independent of blood glucose 
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control (Peterson et al 2004, Wong et al 2004), whether this is a cause-effect relationship 
is uncertain as weight loss produced either by lifestyle modification or gastric bypass does 
not influence myocardial systolic function of the LV (Skilton et al 2007, Wong et al 2006). 
Moreover, whether obesity-associated systolic myocardial abnormalities translate into 
pump dysfunction independent of conventional cardiovascular risk factors is controversial 
(Peterson et al 2004, Wong et al 2004, Pascual et al 2003, Scaglione et al 1992, de Divitiis 
et al 1981, Chakko 1998, Zarich et al 1991, Stoddard et al 1992, de Simone et al 1996, 
Mureddu et al 1996, Iacobellis et al 2002, Karason et al 1998, Carroll et al 2006, du Toit et 
al 2008). Indeed, although animal models of obesity without diabetes mellitus are 
associated with a reduced cardiomyocyte contractile function (Carroll et al 1997, Relling et 
al 2006, Dong et al 2006, Ren et al 2000), these animals have a preserved pump function 
(Carroll et al 2006, du Toit et al 2008). In contrast to previous studies, the present study 
clearly shows that obesity can promote both myocardial contractile disturbances and pump 
dysfunction even in the absence of hyperglycaemia, but that for this effect to occur over a 
relatively short period, the presence of hypertension is required. Whether longer periods of 
dietary-induced obesity induce similar changes in contractile and pump function in the 
absence of hypertension still requires elucidation.  
Although obesity-induced pump dysfunction in SHR in the present study cannot be 
attributed to further increments in BP as measured in the periphery by tail-cuff techniques I 
cannot exclude the possibility that increases in central BP may have occurred. Indeed, 
excess adiposity is an independent predictor of increases in arterial stiffness (Majane et al 
2008) and changes in arterial stiffness which influence central BP through early reflective 
waves are not closely reflected by peripheral BP values (Karamanoglu et al 1993, Williams 
et al 2006). 
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As an increased LVM is a risk factor for the development of pump dysfunction 
(Drazner et al 2004) and cardiomyocyte size is associated with the progression to pump 
dysfunction in hypertensive rats (Gerdes et al 1996), one potential mechanism responsible 
for the obesity-induced effect on pump dysfunction in SHR noted in the present study is an 
interactive effect between obesity and BP to promote increases in LVM. Indeed, in 
agreement with previous studies (see preceding chapter, Avelar et al 2007), in the present 
study an interaction between hypertension and obesity was noted to contribute toward 
increases in LVM. In this regard LVM normalised to tibial length (which accounts for 
growth but not excess adiposity) was augmented in SHR receiving the obesity-inducing 
diet, but not in WKY rats receiving the obesity-inducing diet or in SHR on a normal diet.  
In agreement with previous studies conducted in euglycemic models of obesity in 
rodents (Barouch et al 2006, Zhou et al 2000), dietary-induced increases in cardiomyocyte 
apoptosis was noted in SHR in the present study. In this regard, the excessive 
cardiomyocyte apoptosis closely tracked intrinsic myocardial and pump dysfunction in that 
it only occurred in the SHR group receiving the obesity-inducing diet. Hence, dietary-
induced pump dysfunction may be attributed in-part to excessive cardiomyocyte apoptosis, 
a change that is now considered to be an important pathophysiological process in the 
development of heart failure (Foo et al 2005, Wencker et al 2003). As LVH is associated 
with cardiomyocyte apoptosis (Wang et al 1998), the mechanism of the cardiomyocyte 
apoptosis in obese SHR may occur as a consequence of an augmented LVH. 
Alternatively, excessive cardiomyocyte apoptosis in obesity may relate to changes in 
myocardial substrate metabolism (Barouch et al 2006) with a resultant ectopic lipid 
overload in cardiomyocytes (lipoapoptosis) (Zhou et al 2000) or through increases in 
circulating aldosterone concentrations that occur in obese SHR (Nagase et al 2006), as 
aldosterone may induce apoptotic changes in the myocardium (de Angelis et al 2002). 
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Although not assessed, dietary-induced decreases in intrinsic myocardial systolic 
function noted in SHR in the present study could occur, in-part, as a consequence of 
reductions in cardiomyocyte contractile function as opposed to cell death (apoptosis and 
necrosis). As the dietary-induced decline in intrinsic myocardial systolic function was noted 
in isolated, perfused heart preparations in the absence of circulating factors, an 
attenuation in contractile responsiveness to myocardial adrenergic stimuli (Carroll et al 
1997) or insulin and insulin-like growth factor-1 (Ren et al 2000) is unlikely to explain this 
change. Nevertheless, a reduced cardiomyocyte contractile function in the absence of 
circulating stimuli has been noted in dietary-induced obese animals (Relling et al 2006), 
and in leptin deficient animals (Dong et al 2006) without diabetes mellitus and these 
changes may occur as a consequence of a reduced myocardial contractile efficiency and 
an altered myocardial substrate metabolism (Buchanan et al 2005). 
In the present study an interaction between obesity and hypertension promoted LV 
dilatation. Importantly, the degree of dietary-induced LV dilatation in SHR far exceeded 
that which could be explained by increases in body size, as marked right shifts in LV 
diastolic pressure-volume relations were noted in SHR fed the experimental diet even after 
normalising LV volumes to 100 g body weight. Whether obesity-induced cardiac dilatation 
noted in SHR in the present study is an indirect consequence of decreases in intrinsic 
myocardial contractile function or through direct effects of the diet could not be 
determined. However, irrespective of the cause, as previously demonstrated (Norton et al 
2002), cardiac dilatation is likely to contribute toward progressive pump dysfunction in 
pressure overload states. Importantly, with regard to acknowledged mechanisms of 
cardiac dilatation, the cellular changes responsible for cardiac dilatation in the present 
study, appear to occur through the well recognised actions of activated collagenases 
(MMP-2)(Spinale 2002) as opposed to changes in myocardial collagen concentrations 
(Badenhorst et al 2003b), or reductions in myocardial collagen cross-linking (Woodiwiss et 
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al 2001, Tsotetsi et al 2001, Badenhorst et al 2003a and 2003b). As cardiac dilatation in 
pressure-overload LVH is associated with alterations in collagenases (Polyakova et al 
2004) as well as increases in myocardial collagen concentrations and reductions in 
myocardial collagen cross-linking (Tsotetsi et al 2001, Badenhorst et al 2003b), it is 
possible that the cellular changes associated with cardiac dilatation in the present study 
indicate a unique effect of the obesity-inducing diet together with hypertension, rather than 
primarily a hypertensive effect. 
From a clinical perspective the present study suggests that an obesity-inducing diet 
promotes the development of pump dysfunction, but that this effect is dependent on a 
simultaneous pressure-overload on the heart. Further studies are therefore required to 
determine whether careful BP control in obese individuals is sufficient to either prevent or 
reverse pump dysfunction in obesity. 
In conclusion, the present study indicates that in the absence of a further increase 
in peripheral BP or the presence of hyperglycaemia, an obesity-inducing diet can promote 
the premature progression from compensated cardiac hypertrophy to pump dysfunction. 
This effect occurs through both decreases in intrinsic myocardial systolic function and 
through cardiac dilatation, changes associated with excessive LVH, cardiomyocyte 
apoptosis and myocardial MMP-2 activation, but not through cardiomyocyte necrosis, nor 
alterations in the quantitative or qualitative characteristics of the myocardial interstitium. 
Further studies are required to determine whether BP control alone or alternative 
interventions are required to prevent or reverse pump dysfunction induced by obesity. 
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Summary and Conclusions. 
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Epidemiological trends suggest that obesity is becoming a major public health 
problem in both developed and developing countries ((Ogden et al 2007, Flegal et al 2002, 
Bourne et al 2002). Obesity carries a considerable health risk (Pi-Sunyer 1993, Bellanger 
and Bray 2005, McGee 2005, Giusti 2007, Allison et al 1997, Formiguera and Cantón 
2004, Heitmann et al 2000, Lahmann et al 2002) and a large component of the morbidity 
and mortality associated with obesity is through an increased risk for cardiovascular 
events (Eckel et al 2002, Klein et al 2004a, Bahrami et al 2008, Ingelsson et al 2005, 
Kenchaiah et al 2002, Kenchaiah et al 2004, Poirier et al 2006, Wong and Marwick 2007, 
Contaldo et al 2002, Yusuf et al 2005, Steyn et al 2005, Kurth et al 2002, Ahluwalia et al 
2003, Suk et al 2003). 
In the present thesis I provide evidence to clarify some outstanding issues 
regarding the impact of excess adiposity on a number of cardiovascular changes including 
BP, target organs and cardiac dysfunction. In this regard, although there is now 
considerable evidence from previous and recent studies to suggest that obesity is 
associated with an increased conventional BP, arterial stiffness, an increased LVM and 
cardiac dysfunction, a number of outstanding issues nevertheless remain. In the present 
thesis I have provided substantial evidence in favour of the use of waist circumference as 
opposed to alternative adiposity indexes, as the most appropriate clinical index of 
adiposity when predicting adiposity effects on both conventional and ambulatory BP. 
Further, I have provided clarity on the independent role of excess adiposity as a predictor 
of large artery dysfunction as determined by indexes of arterial stiffness. Moreover, I have 
provided evidence to suggest that excess adiposity promotes pathological LVH in-part by 
enhancing the impact of BP on LV growth. Last, I have provided the first prospective data 
to suggest that dietary-induced excess adiposity may promote cardiac pump dysfunction 
and the mechanisms thereof. The following section summarises these data in the context 
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of our current understanding of the role of obesity in cardiovascular disease, highlighting 
the novel features and implications of these findings. 
Although clinical indexes of central fat, such as waist circumference may be more 
closely associated with conventional BP or account for a greater proportion of the 
variability of BP than BMI in some studies (Okosun 1998, Williams et al 1987, Peiris et al 
1989, Kanai et al 1990, Raison et al 1992, Boyko et al 1995, Lerario et al 1997, Ho et al 
2001, Okosun et al 1999, Hayashi et al 2003, Ding et al 2004, Zhu et al 2005), not all 
studies support this notion. Indeed, in the ARIC study conducted in 15 063 partipants, BMI 
was as closely associated with conventional BP as was waist circumference (Harris et al 
2000). Moreover, there have been outstanding issues regarding the relative impact of 
indexes of central fat and BMI on ambulatory BP, a measurement of BP that is considered 
a better index of cardiovascular outcomes (Verdecchia et al 1994, Clement et al 2003, 
Staessen et al 1999 and Okhubo et al 1998) and target organ effects (Mancia and Parati 
2000) than conventional BP values. In this regard, to my knowledge, up until the time of 
publishing the data described in chapter 2 of the present thesis, studies that have 
compared the relative impact of indexes of central fat and BMI on ambulatory BP have 
either recruited small study samples, have been non-random, have focussed on waist-to-
hip ratio rather than waist circumference as the index of central fat, and have produced 
ambiguous results (Guagnano et al 1994, Guagnano et al 1997, Steptoe et al 1999, Lurbe 
et al 1998 and Feldstein et al 2005). As described in chapter 2 and published in the 
Journal of Hypertension (Majane et al 2007), I was able to show in the first study 
conducted in a relatively large, randomly selected population sample with a high 
prevalence of excess adiposity (65%), that waist circumference is the only clinical index of 
adiposity that was associated with an increased conventional and ambulatory systolic and 
diastolic BP, independent of other indexes of adiposity. However, I did not observe any 
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independent relationship between waist-to-hip ratio and ambulatory systolic or diastolic 
BP. 
With respect to the potential explanation for the independent relationship between 
waist circumference and ambulatory BP beyond alternative adiposity indexes, as 
discussed in chapter 2, visceral fat mass may be more important in mediating BP changes 
than peripheral fat (subcutaneous or other fat areas) (Williams et al 1987, Peiris et al 
1989, Kanai et al 1990, Raison et al 1992, Boyko et al 1995, Lerario et al 1997, Okosun et 
al 1999, Ho et al 2001, Hayashi et al 2003, Ding et al 2004). The lack of consistent 
relationship between waist-to-hip ratio and ambulatory BP may be explained by the poor 
relationship between visceral fat mass and waist-to-hip ratio (Kvist et al 1988, Seidell et al 
1988, Pouliot et al 1994, Wajchenberg et al 2000, Stewart et al 2003). With respect to the 
importance of the data described in chapter 2, presently there is no consensus as to which 
clinical index of adiposity should be employed in cardiovascular risk assessment. In this 
regard, the present data support an important role for the use of waist circumference 
rather than BMI or waist-to-hip ratio when predicting the BP effects of excess adiposity. 
However, prior to advocating the use of waist circumference rather than BMI as the 
preferred clinical index when predicting BP effects, further prospective, longitudinal 
analysis in sex-specific groups is required to identify the most appropriate clinical index of 
adiposity to employ when predicting increases in conventional and ambulatory BP over 
time. This study is presently being conducted by our group under the umbrella of the study 
described in chapter 2. 
Having identified the preferred clinical index of adiposity that most closely reflects 
adiposity effects on BP, I then focussed on the role of obesity in promoting target organ 
changes. As indicated in the introductory chapter, the present thesis was largely designed 
to address outstanding issues with respect to the role of obesity in promoting organ 
changes through mechanisms that cannot be attributed solely to conventional 
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cardiovascular risk factors. One target organ change that I studied was large vessel 
disease as indexed by increases in large artery stiffness. In this regard, increases in the 
stiffness of the wall of large arteries have consistently been shown to be a risk factor for 
cardiovascular events independent of conventional cardiovascular risk factors (Benetos et 
al 1997, Blacher et al 1999a, Blacher et al 1999b, de Simone et al 1999, Laurent et al 
2001, London et al 2001, Guerin et al 2001, Boutouyrie et al 2002, Safar et al 2002, 
Blacher and Safar 2005, Dolan et al 2006, Sutton-Tyrrell et al 2005, Cruickshank et al 
2002, Meaume et al 2001). However, despite the consistency in the reports demonstrating 
relations between indexes of adiposity and arterial stiffness, there is controversy as to 
whether this relationship is independent of factors such as BP, heart rate and diabetes 
mellitus. Indeed, although adiposity is associated with pulse wave velocity (PWV), a 
simple and reliable index of arterial stiffness, some studies have (Sutton-Tyrrell et al 2001, 
Mackey et al 2002, Wildman et al 2003, Ferreira et al 2004), whilst most others have not 
(Ferreira et al 2004, Zebekakis et al 2005, Taquet et al 1993, Amar et al 2001, Nakanishi 
et al 2003, Oren et al 2003, Mitchell et al 2004, Czernichow et al 2005) been able to 
demonstrate strong relations between adiposity indexes and PWV independent of 
haemodynamic factors and diabetes mellitus. 
To address the controversial issue of whether adiposity is independently 
associated with large artery stiffness, in chapter 3 and published in the American Journal 
of Hypertension (Majane et al 2008), I hypothesized that age may determine whether an 
excess adiposity promotes increases in arterial stiffness independent of confounders. This 
hypothesis was derived from the controversies in data showing convincing independent 
relations between clinical indexes of adiposity and PWV in elderly populations (Sutton-
Tyrell et al 2001, Mackey et al 2002), whilst substantial evidence against a strong 
independent relationship between adiposity and PWV was noted in samples that are 
predominantly young-to-middle aged (Ferreira et al 2004, Zebekakis et al 2005, Taquet et 
  
148 
al 1993, Amar et al 2001, Nakanishi et al 2003, Oren et al 2003, Mitchell et al 2004, 
Czernichow et al 2005). In chapter 3 (Majane et al 2008) I was able to show that age 
markedly influenced the independent relationship between indexes of central adiposity 
(waist circumference and waist-to-hip ratio) and PWV in women but not in men after 
adjusting for confounders including BP, HR, and diabetes mellitus. More specifically, in 
women older than the median age of the sample (~42 years), waist circumference and 
waist-to-hip ratio were strongly and independently associated with PWV, whereas in 
women younger than the median age a trend for a negative relationship was noted. The 
effect of waist-to-hip ratio and waist circumference on increases in PWV was ~5-fold 
higher in older than in younger women after adjustments for confounders. 
Thus, in chapter 3, I provide the first evidence to show that in a predominantly 
young-to-middle aged population sample with a high prevalence of excess adiposity, age 
markedly influences the independent relationship between indexes of central adiposity. 
These data provide insights into discrepancies in studies assessing relations between 
adiposity and PWV. From a clinical perspective these data also suggest that although in 
younger women the impact of adiposity on PWV is likely to be mediated principally through 
conventional haemodynamic factors such as BP, the effect of adiposity in older persons 
may be mediated by additional factors not normally included in cardiovascular risk 
assessment. 
With respect to obesity-induced effects on cardiovascular target organ changes, a 
second target organ change that I studied in the present thesis was that of increases in 
LVM. In this regard, LVM is a strong independent predictor of cardiovascular events 
(Casale et al 1986, Devereux et al 2004, Ghali et al 1998, Koren et al 1991, Levy et al 
1990, Levy et al 1994, Verdecchia et al 1996). Unlike normal growth effects on LVM which 
are physiological in nature, obesity-induced LVH may be of pathophysiological 
significance. One potential mechanism that may explain the potential pathological effects 
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of obesity-induced increases in LVM is through an enhanced impact of BP on LVM as 
demonstrated in severe obesity (body mass index>35 kg/m2) (Avelar et al 2007). However, 
obesity may not increase the impact of BP on LVM in milder forms of obesity (Fox et al 
2004, Lauer et al 1992). Nevertheless, in these studies only participants with a narrow 
range of BP levels (Lauer et al 1992) or where ~50% of the sample was receiving 
antihypertensive treatment at the time (Fox et al 2004) were studied. Therefore, in the 
present thesis I assessed in a population sample with a high prevalence of mild-to-
moderate obesity and with a high prevalence of hypertension (~41%), but in whom 
antihypertensive use was limited (~17%), whether adiposity is associated with an 
enhanced impact of BP, or one of the determinants of BP, namely arterial stiffness, on 
LVMI and wall thickness. 
As described in chapter 4 of the present thesis I was able to show marked 
synergistic effects between indexes of adiposity (waist circumference and skin-fold 
thickness) and haemodynamic variables (conventional or 24-hour systolic BP or indexes of 
large artery dysfunction [PWV and pulse pressure]) associated with LVM index and LV 
wall thickness. These data provide the first evidence to indicate that mild-to-moderate 
forms of excess adiposity not only promote the development of increases in BP as is well 
recognized (Majane et al 2007, chapter 2 and as summarized in chapter 1), but also 
enhance the impact of BP on LVM index. In addition, as systolic BP, pulse pressure and 
PWV are all affected by large artery dysfunction, these data suggest that excess adiposity 
not only promotes large artery dysfunction (chapter 3), but also enhances the impact of 
large artery dysfunction on LV growth via systolic BP effects. These data lend further 
support to the recent finding from our group demonstrating a strong BP-independent 
relationship between PWV and LVM and wall thickness in women (Libhaber et al 2008). 
As discussed in chapter 4, the synergy between adiposity and large artery dysfunction or 
BP to promote LV growth clearly represents a pathological afterload effect on the LV. This 
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finding may therefore provide insight into why adiposity-induced increases in LVM are 
associated with deleterious cardiovascular outcomes independent of conventional 
cardiovascular risk factors (de Simone et al 2005), in direct contrast to normal growth-
induced increases in LVM that are considered to be entirely benign.  
Although obesity is risk factor for heart failure independent of other conventional 
cardiovascular risk factors (Bahrami et al 2008, Ingelsson et al 2005, Kenchaiah et al 
2002, Kenchaiah et al 2004, Poirier et al 2006, Wong and Marwick 2007, Contaldo et al 
2002), the mechanisms of this relationship are uncertain. As adjustments for baseline 
cardiac systolic chamber function abolish the independent relationship between obesity 
and heart failure (Bahrami et al 2008), it is possible that heart failure in obesity is mediated 
by pump dysfunction. Nevertheless, whether obesity is associated with cardiac pump 
(chamber) dysfunction independent of conventional cardiovascular risk factors is 
controversial (Peterson et al 2004, Wong et al 2004, Pascual et al 2003, Scaglione et al 
1992, de Divitiis et al 1981, Chakko 1998, Zarich et al 1991, Stoddard et al 1992, de 
Simone et al 1996, Mureddu et al 1996, Iacobellis et al 2002, Karason et al 1998, Carroll 
et al 2006, du Toit et al 2008). Moreover, although sensitive myocardial tissue Doppler 
techniques indicate that obesity is associated with myocardial systolic abnormalities 
independent of BP, age, gender, blood glucose control and LVM (Peterson et al 2004, 
Wong et al 2004); weight loss produced either by lifestyle modification or gastric bypass 
does not influence myocardial systolic function of the LV (Skilton et al 2007, Wong et al 
2006). Furthermore, although animal models of obesity without diabetes mellitus are 
associated with a reduction in isolated cardiomyocyte contractile function (Carroll et al 
1997, Relling et al 2006, Dong et al 2006, Ren et al 2000), euglycaemic animal models of 
obesity have a preserved pump function (Carroll et al 2006, du Toit et al 2008). As a 
reduced cardiac pump function is a well recognized feature of the development of heart 
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failure (Hunt et al 2005), it is therefore clear that further clarity on the role of obesity in the 
development of pump dysfunction independent of conventional risk factors is required. 
In studies demonstrating a relationship between obesity and myocardial systolic 
dysfunction, BP is greater in obese as compared to lean participants (Skilton et al 2007, 
Peterson et al 2004, Wong et al 2004). It is therefore possible that obesity may promote 
the development of myocardial systolic and hence pump dysfunction through an 
interaction with BP effects. As obesity may enhance the impact of BP on LVM (see 
chapter 4, Avelar et al 2007) and an increased LVM is a risk factor for the development of 
pump dysfunction (Drazner et al 2004), in the present thesis I therefore hypothesized that 
one potential mechanism that may explain the relationship between obesity and the 
development of heart failure (Kenchaian et al 2002) is that obesity may enhance the 
detrimental effects of BP on the heart. To test this hypothesis I assessed whether dietary-
induced obesity promotes the development of left ventricular systolic chamber and 
myocardial dysfunction in spontaneously hypertensive rats (SHR) as compared to 
normotensive Wistar Kyoto control (WKY) rats and the mechanisms thereof. I chose to 
perform this study in an animal model of hypertension as a similar prospective study 
conducted in humans would be both unethical and unfeasible within the constraints of 
current resources and a PhD thesis. 
In chapter 5 of the present thesis I describe data to show that predominantly 
visceral obesity induced by feeding a diet designed to produce an increased caloric intake, 
was associated with the premature progression from compensated LVH to LV pump 
dysfunction in SHR, but not in WKY rats. The dietary-induced change in pump function in 
SHR occurred in the absence of further peripheral systolic BP changes or changes in 
blood glucose control (as determined from glycated haemoglobin measurements). Dietary-
induced pump dysfunction in SHR was noted both in vivo (endocardial fractional 
shortening) and ex vivo using a load-independent assessment of chamber function (end 
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systolic chamber elastance). Further, dietary-induced pump dysfunction in SHR was 
associated with excessive LVH (LV weight was normalized for growth effects by indexing 
LV weight to tibial length), a reduced intrinsic myocardial contractile function (end systolic 
myocardial elastance) and marked LV dilatation (increased chamber diameters and a right 
shift in the LV diastolic pressure-volume relationship even after normalising LV volumes 
for the greater body sizes in the obese rats), changes that were associated with increases 
in cardiomyocyte apoptosis and myocardial matrix metalloproteinase-2 activation in SHR, 
but not WKY rats. However, dietary-induced pump dysfunction in SHR was not associated 
with excessive myocardial necrosis, changes in myocardial collagen concentrations, or 
alterations in the quality of myocardial collagen. 
 Importantly, the data described in chapter 5 of the present thesis are the first 
prospective data to show that dietary-induced obesity, in the absence of hyperglycaemia 
or further peripheral BP changes, can promote myocardial contractile disturbances which 
translate into pump dysfunction. Moreover, the data described in chapter 5 suggest 
potential mechanisms of the interactive effects of dietary-induced obesity and 
hypertension to promote pump dysfunction. The study described in chapter 5 clearly 
shows that obesity can promote both myocardial contractile disturbances and pump 
dysfunction even in the absence of hyperglycaemia, but that for this effect to occur over a 
relatively short period, the presence of hypertension is required. Whether longer periods of 
dietary-induced obesity induce similar changes in contractile and pump function in the 
absence of hypertension still requires elucidation. Although in the study described in 
chapter 5 an interaction between obesity and hypertension was noted when assessing the 
impact of these factors on LV weight, whether this is the mechanism of the deleterious 
effect of the diet on pump function cannot be determined. Moreover, although the diet 
failed to promote further increases in peripheral BP beyond what would normally be 
expected to occur in SHR at this age, whether increases in large artery stiffness and 
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hence central BP may still contribute to the outcome requires further studies conducted in 
unanaesthetised, unrestrained rats. 
The specific strengths and limitations of each of the studies described in the 
present thesis have largely been addressed in individual semi-independent chapters. From 
a general perspective however, the strengths of the population-based studies was the 
random recruitment procedures conducted in studies with fairly large study samples, and 
the high quality laboratory and phenotypic assessments. The major limitation of the 
population-based studies is the lack of prospective or intervention data, data that is 
presently being obtained under the umbrella of the studies described in the present thesis. 
With respect to the animal-based study described in the preceding chapter, this study has 
a number of strengths including the careful assessment of cardiac function using well-
published techniques established in our laboratory over many years and the number of 
potential cellular and interstitial mechanisms explored. The weakness of the animal-based 
study is the absence of a number of assessments that may have provided insights into the 
mechanisms of the dietary effects, including ectopic lipid overload in cardiomyocytes, 
isolated cardiomyocyte function, arterial stiffness, and central BP measurements in awake, 
unanaesthetised rats. Furthermore, whether obesity promotes pump dysfunction through 
central hypertensive effects or through excessive LVH could have been assessed by 
including a group of rats receiving hydralazine therapy, a potent antihypertensive agent 
with little impact on LV weight in SHR (Norton et al 1997). Moreover, the role of 
aldosterone in the ability of dietary-induced obesity to promote the progression from 
compensated cardiac hypertrophy to cardiac decompensation could have been assessed 
by evaluating the impact of spironolactone on obesity-induced cardiac effects in SHR 
(Veliotes et al 2005). The latter two studies are obviously studies that are presently being 
conducted in our laboratory. 
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In conclusion therefore, data described in the present thesis provide substantial 
evidence to clarify a number of outstanding issues with respect to the impact of excess 
adiposity on cardiovascular disease. First, I provide strong evidence to suggest that waist 
circumference, rather than BMI, skin-fold thickness or waist-to-hip ratio, is the preferred 
clinical index of adiposity when assessing BP effects. Second, I describe strong cross-
sectional data to suggest that the conventional cardiovascular risk factor-independent 
effect of excess adiposity on large artery dysfunction depends on age in that this effect 
only occurs in people over the median age for the population sample that I studied (~43 
years). Third, in the present thesis I provide evidence to indicate that obesity promotes 
LVH in-part by potentiating the impact of haemodynamic factors such as systolic BP and 
large artery stiffness on LVM. These data therefore provide a mechanism to explain the 
potential pathological effects of obesity-induced LVH. Finally, in a pre-clinical study I 
provide the first prospective evidence to show that dietary-induced obesity is associated 
with the progression from compensated cardiac hypertrophy to cardiac dilatation and 
pump dysfunction and a number of potential mechanisms thereof. 
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